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defInItIons of key terms
Definitions used in this guideline are aligned with current consensus definitions used in 
the Global Health Sector Strategy on HIV/AIDS 2011–2015 (1) and by the United Nations, 
as described in the Joint United Nations Programme on HIV/AIDS (UNAIDS) “Guidance 
note on HIV and sex work”(2) and other relevant World Health Organization (WHO) and 
other United Nations documents. 
Key populations are defined groups who, due to specific higher-risk behaviours, are at 
increased risk of HIV irrespective of the epidemic type or local context. Also, they often 
have legal and social issues related to their behaviours that increase their vulnerability 
to HIV. These guidelines focus on five key populations: 1) men who have sex with 
men, 2) people who inject drugs, 3) people in prisons and other closed settings, 4) sex 
workers and 5) transgender people. People in prisons and other closed settings are 
included in these guidelines also because of the often high levels of incarceration of the 
other groups and the increased risk behaviours and lack of HIV services in these settings. 
The key populations are important to the dynamics of HIV transmission. They also are 
essential partners in an effective response to the epidemic (1). 
Vulnerable populations are groups of people who are particularly vulnerable to HIV 
infection in certain situations or contexts, such as adolescents (particularly adolescent 
girls in sub-Saharan Africa), orphans, street children, people with disabilities and 
migrant and mobile workers. These populations are not affected by HIV uniformly across 
all countries and epidemics. These guidelines do not specifically address vulnerable 
populations, but much of the guidance can apply to them. 
Men who have sex with men refers to all men who engage in sexual and/or romantic 
relations with other men. The words “men” and “sex” are interpreted differently in 
diverse cultures and societies and by the individuals involved. Therefore, the term 
encompasses the large variety of settings and contexts in which male-to-male sex takes 
place, regardless of multiple motivations for engaging in sex, self-determined sexual and 
gender identities, and various identifications with any particular community or social 
group.
People who inject drugs refers to people who inject psychotropic (or psychoactive) 
substances for non-medical purposes. These drugs include, but are not limited to, 
opioids, amphetamine-type stimulants, cocaine, hypno-sedatives and hallucinogens. 
Injection may be through intravenous, intramuscular, subcutaneous or other injectable 
routes. People who self-inject medicines for medical purposes – referred to as 
“therapeutic injection” – are not included in this definition. The definition also does 
not include individuals who self-inject non-psychotropic substances, such as steroids 
or other hormones, for body shaping or improving athletic performance. While these 
guidelines focus on people who inject drugs because of their specific risk of HIV 
transmission due to the sharing of blood-contaminated injection equipment, much of 
this guidance is relevant also for people who inject other substances. 
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People in prisons and other closed settings: There are many different terms used to 
denote places of detention, which hold people who are awaiting trial, who have been 
convicted or who are subject to other conditions of security. Similarly, different terms 
are used for those who are detained. In this guidance document, the term “prisons and 
other closed settings” refers to all places of detention within a country, and the terms 
“prisoners” and “detainees” refer to all those detained in criminal justice and prison 
facilities, including adult and juvenile males and females, during the investigation of 
a crime, while awaiting trial, after conviction, before sentencing and after sentencing. 
This term does not formally include people detained for reasons relating to immigration 
or refugee status, those detained without charge, and those sentenced to compulsory 
treatment and to rehabilitation centres. Nonetheless, most of the considerations in these 
guidelines apply to these people as well (3). 
People who use drugs include people who use psychotropic substances through any 
route of administration, including injection, oral, inhalation, transmucosal (sublingual, 
rectal, intranasal) or transdermal. Often this definition does not include the use of such 
widely used substances as alcoholic and caffeine-containing beverages and foods. 
Sex workers include female, male and transgender adults (18 years of age and 
above) who receive money or goods in exchange for sexual services, either regularly 
or occasionally. Sex work is consensual sex between adults, can take many forms, and 
varies between and within countries and communities. Sex work also varies in the 
degree to which it is more or less “formal”, or organized (4).
As defined in the Convention on the Rights of the Child (CRC), children and adolescents 
under the age of 18 who exchange sex for money, goods or favours are “sexually 
exploited” and not defined as sex workers (5). 
Transgender is an umbrella term for people 
whose gender identity and expression does 
not conform to the norms and expectations 
traditionally associated with the sex assigned 
to them at birth; it includes people who are 
transsexual, transgender or otherwise gender 
non-conforming (6, 7). Transgender people 
may self-identify as transgender, female, male, 
transwoman or transman, trans-sexual or, in specific cultures, as hijra (India), kathoey 
(Thailand), waria (Indonesia) or one of many other transgender identities. They may 
express their genders in a variety of masculine, feminine and/or androgynous ways. The 
high vulnerability and specific health needs of transgender people necessitates a distinct 
and independent status in the global HIV response. 
Many individuals will relate to 
more than one key population. For 
example, some men who have sex 
with men and some transgender 
people may also engage in sex work 
and/or inject drugs. 
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Sexual risk differs among different subgroups within the transgender community. For 
example, sexual risk may be higher among transgender women (male to female) or 
transgender men (female to male) who have receptive anal intercourse with men than 
among transgender men or transgender women who have sex only with women. The 
prevalence of HIV among transgender women in many countries is as high as or higher 
than among men who have sex with men. Owing to these differing sexual risk profiles, 
the focus of this consolidated guideline is on transgender women or transgender men 
who have sex with men rather than on transgender women and transgender men who 
have sex only with women (8).
Children: According to Article 1 of the Convention on the Rights of the Child, “A 
child means every human being below the age of eighteen years unless, under the law 
applicable to the child, majority is attained earlier”(5).
Adolescents: Individuals between the ages of 10 and 19 years old are generally 
considered adolescents. Adolescents are not a homogenous group; physical and 
emotional maturation comes with age, but its progress varies among individuals of the 
same age. Also, different social and cultural factors can affect their health, their ability 
to make important personal decisions and their ability to access services (9). 
This document primarily uses the term “adolescents”. Other terms covering overlapping 
age groups include:
Youth: This term refers to individuals between the ages of 15 and 24 (10).
Young people: This term refers to those between the ages of 10 and 24 (10).
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executIVe summary
purpose 
In this new consolidated guidelines document on HIV prevention, diagnosis, treatment 
and care for key populations, the World Health Organization (WHO) brings together 
all existing guidance relevant to five key populations – men who have sex with men, 
people who inject drugs, people in prisons and other closed settings, sex workers and 
transgender people – and updates selected guidance and recommendations. These 
guidelines aim to: provide a comprehensive package of evidence-based HIV-related 
recommendations for all key populations; increase awareness of the needs of and issues 
important to key populations; improve access, coverage and uptake of effective and 
acceptable services; and catalyze greater national and global commitment to adequate 
funding and services. 
The risk behaviours and vulnerabilities of key populations result in their being 
disproportionately affected by HIV in all countries and settings. These disproportionate 
risks reflect both behaviour common among members of these populations and 
specific legal and social issues that increase their vulnerability. Yet HIV services for 
key populations remain largely inadequate. In many settings HIV incidence in key 
populations continues to increase, even as incidence stabilizes or declines in the general 
population. 
To date, WHO has developed normative guidance separately for each of the five key 
populations, but, in general, guidance has not adequately addressed overarching issues 
relating to key populations. Similarly, the WHO global HIV guidance, including the 
2013 consolidated ARV guidelines, did not specifically consider issues relating to key 
populations. These guidelines aim to address these gaps and limitations. Countries and 
other end-users have indicated the importance of consolidating WHO’s key population 
guidance to aid national programme managers and service providers, including 
those from community-based and community-led programmes, in planning for and 
implementing services for these populations. Thus, this consolidated guidance addresses 
the issues and elements for effective HIV service delivery that are common to all key 
populations as well as those specific to one or more groups. 
format of the guidelines
The guidelines are presented in seven chapters: 
Chapter 1: Background, context, rationale, guiding principles, objectives and the target 
audience.
Chapter 2: Methods and process for developing the guidelines.
Chapter 3: Comprehensive package of interventions.
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Chapter 4: Clinical interventions for key populations. 
Chapter 5: Critical enablers required for successful implementation. 
Chapter 6: Service delivery issues and case studies. 
Chapter 7: Guidance on prioritizing and planning services, monitoring and evaluation, 
target setting, indicators and costing tools.
guidelines development methodology
In October 2013 an External Steering Group met and reviewed all relevant existing 
WHO guidance and identified recommendations requiring updating and new areas 
to be addressed. This group consisted of people from key population networks and 
organizations, academics, researchers, programme managers and implementers, United 
Nations partner organizations, supported by a WHO secretariat. 
The External Steering Group proposed that the consolidated key populations guidelines 
provide recommendations along the continuum of HIV care – prevention, diagnosis, 
linkage, treatment and care – and include recommendations and guidance on the critical 
enablers that are essential to support provision of safe, effective and acceptable HIV 
services. New areas identified included re-reviewing evidence concerning the provision 
of pre-exposure prophylaxis of HIV (PrEP) for men who have sex with men and assessing 
evidence concerning PrEP for people who inject drugs, a group not considered in 
the previous guidance. The External Steering Group also prioritized development of 
recommendations on the community delivery of naloxone for treating opioid overdose 
and updating of recommendations for people in prisons and other closed settings. 
Following the October 2013 meeting of the External Steering Group, a Guidelines 
Development Group was formed, comprising the majority of the External Steering 
Group members along with some additional expert members. Meeting in March 
2014, the Guidelines Development Group unanimously supported a reworded PrEP 
recommendation for men who have sex with men; a majority vote determined the 
strength of the recommendation. In addition, the Guidelines Development Group 
reviewed and fully supported all other areas of the existing guidelines. In March 
2014 a separate Guidelines Development Group reviewed proposed new guidance on 
community delivery of naloxone. 
Following these meetings the draft consolidated key populations guidelines were 
reviewed by external peer reviewers, UN agency reviewers and WHO staff members 
from the Department of HIV and the Department of Mental Health and Substance Abuse, 
other WHO departments and regional teams. 
recommendations
The accompanying table summarizes the recommendations presented in this document.
All recommendations and guidance in the document derive from existing WHO 
guidance with the exception of the new recommendations on PrEP and community 
opioid overdose management. The new PrEP recommendation constitutes a change 
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from a conditional recommendation for PrEP use in demonstration projects to a strong 
recommendation endorsing PrEP as part of a package of prevention services for men 
who have sex with men. The Guidelines Development Group made no recommendation 
on PrEP use for people who inject drugs. (See Chapter 2 for methodology and Chapter 4 
for the updated recommendation.) The new recommendation on opioid overdose 
management supports providing naloxone to people in the community who might 
witness an overdose and instructing them on its administration. The updated evidence 
reviews for the HIV recommendations for people in prisons and other closed settings 
reinforced the existing recommendations. For all other recommendations, the original 
guidance documents, which are referenced in this document, describe how that guidance 
was developed. 
Implications for programming 
Both public health and equity considerations underlie the need to prioritize and improve 
HIV services for key populations. These guidelines for key populations aim to support 
countries to provide more effective and acceptable comprehensive HIV services for key 
populations, to increase coverage and to address current inequities in access. Countries 
will need to assess their specific situations, taking into account current population 
sizes and reviewing current coverage levels and the quality of programmes. It is also 
important to assess and, where possible, to address social and legal barriers to access 
and to make progress as country-specific circumstances allow.
further research 
With partner organizations, the Department of HIV is developing a comprehensive HIV 
service implementation science framework, highlighting key research priorities, including 
those for key populations. 
summary of wHo recommendations concerning key populations
HealtH seCtor InterVentIons
HIV preVentIon
1 The correct and consistent use of condoms with condom-compatible lubricants is 
recommended for all key populations to prevent sexual transmission of HIV and sexually 
transmitted infections (STIs).
2 Among men who have sex with men, pre-exposure prophylaxis (PrEP) is recommended as 
an additional HIV prevention choice within a comprehensive HIV prevention package.  
NEW RECOMMENDATION
3 Where serodiscordant couples can be identified and where additional HIV prevention choices 
for them are needed, daily oral PrEP (specifically tenofovir or the combination of tenofovir 
and emtricitabine) may be considered as a possible additional intervention for the uninfected 
partner.
4 Post-exposure prophylaxis (PEP) should be available to all eligible people from key 
populations on a voluntary basis after possible exposure to HIV. 
5 Voluntary medical male circumcision (VMMC) is recommended as an additional, important 
strategy for the prevention of heterosexually acquired HIV infection in men, particularly in 
settings with hyperendemic and generalized HIV epidemics and low prevalence of male 
circumcision.
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Harm reduCtIon for people wHo use drugs
6 All people from key populations who inject drugs should have access to sterile injecting 
equipment through needle and syringe programmes.
7 All people from key populations who are dependent on opioids should be offered and have 
access to opioid substitution therapy.  
8 All people from key populations with harmful alcohol or other substance use should have 
access to evidence-based interventions, including brief psychosocial interventions involving 
assessment, specific feedback and advice.
9 People likely to witness an opioid overdose should have access to naloxone and be instructed 
in its use for emergency management of suspected opioid overdose. NEW RECOMMENDATION
HIV testIng and CounsellIng (HtC)
10 Voluntary HTC should be routinely offered to all key populations both in the community and 
in clinical settings. Community-based HIV testing and counselling for key populations, 
linked to prevention, care and treatment services, is recommended, in addition to provider-
initiated testing and counselling. 
HIV treatment and Care
11 Key populations living with HIV should have the same access to antiretroviral therapy (ART) 
and to ART management as other populations. 
12 All pregnant women from key populations should have the same access to services 
for prevention of mother-to-child transmission (PMTCT) and follow the same 
recommendations as women in other populations. 
preVentIon and management of CoInfeCtIons and Co-morbIdItIes
13 Key populations should have the same access to tuberculosis (TB) prevention, screening 
and treatment services as other populations at risk of or living with HIV. 
14 Key populations should have the same access to hepatitis B and C prevention, screening 
and treatment services as other populations at risk of or living with HIV. 
15 Routine screening and management of mental health disorders (depression and psychosocial 
stress) should be provided for people from key populations living with HIV in order to optimize 
health outcomes and improve their adherence to ART. Management can range from co-
counselling for HIV and depression to appropriate medical therapies. 
sexual and reproduCtIVe HealtH
16 Screening, diagnosis and treatment of sexually transmitted infections should be offered 
routinely as part of comprehensive HIV prevention and care for key populations. 
17 People from key populations, including those living with HIV, should be able to 
experience full, pleasurable sex lives and have access to a range of reproductive options.
18 Abortion laws and services should protect the health and human rights of all women, 
including those from key populations. 
19 It is important to offer cervical cancer screening to all women from key populations. 
20 It is important that all women from key populations have the same support and access to 
services related to conception and pregnancy care, as women from other groups. 
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CrItICal enablers
1 Laws, policies and practices should be reviewed and, where necessary, revised by policy-
makers and government leaders, with meaningful engagement of stakeholders from key 
population groups, to allow and support the implementation and scale-up of health-care 
services for key populations. 
2 Countries should work towards implementing and enforcing antidiscrimination and 
protective laws, derived from human rights standards, to eliminate stigma, discrimination and 
violence against people from key populations. 
3 Health services should be made available, accessible and acceptable to key populations, 
based on the principles of medical ethics, avoidance of stigma, non-discrimination and the right 
to health. 
4 Programmes should work toward implementing a package of interventions to enhance 
community empowerment among key populations. 
5 Violence against people from key populations should be prevented and addressed in 
partnership with key population-led organizations. All violence against people from key 
populations should be monitored and reported, and redress mechanisms should be established 
to provide justice. 
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1 IntroductIon
1.1 key populations and vulnerable groups
Key populations. The risk behaviours and vulnerabilities of specific populations and their 
networks determine the dynamics of HIV epidemics. These guidelines focus on five key 
population groups, which in almost all settings are disproportionately affected by HIV: 
•	 men who have sex with men
•	 people in prisons and other closed settings1
•	 people who inject drugs
•	 sex workers and 
•	 transgender people. 
These disproportionate risks reflect both behaviour common among members of these 
populations and specific legal and social barriers that further increase their vulnerability. 
Key populations influence epidemic dynamics and play a key role in determining the 
nature and effectiveness of the response to HIV. People living with HIV are central to 
the response to HIV and, therefore, are also often considered as a key population. This 
document, however, does not discuss all people living with HIV as a separate population.
In most countries inadequate coverage and poor quality of services for key populations 
continue to undermine responses to HIV. All countries should consider the importance 
of reaching these key populations, understanding their needs and providing equitable, 
accessible and acceptable services. To accomplish this, it is essential to work with key 
population groups and networks as partners in developing and providing services (1). 
Vulnerable groups. In certain contexts other groups also are particularly vulnerable 
to HIV infection, for example, migrant workers, refugees, long-distance truck drivers, 
military personnel, miners, and, in southern Africa, young women. These populations 
are not uniformly vulnerable or equally affected across different countries and epidemic 
settings. Countries should also identify these additional populations specific to their 
settings and focus attention and develop and tailor services accordingly. 
A focus on key populations. Overall, countries should prioritize their HIV responses 
to focus on the populations that are most vulnerable, experience the greatest 
burden of HIV and are currently underserved. These populations will include both 
specific vulnerable populations and, in all settings, key populations. These guidelines 
provide recommendations for the five key populations listed above (both adults and 
adolescents), while recognizing that countries will need to tailor their response to the 
1 UNAIDS currently defines ”key populations” as men who have sex with men, sex workers, persons who inject drugs and transgender 
people, but recognizes that prisoners, too, are particularly vulnerable to HIV and frequently lack adequate access to services.
Without addressing the needs 
of key populations, a sustainable 
response to HIV will not be 
achieved.
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size of these populations and also address the needs of vulnerable populations (see 
box). Detailed guidance on treatment and care of people living with HIV is provided 
in the WHO Consolidated guidelines on the use of antiretroviral drugs for treating and 
preventing HIV infection (2).
Without addressing the needs of key populations, a sustainable HIV response will not 
be achieved. To date, however, in most countries with generalized HIV epidemics, the 
response has focused almost exclusively on the general population. Even countries 
recognizing that HIV epidemics are concentrated in key populations often are reluctant 
to implement adequate interventions that reach those most in need. 
An effective response requires more than supporting services and programmes for key 
populations; it also requires systemic and environmental changes that only concerted 
action can bring about. For members of both key populations and vulnerable groups, 
many factors that influence a person’s risk are largely outside that person’s control. 
Particularly for key populations, social, legal, structural and other contextual factors 
both increase vulnerability to HIV and obstruct access to HIV services. Such factors 
include punitive legislation and policing practices, stigma and discrimination, poverty, 
violence and high levels of homelessness in some sub-populations. These factors affect 
how well individuals or populations can protect themselves from, and cope with, HIV 
infection; they can limit access to information, prevention services and commodities, 
and care and treatment. In addition, other health services specific to the needs of key 
populations are often scarce or non-existent – for example, gender affirming treatment 
for transgender people and harm reduction services for people who inject drugs. 
Geographic setting and social context also can affect a person’s vulnerability. 
Members of all key populations continue to experience intense stigma and 
discrimination, legal barriers and constraints to accessing services and often low 
prioritization by the public health system, including ministries of health. In many settings 
rationale for consolidated guidelines on key populations
World Health Organization (WHO) guidance exists on each of the five key 
populations, but it has not adequately addressed issues common to all these 
key populations nor has it addressed countries’ needs for a coherent approach 
informed by situational analysis. This document seeks to bring together WHO and 
UN partners’ guidelines on the five key population groups into one document. This 
document also makes reference to WHO tools and other documents on programme 
activities relevant to the health of key populations, such as strategic information/
monitoring and evaluation for key populations, along with publications from 
United Nations partners and new material to fill identified gaps. 
These guidelines consider the elements common to all key populations as well as 
highlighting specific issues and risks unique to each group. This approach is meant 
to help countries to plan, develop and monitor, more effectively and efficiently, 
acceptable and appropriate programmes for key populations relevant to their 
particular epidemiological context. The guidelines discuss implementation issues 
that services must address to achieve equity and maximize impact.
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community-based organizations provide important services for key populations. Better 
partnerships and linkages between community organizations and ministries of health 
are crucial. Equitable access to, and provision of, HIV and related health services to key 
populations are a high priority, requiring adequate domestic and external funding. 
1.2 HIV in key populations 
There is a clear epidemiological rationale for HIV 
programmes to focus on key population groups. In 
many settings HIV incidence in the general population 
has stabilized or fallen. However, globally, key 
populations continue to experience significant HIV 
burden, and they influence the dynamics of HIV 
epidemics. 
In general, health data, including HIV prevalence data, are less robust for key 
populations than for general populations due to complexities in sampling (and lack 
of size estimation data), legal concerns and issues of stigma and discrimination. Laws 
criminalizing the behaviour of key populations make it difficult to collect representative 
data. Under such circumstances people are reluctant to be counted as members of these 
populations.
1.2.1 men who have sex with men
Epidemics of HIV in men who have sex with men continue to expand in most countries. 
In major urban areas HIV prevalence among men who have sex with men is on average 
13 times greater than in the general population (3). One reason for the high HIV 
prevalence among men who have sex with men may be that HIV transmission through 
anal intercourse without a condom is more efficient than through vaginal intercourse 
without a condom, and individual-level risks for HIV acquisition among men who have 
sex with men include unprotected receptive anal intercourse, high number of male 
partners, and concomitant injecting drug use (4, 5, 6). 
By region, estimates of HIV prevalence among men 
who have sex with men range from 3.0% in the Middle 
East and North Africa to 25.4% in the Caribbean (4). 
In Kenya, the only African country with HIV incidence 
data, an annual incidence of greater than 20% was 
reported recently in Mombasa (4). Other countries in Africa report high prevalence, for 
example, Côte d’Ivoire, where the prevalence of HIV among men who have sex with men 
has been estimated at 18% (7, 8). In other regions where HIV incidence among men who 
have sex with men is reported or modelled, there is no evidence of decrease. In fact, for 
example, China and Thailand report increasing incidence. 
Discriminatory legislation, stigma (including by health workers) and homophobic 
violence in many countries pose major barriers to providing HIV services for men 
who have sex with men and limit their use of what services do exist. Many countries 
criminalize sex with the same gender (either male–male only or both male–male 
and female–female). As of December 2011 same-sex practices were criminalized in 
Key populations experience 
significant HIV burden, and 
they influence the dynamics 
of HIV epidemics.
Globally, epidemics of HIV in 
men who have sex with men 
continue to expand.
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38 of 53 countries in Africa (9). In the Americas, Asia, Africa and the Middle East, 
83 countries have laws that make sex between men illegal (10). The range of legal 
sanctions and the extent to which criminal law is enforced differs among countries (11).
1.2.2 people in prisons and other closed settings 
There are more than 10 million men and women in prisons and other closed settings, 
with an annual turnover of around 30 million moving between prison and the community 
(17). Globally, the prevalence of HIV, sexually transmitted infections, hepatitis B and C 
and tuberculosis in prison populations is estimated to be twice to ten times higher than 
in the general population (18). Higher HIV prevalence and HIV risk are seen among both 
prisoners and those working in prisons and their families in many settings (19). 
In addition to HIV risk behaviours in prison (unsafe sexual activities, injecting drug 
use and tattooing), factors related to the prison infrastructure, prison management 
and the criminal justice system contribute to increased risk of HIV, hepatitis B and 
C and tuberculosis in prisons (20). Due to the conditions of imprisonment, including 
overcrowding, sexual violence, drug use and lack of access to HIV prevention 
commodities such as condoms and lubricants, transmission risk is very high (18). 
In some settings HIV prevalence rates are higher among women in prisons than among 
men and much higher than among women in the general population. For example, 
in Moldova in 2005, HIV prevalence among female prisoners was 9.6% compared 
with male prisoners at 1.5–5% and women in the general populations at <0.5% (21). 
In Canada in 2002 HIV prevalence was reported at 3.71% among female prisoners 
compared with 1.96% among male prisoners and <0.5% among women in the general 
population (22). 
1.2.3 people who inject drugs
Worldwide, 158 countries have reported injecting drug use, and 123 of these countries 
(78%) have reported HIV among people who inject drugs (12, 13). Prevalence data on 
the extent of injecting drug use is not available for almost half of these countries, in 
particular in Africa, the Middle East and Latin America. The United Nations Office on 
Drugs and Crime (UNODC) jointly with WHO, UNAIDS and the World Bank estimated 
that in 2012 worldwide about 12.7 million (range: 8.9 million–22.4 million) people had 
recently injected drugs and that, of these, 1.7 million (range: 0.9 million–4.8 million) 
people (13.1%) were living with HIV. 
Rates of HIV infection are high among people who inject drugs. For example, in Pakistan 
HIV prevalence among people who inject drugs is estimated at 37.8%, based on 2011 
surveillance data, almost quadruple the rate in 2005 (15). In Indonesia HIV prevalence 
among people who inject drugs is estimated to be 36.4% (compared with 0.4% in the 
general population ages 15–49 years); in Ukraine at least 20% (compared with 0.9%), 
and in Myanmar 18% (compared with 0.6%) (16). Based on data from 49 countries, the 
risk of HIV infection averaged 22 times greater among people who inject drugs than 
among the general population. In 11 of these countries the risk was at least 50 times 
higher. In Eastern Europe an estimated 40% of new HIV infections occur among people 
who inject drugs and their sexual partners (3). 
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Because of the illegality of sex work, drug use, and same-sex behaviour in many 
countries, many people from various key populations are incarcerated at some point in 
their lives. Since being held in detention is itself a risk factor for HIV, it further increases 
HIV risk for people from other key populations. Settings with forced gender segregation 
(e.g. prisons) are important contexts for male-to-male sexual activity not linked to 
homosexual identity. 
Access to HIV testing and counselling and to HIV prevention, treatment, and care 
programmes is often poor in prisons and other closed settings. Few countries implement 
comprehensive HIV programmes in prisons (18). Not only are such services needed in 
prison and other closed settings, but also they need linkages to HIV services in the 
community to maintain continuity after a person is released.
1.2.4 sex workers
Globally, the average HIV prevalence among sex workers is estimated to be 
approximately 12%. There is large variation within regions in HIV prevalence and odds 
ratios for HIV infection. In 26 countries with medium and high HIV prevalence in the 
general population, 30.7% of sex workers were HIV-positive (3, 23). For example, HIV 
prevalence among sex workers in Nigeria was estimated at 24.5% (compared with 3.7% 
among the general population ages 15–49 years), in Latvia at 22.2% (compared with 
0.7% in the general population), and in Rwanda at 50.8% (compared with 2.9% in the 
general population) (3). 
Sex workers are at an increased risk due to exposure to multiple sexual partners and, 
sometimes, inconsistent condom use, often due to clients’ unwillingness or coercion. 
Legal issues, stigma, discrimination and violence pose barriers to HIV services for sex 
workers.
1.2.5 transgender people
A meta-analysis published in 2013 highlighted the particular vulnerability to HIV of 
transgender women. Data were available only for countries with male-predominant 
HIV epidemics, which included the United States of America, six Asia–Pacific countries, 
five in Latin America, and three in Europe. The pooled HIV prevalence was 19.1%. 
Among 7197 transgender women sampled in 10 low- and middle-income countries, HIV 
prevalence was 17.7%. Among 3869 transgender women sampled in five high-income 
countries, HIV prevalence was 21.6% (24). 
1.2.6 overlapping vulnerabilities and differing risks
Many people from key populations engage in more than one high-risk behaviour (e.g. 
injecting drugs and sex work, or a man who has sex with other men who also injects 
drugs). Thus, they are likely to have higher HIV prevalence rates than those with only 
one type of risk. 
Subgroups of key populations may have especially high risk for HIV infection (25, 26). 
For example, a cross-sectional study of 1999 female sex workers in Viet Nam found that 
HIV prevalence was significantly greater among street-based sex workers than among 
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sex workers in entertainment establishments (3.8% versus 1.8%, p = 0.02) (27). The 
subgroups with higher risk for HIV are not efficiently covered by current surveillance or 
intervention programmes. 
1.2.7 adolescents and young people from key populations 
Adolescents and young people from key populations are at significant HIV risk, higher 
than that of their older peers in these populations. Studies are limited, but they 
consistently show that adolescents and young people from key populations are even 
more vulnerable than older cohorts to STIs, HIV and other sexual and reproductive 
health problems (28). Rapid physical, emotional and mental development, complex 
psychosocial and socio-economic factors and poor access to and uptake of services 
increase their vulnerability and risk (29). Particularly for those under age 18 years, policy 
and legal barriers related to age of consent often prevent access to a range of health 
services, including HIV testing and counselling (HTC), harm reduction and other services 
provided specifically for key populations (30). Such barriers also limit adolescents’ ability 
to exercise their right to informed and independent decision-making. 
Adolescents from key populations may face stigma, discrimination and violence even 
greater than that faced by older people from key populations. Fearing discrimination 
and/or possible legal consequences, many adolescents from key populations are 
reluctant to attend diagnostic and treatment services. Consequently, they remain hidden 
from many essential health interventions, further perpetuating their exclusion (31). 
Reliable and representative epidemiological and behavioural data on adolescents and 
young people from key population groups remain limited (32). Young people remain 
largely invisible in routine HIV surveillance 
and in research on HIV prevalence and risk. 
This lack of data often leads to neglect 
of their specific needs by policies and 
programmes designed for youth generally 
and by services for adults from key 
populations (32).1 
1.3 addressing key populations: a wise investment 
The recent move toward more strategic use of HIV resources (33) draws attention to 
the value of addressing HIV in key populations. In both concentrated and generalized 
epidemics, greater investment in a country’s key populations is likely to improve the 
cost-effectiveness of the response to HIV.
To date, investments in most countries have focused on the general population. In 
concentrated epidemics, however, almost by definition the great majority of infections 
are in key populations and, sometimes, specific vulnerable groups. Even in generalized 
1 WHO, the Joint United Nations Programme on HIV/AIDS (UNAIDS), the United Nations Population Fund (UNFPA), the United Nations 
Children’s Fund (UNICEF), the United Nations Development Programme (UNDP), the United Nations Office on Drugs and Crime (UNODC) 
and key community networks have developed four technical briefs on young people from key populations. These policy briefs are based 
on reviews of epidemiological data, the literature on service delivery, a policy analysis, and qualitative research on the values and 
preferences of young people from key populations. These guidelines include key messages from this work. The technical briefs are 
available in Web Annex 6.
The specific needs of young people from 
key populations are neglected both by 
programmes designed for youth generally 
and by programmes for adults from key 
populations.
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epidemics key populations often account for a large share of HIV prevalence, and 
incidence in certain key populations often has continued to rise even when rates in the 
general population have stabilized or declined. 
Estimates by the Joint United Nations Programme on HIV/AIDS (UNAIDS) suggest 
that as many as 50% of all new HIV infections worldwide occur in people from key 
populations.1 In countries in Asia and Eastern Europe and Central Asia, people from 
key populations account for more than half of new infections – from 53% to 62%. Even 
in the sub-Saharan African countries with generalized epidemics that have carried out 
modes of transmission (MOT) analyses, 
the proportion of new infections in key 
populations is substantial, although it 
varies greatly – for example, an estimated 
10% in Uganda, 30% in Burkina Faso, 
34% in Kenya, 37% in Nigeria, 43% in 
Ghana and 45% in Benin.
1.3.1 key to the dynamics of epidemics
Another reason that investment in key populations is cost-effective is the central role 
of key populations in the dynamics of epidemics. People from key populations can also 
transmit HIV to other populations – for example, sex workers’ clients and the sexual 
partners of people who inject drugs. Thus, infections in people from key populations can 
have a multiplier effect. 
In an analysis of six countries in West Africa, for example, the proportion of new infections 
occurring in the sexual partners of people considered at “higher-risk” ranged from 20% in 
Burkina Faso and Nigeria to around 30% in Benin, Côte d’Ivoire, and Ghana and possibly 
as high as 49% in Senegal (34). Meanwhile, the proportion of HIV prevention expenditures 
devoted specifically to programmes for sex workers, their clients, men who have sex with 
men and people who inject drugs was 1.7% in Burkina Faso, 0.4% in Côte d’Ivoire and 
0.24% in Ghana, whereas the percentage of new infections estimated to occur in these 
population groups was 30%, 28% and 43%, respectively (35). 
1.3.2 expanding coverage can make a difference
Projections suggest that the impacts 
of improved service coverage of key 
populations could range from averting a 
considerable number of new infections 
in countries with generalized epidemics 
to stabilizing or even turning around 
growing incidence rates in countries with 
concentrated epidemics. 
For example, in Asia HIV transmission occurs primarily through unprotected commercial 
sex, injecting drug use, and unprotected sex between men. Increasing condom use 
by sex workers and their clients, due to effective condom promotion, is credited with 
1 UNAIDS 2013 unpublished Spectrum estimates.
For a country the impact of improved 
coverage for key populations could range 
from averting a considerable number of 
new infections to stabilizing or even turning 
around growing overall incidence rates.
Estimates by the Joint United Nations 
Programme on HIV/AIDS (UNAIDS) suggest 
that as many as 50% of all new HIV 
infections worldwide occur in people 
from key populations.
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reversing the rising trend in prevalence in the mid-1990s. In recent years, however, 
annual incidence rates have changed little. Without further and well-focused investment, 
prevalence may start rising again (36). According to a 2008 estimate, an expanded 
programme of HIV interventions focused on these higher-risk behaviours would avert 
five million new infections between 2007 and 2020 – a number about equal to the 
number living with HIV in the region in 2007. In addition, the number of HIV-related 
deaths would decrease by 40%, and in 2020 there would be 3.1 million fewer people 
living with HIV (37). 
In 2011 the World Bank projected that, if Peru did not increase the coverage of 
programming for men who have sex with men, the number of new infections per year 
in the general population would grow from about 14 000 in 2008 to about 20 000 in 
2015. In contrast, expanding coverage of programmes specifically for men who have sex 
with men would at least stabilize the number of new infections per year in the general 
population or even start to decrease it. 
Similarly, in Thailand full programme coverage for men who have sex with men would 
decrease the annual number of new infections in the general population from 22 500 in 
2008 to 20 000 in 2015; otherwise, the number would rise to 27 200 (38). 
1.4 scope of these key population guidelines
These guidelines outline a public health response to HIV for the five key populations. 
They present and discuss new recommendations and a range of recommendations and 
guidance from current WHO guidelines, including the 2013 Consolidated guidelines 
on the use of antiretroviral drugs for treating and preventing HIV infection (2). They 
summarize the components of a comprehensive package of interventions for key 
populations and consider implementation issues, challenges, and opportunities. The 
guidelines also provide help on prioritizing and planning services.
A number of case studies appear in Chapters 5 and 6. They include considerations for 
each key population group, describing a diversity of interventions and service delivery 
approaches across a range of country and regional programme experiences. 
1.5 using these guidelines
As in the consolidated ARV guidelines, these guidelines consider the need to support 
services across the cascade of HIV prevention, diagnosis, care and treatment (Fig. 1.1). 
symbols used throughout the document:
overarching WHO recommendations are in line with existing WHO 
recommendations and are shaded in blue (see below), and the source of the 
recommendation is provided for further reference,
new WHO recommendations developed specifically for this guidance,
recommendations under development – key clinical areas where WHO is 
developing guidelines. 
PIPELINE
NEW
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Within these guidelines the heading “Good practice recommendations” indicates 
recommendations that may be helpful but do not need grading and are those in which 
it is sufficiently obvious that desirable effects outweigh undesirable effects. They often 
pertain to human rights principles reflected in a number of international agreements and 
to issues of equity and ethics.
colour coding in this document:
All key population groups
Men who have sex with men
People in prisons and other closed settings
People who inject drugs
Sex workers
Transgender people
Adolescents from key populations
fig. 1.1 cascade of HIV prevention, diagnosis, care and treatment
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The background documents developed to support these guidelines include studies of the 
values and preferences of key populations and service providers. The systematic reviews 
and GRADE (Grading of Recommendations, Assessment, Development and Evaluation) 
tables for new recommendations appear in full in Web Annexes 1 and 2. 
1.6 goal and objectives
These guidelines seek to provide consolidated guidance to inform the development and 
implementation of HIV policies, programmes and services for key populations. 
The guidelines have the following specific objectives:
•	 consolidate guidance for health sector interventions for HIV for each key 
population;
•	 outline common HIV and related health service packages that are beneficial 
and acceptable for all key populations and additional services needed for specific key 
population groups;
•	 update guidance for planning, delivering, monitoring and evaluating HIV prevention, 
diagnosis, care and treatment interventions for each key population;
•	 provide gender- and age-specific guidance for HIV interventions for members of 
key populations, including adolescents.
1.7 target audience
These guidelines are addressed primarily to national HIV programme managers and 
other decision-makers within ministries of health and those responsible for health 
policies, programmes and services in prisons. In addition, the guidelines will be relevant 
for managers at national and sub-national levels responsible for services for TB, viral 
hepatitis, sexual and reproductive health, harm reduction and drug dependence, and 
mental health; community-led civil society organizations and implementing programmes; 
and development and funding agencies.
1.8 guidelines principles
The framework for the development of these guidelines is based on human rights 
principles reflected in a number of international agreements (39, 40). 
•	 Human rights: Fundamental to development of 
these guidelines is the protection of human rights 
for all members of each key population. Legislators 
and other government authorities should establish 
and enforce antidiscrimination and protective laws, 
derived from international human rights standards, 
in order to eliminate stigma, discrimination and 
violence faced by key populations and to reduce 
their vulnerability to HIV (40).
Guiding principles 
•	 human	rights
•	 access	to	quality	health	care
•	 access	to	justice
•	 acceptability	of	services
•	 health	literacy
•	 integrated	service	provision.
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•	 Access to quality health care is a human right. It includes the right of members 
of key populations to appropriate quality health care without discrimination. Health-
care providers and institutions must serve people from key populations based on 
the principles of medical ethics and the right to health (18). Health services should 
be accessible to key populations. This guidance can be effective only when services 
are acceptable and high quality and widely implemented. Poor quality and restricted 
access to services will limit the individual benefit and public health impact of the 
recommendations.
•	 Access to justice is a major priority for people from key populations, due to high 
rates of contact with law enforcement services and the current illegality of their 
behaviours in many countries. Access to justice includes freedom from arbitrary arrest 
and detention, the right to a fair trial, freedom from torture and cruel, inhuman and 
degrading treatment and the right, including in prisons and other closed settings, 
to the highest attainable standard of health (41). The protection of human rights, 
including the rights to employment, housing and health care, for people from key 
populations requires collaboration between health-care and law enforcement 
agencies, including those that manage prisons and other closed institutions. 
Detainment in closed settings should not impede the right to maintain dignity and 
health (18). 
•	 Acceptability of services is a key aspect of effectiveness. Interventions to 
reduce the burden of HIV among people from key populations must be respectful, 
acceptable, appropriate and affordable to recipients in order to enlist their 
participation and ensure their retention in care. Services for members of key 
populations often employ appropriate models of service delivery but lack expertise in 
HIV. Conversely, people from key populations may not find specialized HIV services 
acceptable. There is a need to build service capacity on both fronts. Consultation with 
organizations of people from key populations and including peer workers in service 
delivery are effective ways to work towards this goal (42). Mechanism of regular and 
ongoing feedback from beneficiaries to service providers will help inform and improve 
the acceptability of services to key populations.
•	 Health literacy: People from key populations often lack sufficient health and 
treatment literacy. This may hinder their decision-making on HIV risk behaviours and 
their health-seeking behaviour. Health services should regularly and routinely provide 
accurate health and treatment information to members of key populations. At the 
same time health services should strengthen providers’ ability to prevent and to treat 
HIV in people from key populations, including adolescents (42).
•	 Integrated service provision: People from key populations commonly have 
multiple co-morbidities and poor social situations. For example, HIV, viral hepatitis, 
tuberculosis, other infectious diseases and mental health conditions are common 
in key populations. Integrated services provide the opportunity for patient-centred 
prevention, care and treatment for the multitude of issues affecting key populations. 
In addition, integrated services facilitate better communication and care. Thus, 
wherever feasible, service delivery for key populations should be integrated. When 
this is not possible, strong links among health services working with key populations 
should be established and maintained (43).
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2 metHodology and process for 
deVelopment of tHe guIdelInes
2.1 overview
The WHO Department of HIV led development of these WHO consolidated key 
populations guidelines, following the WHO procedures and reporting standards laid out 
in the WHO handbook for guideline development, 2012 (1).
These guidelines combine existing WHO recommendations, new recommendations and 
guidance published by WHO together with UN partners. Key recommendations from the 
WHO 2013 Consolidated guidelines on the use of antiretroviral drugs for treating and 
preventing HIV infection (2) are included, with specific considerations for each of the key 
population groups highlighted.  
2.2 establishing guideline groups
The WHO HIV Department set up four groups to perform specific guideline development 
functions. Members of the groups were selected so as to ensure a range of expertise 
and experience, including appropriate geographical, gender and key population 
representation and expertise. The four groups and their functions were:
The WHO Guideline Steering Group on HIV and Key Populations, chaired 
by the WHO Department of HIV, led the guideline development process. It 
included participants from the WHO Department of Maternal, Newborn, Child 
and Adolescent Heath, the Department of Mental Health and Substance Abuse, 
the Department of Reproductive Health and Research, the Global Hepatitis 
Programme, and the Global TB Programme. 
The External Steering Group, composed of a geographically and gender-
balanced group of 25 academics, researchers, programme managers, 
implementers and people from key population networks and organizations, 
provided WHO with guidance on scope, content and new areas to be addressed. 
The 26-member Guidelines Development Group consisted of the majority 
of the External Steering Group along with some additional expert members. 
This group was responsible for formulating new WHO recommendations, good 
practice guidance and consensus on the final content. 
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Involvement of key population groups and networks
Crucial to development of these guidelines has been the partnership with, and the 
engagement of, key population groups and networks at all stages of the process, both 
as members of the guidelines and peer review groups and as partners in developing the 
values and preferences investigation methodology and assessment, as described below. 
conflicts of interest
All External Steering Group participants, Guidelines Development Group participants and 
External Peer Review Group members submitted Declarations of Interest (DOI) to the 
WHO secretariat. The WHO secretariat and the Guidelines Development Group reviewed 
all declarations and found no conflicts of interest sufficient to preclude anyone from 
participating in the development of the guidelines. A full compilation of the declarations 
is available on request.
2.3 defining the scope of the guidelines
To develop these guidelines, the WHO Guideline Steering Group mapped all existing 
WHO HIV guidance specifically concerned with the five key population groups; then 
it reviewed these and other materials to identify gaps, overlaps, inconsistencies and 
determine relevance. The outcome of the mapping exercise was presented to the 
External Steering Group at a scoping meeting in October 2013. The group reviewed 
the mapping and made recommendations on the scope of the guidelines (populations 
and range of interventions to be covered) and noted two areas needing new guidance: 
1) pre-exposure prophylaxis (PrEP) and 2) opioid overdose prevention and 
management. 
other guidelines under development 
The Department of HIV and other WHO departments currently are developing or 
updating a number of guidelines relevant to key populations. These include: 
•	 hepatitis C treatment (completed by the global hepatitis team during the 
development of these guidelines and included here) and hepatitis B treatment and 
hepatitis B and C screening (to be completed during 2014–15);
•	 contraception and HIV guidance (completed by the Department of Reproductive 
Health and Research and included here); 
•	 post-exposure prophylaxis (PEP) guidance (to be completed by late 2014 by the 
HIV Department and to be included in an updated version of this guidance);
The External Peer Review Group was selected in consultation with the WHO 
regional offices to assure geographical and gender balance. In total 73 peer 
reviewers from academia, policy and research, implementing programmes and 
key population networks and organizations reviewed the guidelines. In general, 
reviewers made suggestions to improve the clarity of the document and provided 
minor additions and corrections to the narrative.
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•	 STI guidance (to be completed by early 2015 by the Department of Reproductive 
Health and Research and to be included in an updated version of this guidance).
audience 
The External Steering Group identified the audience for these guidelines. Health services 
in low-resource settings will benefit most from the guidance presented here, as they 
face the greatest challenges in providing services tailored to key populations. However, 
these guidelines are relevant for all HIV epidemic and economic settings and are, 
therefore, considered global guidance. Regions and countries can adapt these global 
recommendations to local needs, HIV epidemic contexts and existing services in order to 
facilitate their implementation.
2.4 review of the evidence 
These guidelines include both relevant existing recommendations and new 
recommendations. Development of the new recommendations began with systematic 
reviews of the evidence. The Guidelines Development Group recommended the 
commissioning of new literature reviews and appraisal of existing reviews and surveys 
investigating values and preferences, along with reviews of the costs and feasibility of 
implementation. Also, WHO commissioned new studies and reviewed existing studies 
of values and preferences related to existing recommendations to help ensure that the 
guidance appropriately reflects the concerns of key populations. 
2.4.1 Information on prisons and other closed settings
In 2007 an extensive literature review was conducted to inform the development of 
the WHO publication Effectiveness of interventions to address HIV in prisons (3, 4). In 
2014 this work was updated for these guidelines, using an abbreviated literature review 
focusing on materials developed between 2007 and 2014. Results supported the 2007 
review; no new evidence was found that would change the recommendations made in 
the 2007 guidelines. The Guideline Development Group and United Nations Office on 
Drugs and Crime (UNODC) reviewed, confirmed and accepted this conclusion. The 2014 
review identified a need for further research in this area; Web Annex 4 includes potential 
research areas. 
2.5 development of the pre-exposure prophylaxis recommendations
To inform recommendations on PrEP, evidence questions were framed in the PICO 
format: Population, Intervention, Comparator, Outcome. External researchers used 
the PICO questions to develop search protocols and perform systematic reviews of the 
scientific evidence; Web Annexes 1 and 2 present details. 
WHO convened the guideline development meeting in March 2014 to update 
recommendations regarding PrEP use among men who have sex with men (5) and to look 
at the evidence for formulating a new recommendation on PrEP use among people who 
inject drugs, as well as to review all sections of the consolidated guidelines. Individuals 
representing a broad range of stakeholders participated in the guideline development 
meeting as either Guideline Development Group members or expert observers. 
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Participants at this meeting assessed the evidence for both PICO questions concerning 
PrEP, along with the risks and benefits, values and preferences and cost-benefits/
feasibility associated with each possible intervention and made recommendations (see 
Section 4.1.5.1).
2.6 evidence assessment 
Under the WHO guideline development process, the guideline development group 
formulates the recommendations guided by the quality of available evidence. Other 
factors – values and preferences, costs and feasibility – are also taken into consideration 
when determining the strength of the recommendation.
2.6.1 How to interpret the quality of evidence
The higher the quality of scientific evidence, the more likely that a strong 
recommendation can be made. The GRADE approach to recommendation development, 
which WHO has adopted, defines the quality of evidence as the extent to which one can 
be confident that the reported estimates of effect (desirable or undesirable) available 
from the evidence are close to the actual effects of interest (6, 7, 8). The GRADE 
approach specifies four levels of quality of evidence (9) (Table 2.1).
table 2.1 significance of the four grade levels of evidence
Quality of evidence Rationale
High Further research is very unlikely to change our confidence in the 
estimate of effect.
Moderate Further research is likely to have an important impact on our 
confidence in the effect.
Low Further research is very likely to have an important impact on the 
estimate of effect and is likely to change the estimate.
Very low Any estimate of effect is very uncertain.
2.6.2 determining the strength of a recommendation 
The strength of a recommendation reflects the degree of confidence of the guidelines 
group that the desirable effects of the recommendation outweigh the undesirable 
effects (Table 2.2). Desirable effects (potential benefits) may include beneficial 
health outcomes (e.g. reduced incidence of HIV and reduced morbidity and mortality); 
reduction of burden on the individual and/or health services; and potential cost-savings 
for the individual, communities, programme and/or health system. Undesirable effects 
(potential harms) include those affecting individuals, families, communities or health 
services. Additional burdens considered include the resource use and cost implications of 
implementing the recommendations that programmes, care providers or patients would 
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have to bear; adverse clinical outcomes (e.g. drug resistance, drug toxicities); and legal 
ramifications where certain practices are criminalized.
The strength of a recommendation can be either strong or conditional. 
A strong recommendation (for or against) is one for which there is confidence that the 
desirable effects of adherence to the recommendation clearly outweigh the undesirable 
effects.
A conditional recommendation (for or against) is one for which the quality of 
evidence may be low or may apply only to specific groups or settings; or the panel 
concludes that the desirable effects of adherence to the recommendation probably 
outweigh the undesirable effects or are closely balanced, but the panel is not confident 
about these trade-offs in all situations. 
If implemented, a conditional recommendation should be monitored closely and 
evaluated rigorously. Further research will be required to address the uncertainties 
and is likely to provide new evidence that may change the calculation of the balance of 
trade-offs. 
The values and preferences of the end users (key populations), feasibility and cost 
as well as consideration of potential benefits and harms contribute to determining the 
strength of a recommendation. 
table 2.2 domains considered when assessing the strength of 
recommendations
Domain Rationale
Benefits and risks When a new recommendation is developed, desirable effects 
(benefits) need to be weighed against undesirable effects (risks), 
considering any previous recommendation or another alternative. 
The larger the gap or gradient in favour of the benefits over the 
risks, the more likely that a strong recommendation will be made.
Values and preferences 
(acceptability)
If the recommendation is likely to be widely accepted or valued 
highly, it is likely that a strong recommendation will be made. 
If there is a great deal of variability or strong reasons that the 
recommended course of action is unlikely to be accepted, it is 
more likely that a conditional recommendation will be made.
Costs/financial 
implications
Lower costs (monetary, infrastructure, equipment or human 
resources) or greater cost-effectiveness are more likely to support 
a strong recommendation.
Feasibility If an intervention is achievable in a setting where the greatest 
impact is expected, a strong recommendation is appropriate.
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Surveys, qualitative studies and literature reviews were commissioned and other 
available material was appraised to investigate the values and preferences of key 
populations and service providers and benefits, harms, cost and feasibility concerning 
new areas of guidance, existing recommendations and service provision issues. Specific 
attention was paid to the values and preferences of adolescents in key populations.1 
Evidence on values and preferences included findings developed at workshops with 
members of key populations in a range of countries; a multi-regional, anonymous 
e-survey of men who have sex with men; in-depth key informant interviews with 
selected service providers and people who inject drugs; in-depth interviews with 
men who have sex with men; and a literature review of values and preference of key 
populations concerning PrEP. Web Annex 3 provides full reports and a table outlining the 
range of activities undertaken.
2.7 review of service delivery, implementation approaches and case 
studies 
A large-scale call for examples of good practices was undertaken to identify effective 
and acceptable delivery approaches for key populations. These case studies, presented 
in Chapters 5 and 6, offer insights into successful implementation of services for key 
population groups. Web Annex 5 presents more information on these case studies. 
2.8 producing the guidelines
Following the Guideline Development Group consultation, the full draft guidelines were 
revised and circulated electronically to both the Guidelines Development Group and the 
External Peer Review Group for comments and feedback. All responses were considered 
and, as appropriate, addressed in the final draft. 
2.9 plans for dissemination
The guidelines are being disseminated as a printed publication and electronically on the 
WHO web site including all Annexes. 
2.10 updating
The Department of HIV has committed to providing regular updates of consolidated 
key population guidelines when new or revised guidance becomes available, including 
relevant new guidance developed by other WHO departments.
1 WHO, UNAIDS, the United Nations Population Fund (UNFPA), the United Nations Children’s Fund (UNICEF), the United Nations 
Development Programme (UNDP) and UNODC have developed four technical briefs on young people from key populations. These policy 
briefs are based on reviews of epidemiological data, the literature on service delivery, a policy analysis, and qualitative research on the 
values and preferences of young people from key populations. These guidelines include key messages from this work. See Web Annex 6.
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3 compreHensIVe package of 
InterVentIons
3.1 services for all key populations
A combination of interventions is required to respond effectively to HIV among key 
populations. The following comprehensive package of interventions is recommended 
to assist countries with programming for HIV prevention and treatment among key 
populations. While Chapters 4 and 5 describe the interventions in much more detail, 
here we summarize the overarching headings. 
1 Needle and syringe programmes are important for people who inject drugs and also for transgender people who require sterile injecting 
equipment to safely inject hormones for gender affirmation. Other important areas include for tattooing, piercing and other forms of skin 
penetration, which are particularly relevant in prisons and other closed settings.
2 Including contraception, diagnosis and treatment of STIs, cervical screening, etc. (see Chapter 4).
the package has two parts:
a) Essential health sector interventions (see Chapter 4 for detail)
1. comprehensive condom and lubricant programming
2. harm reduction interventions for substance use, in particular needle 
and syringe programmes1 and opioid substitution therapy 
3. behavioural interventions
4. HIV testing and counselling
5. HIV treatment and care
6. prevention and management of co-infections and other co-
morbidities, including viral hepatitis, TB and mental health conditions 
7. sexual and reproductive health interventions.2  
b) Essential strategies for an enabling environment (see Chapter 5 for 
detail)
1. supportive legislation, policy and financial commitment, including 
decriminalization of behaviours of key populations 
2. addressing stigma and discrimination 
3. community empowerment
4. addressing violence against people from key populations.
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The interventions and strategies in this package 
are significantly interdependent. The health 
sector interventions yield the most benefit 
when they are available in combination and 
when the necessary enabling environmental 
factors are in place. These health sector interventions should not be delayed because the 
enabling environmental factors are missing. The presence of the enabling factors will 
greatly increase their impact, however. Thus, while the enabling factors may be largely 
outside the control of the health sector, it is important for the health sector to address 
them jointly with other sectors. 
In addition to the interventions listed, people from key populations need access to 
general medical, social welfare and legal services so that they can attain the highest 
possible standards of health and well-being.
3.2 specific considerations
The comprehensive package outlined above is relevant for all people in key populations. 
Additional elements for specific key populations are summarized below and detailed in 
Chapters 4 and 5.
3.2.1 prisons and other closed settings 
The services for prevention and treatment of HIV in the community should also be 
provided to people in prison and other closed settings. The proven efficacy of these 
interventions in the community will not change when they are delivered in prisons and 
other closed settings. However, there may be some specific considerations as to how 
best to deliver these services in prisons and other closed settings to maximize their 
effectiveness. To improve the equity of health care in these settings, consideration 
should be given to assigning responsibility for prison health to the ministry of health 
rather than the ministry of justice or interior (3).
In 2013 UNODC and partners agreed on a comprehensive package for effective HIV 
prevention and treatment in prisons and other closed settings. In addition to the 
recommended interventions for people in the community, interventions relevant to 
closed settings include: 
•	 prevention of HIV transmission through medical and dental services
•	 prevention of transmission of HIV and other bloodborne diseases through tattooing, 
piercing and other forms of skin penetration
•	 protecting staff from occupational hazards.
Some other interventions are important and should not be overlooked, such as the 
distribution of toothbrushes and shavers in basic hygiene kits, adequate nutrition, 
intimate visit programmes, palliative care and compassionate release for terminal 
cases (4).
The interventions and strategies 
included in this package are 
significantly interdependent.
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3.2.2 people who inject drugs
This package is essentially the same as the comprehensive package for HIV prevention, 
treatment and care for people who inject drugs that has been widely endorsed at the 
highest political level and by major donor agencies (1, 2). While the harm reduction 
interventions for substance use are part of this overall comprehensive package for key 
populations, it is important that countries where injecting drug use occurs prioritize 
immediate implementation of needle and syringe programmes and opioid 
substitution therapy (NSPs and OST). Implementation of these essential harm 
reduction services should facilitate and enhance access to HIV-specific services, such 
as HIV testing and counselling and antiretroviral therapy, and improve adherence to 
treatment. Harm reduction interventions for people who use drugs but who do not inject 
are also important. They should include evidence-based drug dependence treatment and 
provision of non-injecting drug use paraphernalia as appropriate to the local context and 
patterns of drug use.
3.2.3 adolescents from key populations
The comprehensive package of interventions is also relevant for adolescents from key 
populations. Programming for adolescents should also include:
•	 HPV vaccination as part of national HPV programmes. 
Countries are encouraged to:
•	 examine their current consent policies and consider revising them to reduce age-
related barriers to access and uptake of HIV services.
Critical knowledge gaps remain, however, concerning how best to implement 
programmes that address adolescents’ immediate needs (5). However, it is essential 
that services are designed and delivered in a way that takes into account the multiple, 
overlapping vulnerabilities that confront adolescents from key populations, and their 
different needs based on their age, specific behaviours, the complexities of their social 
and legal environment and the epidemic setting.
4
HealtH sector InterVentIons
4.1 Prevention 26
4.1.1 Comprehensive condom and lubricant programming 26
4.1.2 Harm reduction for people who inject drugs 29
4.1.3 Behavioural interventions 40
4.1.4 Prevention of transmission in health-care settings 43
4.1.5 ARV-related prevention 44
4.1.6 Voluntary medical male circumcision for HIV prevention 54
4.2 HIV testing and counselling 56
4.3 Linkage and enrolment in care 60
4.4 HIV treatment and care 60
4.4.1 Antiretroviral therapy 60
4.4.2 Prevention of mother-to-child transmission 63
4.4.3 ART drug interactions 66
4.5 Prevention and management of coinfections and co-morbidities 68
4.5.1 Tuberculosis 68
4.5.2 Viral hepatitis 72
4.5.3 Mental health 76
4.6 General care 78
4.6.1 Nutrition 78
4.6.2 Sexual and reproductive health interventions 78
26 Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations
4 HealtH sector InVerVentIons
4.1 prevention
4.1.1 comprehensive condom and lubricant programming
Background and rationale
Increasing the availability, accessibility, affordability and use of male and female 
condoms and condom-compatible lubricants among people from key populations 
through targeted distribution programmes is an essential component of the HIV 
response. 
Consistent and correct use of male condoms 
reduces sexual transmission of HIV and 
other STIs in both vaginal and anal sex by 
up to 94%. Use of water- or silicone-based 
lubricants (as opposed to petroleum-based) 
helps to prevent condoms from breaking and slipping (1, 2, 3, 4). While fewer data 
are available on female condoms, evidence suggests that use of female condoms also 
prevents HIV and STIs (4). 
Effective condom programming is particularly important for key populations. 
Unprotected sex and other high-risk behaviours such as substance use often coincide for 
key populations, in particular adolescents from key populations (5, 6, 7). 
recommendations and guidance
ALL KEY POPULATION GROUPS
The correct and consistent use of condoms with condom-compatible lubricants is 
recommended for all key populations to prevent sexual transmission of HIV and STIs 
(strong recommendation, moderate quality of evidence) (3, 8, 9, 10).  
related recommendations and contextual issues for specific key population groups
MEN WHO HAVE SEx WITH MEN
•	 Condoms and condom-compatible lubricants are recommended for anal sex (3). 
•	 Adequate provision of lubricants needs to be emphasized. 
Consistent and correct use of male 
condoms reduces sexual transmission 
of HIV and other STIs by up to 94%.
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PEOPLE IN PRISONS AND OTHER CLOSED SETTINGS 
Sexual activity takes place in prisons and other closed settings, but generally access 
to condoms there is limited. It is important to introduce, and expand to scale, 
condom and lubricant distribution programmes in prisons and other closed settings, 
without quantity restriction, with anonymity and in an easily accessible manner (e.g. 
condom vending machines) (9, 11). 
PEOPLE WHO INJECT DRUGS 
•	 Condom programming is an essential component of the comprehensive harm 
reduction package for people who inject drugs and their sexual partners (8). 
•	 Sexual transmission of HIV is often overlooked in people who inject drugs. 
However, there is significant HIV transmission to non-injecting sexual partners. 
Furthermore, stimulant use, through both injecting and non-injecting routes, is 
often associated with unsafe sexual behaviours (8, 12, 13). 
SEx WORKERS (AND CLIENTS OF SEx WORKERS)
•	 Correct and consistent use of condoms and condom-compatible lubricants is 
recommended for sex workers and their clients (10). 
•	 Sex workers, female or male, often face power imbalances that limit their 
ability to use condoms with clients. (See Chapter 5 on critical enablers.) Female 
sex workers who inject drugs may be particularly vulnerable to these power 
imbalances. The female condom has the advantages over the male condom 
that the woman can initiate its use and it can be inserted up to several hours 
before intercourse (14). Peer-led and outreach approaches may help to increase 
knowledge, develop skills and empower sex workers to use condoms and 
lubricants consistently.
TRANSGENDER PEOPLE
•	 Condoms and condom-compatible lubricants are recommended for anal sex (3).
•	 Adequate provision of lubricants for transgender women and transgender men 
who have sex with men needs emphasis. 
ADOLESCENTS FROM KEY POPULATIONS 
Adolescents’ emotional, intellectual and social capacities are continuously evolving. 
Young people from key populations, perhaps more so than their peers in the general 
population, experience power imbalances in sexual relationships that limit their 
ability to use condoms (5, 15, 16). Peer-led and outreach approaches may help to 
distribute condoms and lubricants, increase knowledge, develop skills and empower 
adolescents from key populations to use condoms and lubricants correctly and 
consistently (17). 
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Implementation considerations 
Legislation and law enforcement approaches need to support condom 
programming. Possession of condoms should not be used as evidence of criminal 
activity, and police should not harass those carrying condoms (10).
Promote access. While condoms and lubricants may be widely sold in most countries, 
providing condoms with lubricants free to key populations removes any barrier that cost 
may pose (17, 18). Condoms, both male and female condoms in various sizes, should 
be available through multiple outlets that reach all the different key populations and 
particularly young people in these populations. Condom promotion campaigns should 
increase awareness, promote the acceptability and benefits of condom use and help to 
overcome social and personal obstacles to their use (10). 
Lubricant. Condom-compatible lubricant should always be distributed along with male 
and female condoms. Lubricant decreases the risk of condom breakage and slippage and 
can reduce discomfort during penetrative sex (10). Plenty of lubricant should always be 
used during anal sex (19). Lubricants that are water- or silicone-based do not damage 
latex condoms; oil-based lubricants do and so should not be used with latex condoms.
Information and skills-building. Along with promotion and supply, programmes for 
key populations should offer information and skills-building in negotiating condom 
use (10). In addition, behavioural interventions can encourage consistent condom use. All 
condom programmes should address the complex gender, religious and cultural factors 
that can impede condom use. Particularly, before introducing condom distribution 
programmes in prisons, education and information for both prisoners and prison staff 
should be carefully planned (9). 
further reading
•	 Condom programming for HIV prevention: a manual for service providers. New York, UNFPA, 
2005. http://www.unfpa.org/public/global/pid/1291
•	 Comprehensive condom programming: a guide for resource mobilization and country 
programming. New York, UNFPA, 2010. http://www.unfpa.org/webdav/site/global/shared/
documents/publications/2011/CCP.pdf 
•	 WHO,	UNFPA,	UNAIDS,	NSWP,	World	Bank.	Implementing comprehensive HIV/STI 
programmes with sex workers: practical approaches from collaborative interventions. 
(Chapter 4). Geneva, WHO, 2013. http://www.who.int/hiv/pub/sti/sex_worker_
implementation/en/ 
•	 Male latex condom specification, prequalification and guidelines for procurement. 
Geneva, WHO, 2010. http://www.who.int/reproductivehealth/publications/family_
planning/9789241599900/en/  
•	 WHO,	UNFPA,	FHI360.	Use and procurement of additional lubricants with male 
and female condoms – advisory note. Geneva, WHO, 2012. http://apps.who.int/iris/
bitstream/10665/76580/1/WHO_RHR_12.33_eng.pdf
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4.1.2 Harm reduction for people who inject drugs
Background and rationale
People who inject drugs are at risk of HIV and other bloodborne viral infections (such 
as hepatitis B and C) through the sharing of contaminated injecting equipment. In some 
settings drug use may be more prevalent among people from other key populations than 
in the general population. 
The comprehensive package. A comprehensive package of evidence-based 
interventions to reduce harms associated with injecting drug use is outlined in the 
WHO, UNAIDS, UNODC technical guide for countries to set targets for universal access 
to HIV prevention, treatment and care for injecting drug users (8). This publication 
and the package of interventions have been widely endorsed by the United Nations 
(20, 21, 22, 23, 24) and major international donors including the Global Fund to Fight 
AIDS, Tuberculosis and Malaria and the United States President’s Emergency Plan for 
AIDS Relief (PEPFAR). 
the comprehensive harm reduction package
1. Needle and syringe programmes (NSPs)
2. Opioid substitution therapy (OST) and other evidence-based drug dependence 
treatment
3. HIV testing and counselling
4. Antiretroviral therapy
5. Prevention and treatment of STIs
6. Condom programmes for people who inject drugs and their sexual partners 
7. Targeted information, education and communication for people who inject 
drugs and their sexual partners
8. Prevention, vaccination, diagnosis and treatment for viral hepatitis 
9. Prevention, diagnosis and treatment of TB. 
Only the first two interventions, NSP and OST and other drug dependence treatment, are 
specific to drug use; they are discussed in this chapter. 
Community-based outreach. Community-based outreach is not listed as a separate 
intervention in the package, but it is an effective method of reaching people, particularly 
those who face barriers to obtaining mainstream services, as is often the case for people 
from key populations. Outreach is a highly effective means of delivering HIV prevention 
interventions such as NSPs, condom programmes and targeted communication, as well 
as a useful access point for referral to OST and ART. Hence, outreach is an essential 
component of all HIV-related programmes (25). 
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A number of other interventions are not included in the comprehensive harm reduction 
package because of insufficient evidence of their effectiveness for HIV prevention and 
treatment. However, one new recommendation on community distribution of naloxone is 
now included and described in detail at the end of this chapter.
Reducing harms related to injecting substances for gender affirmation. Distinct 
from injecting drug use as described above is the injection of substances by transgender 
people for gender affirmation. Where hormone therapy for gender affirmation is used, it 
is important for health care services to ensure that appropriate preparations are used, to 
avoid incorrect dosing, and to properly manage any adverse events, as well as to reduce 
sharing of injection equipment. As yet, there is no WHO guidance on hormone therapy 
for gender affirmation.
The injection of hormones is distinct from the injection of non-medical silicone 
preparations and other fillers for direct body modification (26, 27). Injection of 
loose silicone and other fillers has been linked to such health harms as infection, 
disfigurement, migration of the injected substance within the body and systemic illness 
(28, 29, 30). It is important for transgender people to be counselled about the health 
risks of these injections and afforded access to health-care services that provide safer 
methods for gender affirmation.
Adolescents who inject drugs.1 Adolescents who inject drugs face additional risks 
and barriers to services due to multiple legal, developmental and environmental factors. 
Adolescents often have less knowledge of safer injecting practices and of services. 
In many countries age restrictions and/or parental consent requirements exclude 
adolescents from NSP and OST programmes. Adolescents and young people may require 
specific and more creative engagement strategies to promote uptake of services. 
Engaging parents of adolescents who inject drugs in harm reduction programmes may 
help to ensure adequate support to the adolescent. However, it is important to obtain 
the adolescent’s consent before involving the parents.
4.1.2.1 needle and syringe programmes 
Background and rationale
Once HIV is introduced in a population of people 
who inject drugs and commonly share syringes 
and injecting equipment, prevalence rates can 
reach epidemic proportions very quickly (31). 
Distributing free or low-cost sterile injecting 
equipment to people who inject facilitates the use of clean needles and syringes and 
reduces the number of injections with used needles and syringes (8, 32, 33, 34, 35, 36, 37). 
NSPs substantially and cost-effectively reduce HIV transmission among people who 
inject drugs (36). NSPs may also reduce transmission of other bloodborne viruses, such 
as viral hepatitis B and C, among people who inject drugs (35, 36, 38, 39, 40). At the 
same time, needle and syringe programmes do not encourage drug use. There is no 
evidence of major unintended negative consequences of NSPs, such as initiation of 
1 See also Web Annex 6, briefs on young key populations.
NSPs substantially and cost-
effectively reduce HIV transmission 
among people who inject drugs.
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injecting among people who have not injected previously or an increase in injecting at 
either the individual or societal level (41, 42, 43, 44). 
NSPs may serve as an important point of entry to other services. NSPs aim to engage 
their clients repeatedly on a regular basis. Thus, they have multiple opportunities 
to facilitate access to other health services such as OST and other drug dependence 
treatment, HTC, and treatment of HIV, TB and viral hepatitis (45). Also, NSPs may offer 
basic health care and address other specific issues that commonly affect people who 
inject drugs, such as wound care and overdose prevention. Various models of needle 
and syringe distribution and service delivery can be employed, including distribution at 
fixed sites such as pharmacies, automatic dispensing machines or vending machines, and 
mobile and outreach services (8, 36). Additionally, given the high incarceration rates of 
people who inject drugs, access to sterile injecting equipment and NSP are important 
components of prison health services (4). 
To prevent HIV transmission through injecting drug use, it is crucial to provide not 
only information on how to do so, through safer injecting and avoiding sharing 
injecting equipment, but also the means to do so, through distribution of free or 
low-cost sterile injecting equipment. Needle and syringe programmes also provide 
the opportunity for referral to other health and related services, including HTC and 
drug-dependence treatment.
recommendations and guidance
ALL KEY POPULATION GROUPS
All individuals from key populations who inject drugs should have access to 
sterile injecting equipment through needle and syringe programmes (strong 
recommendation, low quality of evidence) (8, 32, 36, 46). 
Additional remarks 
•	 It is suggested that needle and syringe programmes provide low dead-space 
syringes (LDSS) along with information about their preventive advantage over 
conventional syringes (39).
•	 Injecting equipment should be appropriate to the local context, taking into 
account such factors as the type and preparation of drugs that are commonly 
injected (8, 27).
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related recommendations and contextual issues for specific key population groups
PEOPLE IN PRISONS AND OTHER CLOSED SETTINGS 
•	 It is important to provide people in prisons and other closed settings with 
prevention measures, such as condoms and clean injecting equipment, and not 
just with information about avoiding risks. People in prisons and other closed 
settings should have easy, confidential access to NSPs (9). 
•	 Prison systems should pilot-test and evaluate safer tattooing initiatives to assess 
whether they reduce the sharing and re-use of tattooing equipment and, thereby, 
reduce infections (9, 11).
TRANSGENDER PEOPLE
Transgender people who inject substances for gender affirmation should use sterile 
injecting equipment and practice safe injecting practices to reduce the risk of 
infection with bloodborne pathogens such as HIV, hepatitis B and hepatitis C (3).
ADOLESCENTS FROM KEY POPULATIONS 
WHO guidance does not specify age restrictions for needle and syringe programmes. 
Implementation considerations
Structural change is needed to create a supportive policy, legal and social environment 
that facilitates equitable access to HIV prevention and treatment for all, including NSPs 
for people who inject drugs (8).
Advocacy citing public health evidence is often required with various sectors, especially 
law enforcement agencies and the local community, to foster an environment that 
enables NSPs to function fully (8, 36, 45, 47). 
Criminalization counterproductive. If carrying used needles and syringes is a criminal 
offence or may be used as evidence of drug use, people who inject drugs may be 
reluctant to take used equipment to NSPs for disposal (27, 36, 45). 
Serving key populations. It is important that NSPs are sensitized to the health 
needs of each key population. Key population organizations can either provide these 
interventions themselves or have effective referral pathways to services that do (32). 
Other equipment. In addition to needles and syringes, other injecting-related 
equipment may also be provided, including alcohol swabs, ampoules of sterile water, 
filters, tourniquets, mixing vessels (e.g. spoons or “cookers”) and acidifiers (e.g. 
ascorbic acid or citric acid powders) (8, 27). 
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Safe disposal. NSPs should set up systems for safe disposal of injecting equipment 
and promote their use (8, 27). There are various models for safe disposal systems, 
including distributing puncture-resistant one-way containers. Effective safe disposal 
reduces the amount of contaminated equipment in the community, thus reducing reuse 
and unintended needle-sticks and limiting negative reactions from the community. 
Information provided also can cover opportunities for reducing drug use in the 
longer term.
Information and education in prisons and other closed settings. Prisoners and 
prison staff should receive information about the programmes and participate in their 
design and implementation. Carefully evaluated pilot programmes of prison-based NSPs 
may be important to pave the way for ongoing full-scale programmes, but expansion 
of programmes should not wait for results from pilot programmes, particularly where 
injecting is common in prisons (9). 
further reading
•	 WHO,	UNODC,	UNAIDS.	Technical guide for countries to set targets for universal access to 
HIV prevention, treatment and care for injecting drug users – 2012 revision. Geneva, WHO, 
2012. http://www.who.int/hiv/pub/idu/targets_universal_access/en/
•	 WHO,	UNAIDS,	UNODC.	Guide to starting and managing needle and syringe programmes. 
Geneva, WHO, 2007. http://whqlibdoc.who.int/publications/2007/9789241596275_eng.pdf 
•	 Effectiveness of sterile needle and syringe programming in reducing HIV/AIDS among 
injecting drug users. Geneva, WHO, 2004. http://www.who.int/hiv/pub/idu/e4a-needle/en/ 
•	 Best practices for injections and related procedures toolkit. Geneva, WHO, 2010. http://
whqlibdoc.who.int/publications/2010/9789241599252_eng.pdf 
4.1.2.2 opioid substitution therapy  
Background and rationale
Interventions that effectively treat drug 
dependence can reduce illicit drug use and, hence, 
the frequency of injection, as well as improve 
health and social functioning (8). For people 
dependent on opioids, agonist opioid substitution 
therapy (OST) – sometimes referred to as 
medically assisted treatment (MAT) – is highly effective in reducing injecting behaviours 
that put opioid-dependent people at risk for HIV (33, 34, 48, 49, 50). OST can reduce 
opioid use and improve retention in HIV treatment (51, 52, 53). Access and adherence 
to OST can improve health outcomes (4) , reduce overdose and resulting mortality (54) , 
reduce criminal activity (55) , result in better psychosocial outcomes (56) and decrease 
risk to pregnant women dependent upon drugs and to their infants (57).
Methadone and buprenorphine, both of which are on the WHO list of essential 
medicines, are the most commonly used opioid agonists (58). Methadone is a synthetic 
OST is highly effective in reducing 
injecting behaviours that put 
opioid-dependent people at risk 
for HIV.
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opioid used to treat heroin and other opioid dependence. It reduces opioid withdrawal 
symptoms and the euphoric effect when opioids are used. Methadone is taken orally 
on a daily basis; it is important to assure that the dose is sufficient (60–120 mg) and is 
given for sufficient duration (8, 50). Buprenorphine is a partial agonist; its effectiveness 
in treating opioid dependence is similar to that of methadone. It is taken mainly in its 
sublingual form (8–24 mg/day). OST programmes should create supportive environments 
and relationships to facilitate coordinated treatment of co-morbid mental and physical 
health issues and address relevant psychosocial factors (50). 
•	 To achieve optimal coverage and treatment outcomes, opioid substitution therapy 
should be provided free of charge or covered by public health-care insurance 
and should be accessible to all those in need, including those in prison and other 
closed settings (50). 
•	 OST should not be compulsory; patients must give informed consent for 
treatment (8, 50). 
•	 To be most effective, OST should be provided as maintenance treatment for 
sufficient duration and at adequate doses (8, 50). 
recommendations and guidance
ALL KEY POPULATION GROUPS
All people from key populations who are dependent on opioids should be offered 
opioid substitution therapy in keeping with WHO guidance (strong recommendation, 
low quality of evidence) (8, 32, 50) , including those in prison and other closed 
settings (9). 
Additional remarks 
•	 To maximize the safety and effectiveness of OST programmes, policies and 
regulations should encourage flexible dosing structures, without restricting dose 
levels or duration of treatment (50). Usual methadone maintenance doses should 
be in the range of a minimum of 60–120 mg per day, and average buprenorphine 
maintenance doses should be at least 8 mg per day (50). Take-home doses can be 
offered when the dose and social situation are stable and when there is little risk 
of diversion for illegitimate purposes (50). OST is most effective as a maintenance 
treatment for longer periods of time (treatment for years may be necessary). 
Detoxification or opioid withdrawal (rather than maintenance treatment) results 
in poor outcomes in the long term. However, patients should be helped to 
withdraw from opioids if it is their informed choice to do so (50). 
•	 OST should be used for the treatment of opioid dependence in pregnancy rather 
than attempt opioid detoxification (50, 59).
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•	 Psychosocial support should be available to all opioid-dependent people, 
in association with pharmacological treatments of opioid dependence. At 
a minimum this support should include assessment of psychosocial needs, 
supportive counselling and links to family and community services (50). 
•	 For opioid-dependent people with TB, viral hepatitis B or C or HIV, opioid 
agonists should be administered in conjunction with medical treatment. There 
is no need to wait for abstinence from opioids to start treatment for these 
conditions (50). 
•	 Treatment services should offer hepatitis B vaccination to all opioid-dependent 
patients (whether or not they are participating in OST programmes) (50). 
•	 Care settings that provide OST should initiate and maintain ART for eligible 
people living with HIV (4). 
related recommendations and contextual issues for specific key population groups
PEOPLE IN PRISONS AND OTHER CLOSED SETTINGS 
•	 Prison authorities in countries where OST is available in the community should 
urgently introduce OST programmes and expand them to scale as soon as 
possible (9). 
•	 Countries should affirm and strengthen the principle of providing treatment, 
education and rehabilitation as an alternative to conviction and punishment for 
drug-related offences (8).
•	 Care should be taken to see that people on OST before entering prisons or other 
closed settings can continue OST without interruption while imprisoned and when 
transferred between settings (9, 50) and can be linked to community-based OST 
upon release (60). 
•	 Provision of OST before release can help reduce overdose-related mortality (61).
TRANSGENDER PEOPLE
There is no evidence of drug interactions between opioid substitution therapy and 
medications used for gender affirmation; however, research is very limited.
ADOLESCENTS FROM KEY POPULATIONS 
WHO guidance does not specify age restrictions for opioid substitution therapy.
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Implementation considerations
Documented processes should be established to ensure the safe and legal 
procurement, storage, dispensing and dosing of medicines, particularly methadone and 
buprenorphine (50). 
Supervision. In the early phase of treatment, administration of methadone and 
buprenorphine doses should be directly supervised (50). 
Take-home doses can be recommended when the dose and social situation are stable 
and when there is a low risk of diversion for illegitimate purposes (50). 
Involuntary discharge from treatment is sometimes justified to ensure the safety 
of staff and other patients, but failure to follow programme rules alone should not 
generally be cause for involuntary discharge. Before involuntary discharge reasonable 
measures to improve the situation should be taken, including re-evaluation of the 
treatment approach (50). 
further reading
•	 Guidelines for psychosocially assisted pharmacotherapy for the management of opioid 
dependence. Geneva, WHO, 2009. http://www.who.int/hiv/pub/idu/opioid/en/index.html 
•	 Technical guide for countries to set targets for universal access to HIV prevention, treatment 
and care for injecting drug users – 2012 revision. Geneva, WHO, 2012. http://www.who.int/
hiv/pub/idu/targets_universal_access/en/ 
•	 Operational guidelines for the management of opioid dependence in the South-East Asia 
Region. New Delhi, WHO Regional Office for South-East Asia, 2008. http://www.who.int/hiv/
pub/idu/op_guide_opioid_depend/en/index.html 
•	 Guidelines for identification and management of substance use and substance use disorders 
in pregnancy. Geneva, WHO, 2014. http://www.who.int/substance_abuse/publications/
pregnancy_guidelines/en/ 
4.1.2.3 other drug dependence treatment
Background and rationale
The objective of drug dependence 
treatment is to achieve and maintain 
physical, psychological and social 
well-being by reducing the risk-taking 
associated with drug use, reducing levels 
of drug use, or completely abstaining 
from drug use. Because of the chronic, 
relapsing nature of drug dependence and the need to address social and psychological 
dimensions, achieving abstinence, if desired, is often a lengthy and difficult process. 
Providing “stepping stones” or “stabilizing strategies” – short-term, more achievable 
goals – can help to define and structure progress. It can also help to reduce drug-related 
harms, one of which is the transmission of bloodborne viruses such as HIV and hepatitis 
B and C (62).
The evidence on HIV prevention is not 
as strong as for NSP and OST. Still, other 
drug dependence interventions are strongly 
recommended where non-opioid drugs are 
widely used or OST remains unavailable.
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The available evidence on the impact of other forms of drug dependence treatment on 
HIV incidence is less compelling than that for OST (8, 63). Still, these other interventions 
are recommended where non-opioid drugs such as amphetamine-type stimulants, 
cocaine, sedatives and hypnotics are widely used and also where OST remains 
unavailable (8). Drug dependence treatment helps to prevent HIV by reducing injecting 
drug use, reducing the sharing of injecting equipment, reducing sexual risk behaviours 
and creating opportunities for HIV education and medical care (64). 
Treatment of drug dependence typically blends different treatment modalities, but 
approaches may be simply categorized as psychosocial (abstinence-based or behavioural 
interventions) or pharmacological. Pharmacological modalities can be further 
categorized as detoxification, relapse prevention and treatments to reduce drug craving 
and use (62).
Detention is not treatment. In a number of countries, people who use or inject drugs 
are apprehended and confined to detention centres, ostensibly for the purpose of drug 
treatment and rehabilitation but without trial or clinical assessment of dependence, 
and clinical treatment outcomes rarely determine the duration of detention. Typically, 
these centres lack medical supervision of drug withdrawal, and evidence-based drug 
dependence treatment is not offered. Detainees may be forced to engage in unpaid 
labour or military-style drills and may be subject to physical punishment. Following 
release from these centres, many relapse to drug use, and the risk of overdose may be 
increased (65). 
These approaches infringe on human rights. Furthermore, there is no evidence that 
they effectively treat drug dependence or reduce HIV transmission. Hence, they cannot 
be considered drug dependence treatment (8). For these reasons, WHO and other UN 
partners do not support these forms of detention and call on Member States to close 
compulsory drug detention and rehabilitation centres and to implement voluntary, 
evidence-informed and rights-based health and social services in the community (66). 
Containing the spread of HIV is more successful where there is a comprehensive and 
varied range of evidence-based services for drug dependence treatment (62).  
recommendations and guidance
ALL KEY POPULATION GROUPS
All key populations with harmful alcohol or other substance use should have access 
to evidence-based interventions, including brief psychosocial interventions involving 
assessment, specific feedback and advice (conditional recommendation, very low 
quality of evidence) (3, 46). 
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PEOPLE IN PRISONS AND OTHER CLOSED SETTINGS 
•	 People in prisons should have access to the same evidence-based treatment 
options for substance dependence as people in the community (9, 60).
•	 To reduce over-incarceration and prison overcrowding, which increase the risk of 
HIV infection, it is important that countries review their laws and policies that 
criminalize people for their consumption of alcohol or drugs (9, 60). 
ADOLESCENTS FROM KEY POPULATIONS 
Treatment should be provided in the best interests of the adolescent concerned and 
in consultation with her or him.
Implementation considerations
Psychosocial interventions should be part of comprehensive treatment for drug 
dependence (39, 50). 
Alternatives to criminalization. Countries should affirm and strengthen the principle 
of providing treatment, education and rehabilitation as an alternative to conviction 
and punishment for drug-related offences. Currently, many countries make major 
expenditures on imprisonment of drug dependent people, an approach associated with 
very high relapse rates soon after release. There is no evidence that such an approach is 
effective or cost-effective (8). 
further reading
•	 mhGAP intervention guide for mental, neurological and substance use disorders in non-
specialized health settings. Geneva, WHO, 2011. http://www.who.int/mental_health/
publications/mhGAP_intervention_guide/en/index.htm  
•	 Technical briefs on amphetamine-type substances. Manila, WHO Regional Office for the 
Western Pacific, 2011. http://www.who.int/hiv/pub/idu/ats_tech_brief/en/index.html
•	 Basic principles for treatment and psychosocial support of drug dependent people living 
with HIV/ AIDS. Geneva, WHO, 2006. http://www.who.int/substance_abuse/publications/
basic_principles_drug_hiv.pdf  
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4.1.2.4 opioid overdose prevention and management
Background and rationale
Worldwide, drug overdose is the leading cause of death among people who inject drugs 
and a common cause of non-HIV-related deaths among people with HIV. An estimated 
69 000 people die from overdose each year (67).
Opioid overdose is both preventable and, if witnessed, 
treatable. OST provides the most effective prevention 
among people dependent on opioids (50). Opioid 
overdose is treatable by respiratory support and via 
the short-acting opioid antagonist naloxone. Naloxone 
has a long clinical history of successful use for the treatment of opioid overdose. The 
medication has no effect if opioids are absent and has no potential for abuse. Naloxone 
is included on the WHO Model List of Essential Medicines (68). 
While naloxone has long been widely used by medical staff and in health-care facilities, 
a number of countries in several regions have recently started community-based 
distribution, i.e. allowing distribution and administration by people dependent on 
opioids and their peers and family members as well as by first-responders such as police 
and emergency services. Greater availability of naloxone through community-based 
distribution could help reduce the high rates of opioid overdose, particularly where 
access to essential health services is limited for people who inject drugs. 
recommendations and guidance
ALL KEY POPULATION GROUPS
•	 People likely to witness an opioid overdose should have access to naloxone and 
be instructed in its use for emergency management of suspected opioid overdose 
(strong recommendation, very low quality of evidence) (69). 
•	 Naloxone is effective when delivered by intramuscular, intranasal, intravenous 
and subcutaneous routes. Persons administering naloxone should select the route 
based on formulation available, skills in administration, setting and local context 
(conditional recommendation, very low quality of evidence) (69).
•	 In suspected opioid overdose, first-responders should focus on maintaining an 
airway, assisting ventilation and giving naloxone (strong recommendation, very 
low quality of evidence) (69).
•	 After successful resuscitation following administration of naloxone, the affected 
person’s level of consciousness and breathing should be closely observed – 
where possible, until the person has fully recovered (strong recommendation, 
very low quality of evidence) (69).
Opioid overdose is both 
preventable and, if witnessed, 
treatable.
40 Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations
related recommendations and contextual issues for specific key population groups
ADOLESCENTS FROM KEY POPULATIONS 
WHO guidance does not specify age restrictions for overdose management. 
Implementation considerations
Legal and policy issues. There may be both legal and policy barriers to the access 
and use of naloxone by lay first responders, which may need to be reviewed in order to 
implement this recommendation. 
Dose. Where possible, efforts should be made to tailor the dose to avoid marked 
opioid withdrawal symptoms. The choice of initial dose will depend on formulation and 
context, however doses above 0.8mg IM/IV/SC are more likely to precipitate significant 
withdrawal symptoms.
further reading
•	 Community management of opioid overdose. Geneva, WHO, forthcoming.
•	 WHO model list of essential medicines, 18th list. Geneva, WHO, 2013. http://www.who.int/
medicines/publications/essentialmedicines/18th_EML_Final_web_8Jul13.pdf 
•	 UNODC,	WHO.	Discussion paper. Opioid overdose: preventing and reducing opioid 
overdose mortality. Vienna, United Nations, 2013. http://www.unodc.org/docs/treatment/
overdose.pdf 
4.1.3 Behavioural interventions
Background and rationale
To reduce their risk of acquiring STIs or HIV, people 
must understand their risk and have the knowledge, 
skills and belief in their self-efficacy to reduce that 
risk. Behavioural interventions provide information, 
motivation, education and skills-building to help 
individuals reduce risky behaviours and sustain this 
positive change.
Behavioural interventions may address individuals or groups. One-on-one counselling 
may focus on awareness of personal risk and risk reduction strategies; for example, 
counsellors or community workers may discuss risk behaviours, relate a participant’s 
activities directly to HIV risk, and consider strategies to reduce this risk. In contrast, 
peer-to-peer interventions and group sessions may focus more on awareness of risk 
overall, with group sessions offering the added benefit of group support for finding 
Behavioural interventions 
help individuals support safer 
behaviours and sustain this 
positive change.
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workable risk-reduction strategies. Social marketing campaigns also may help by 
promoting testing, treatment and other services.
Behavioural change interventions can be delivered as part of the other interventions 
in the comprehensive package. They may take place face-to-face or through broadcast 
mass media and digital media such as the Internet. Choices of content and approach, as 
well as of the medium, should be based on good formative analysis of the local situation. 
Although the logic of behavioural interventions is primarily based on individual 
awareness and decision-making about risk, such interventions also can operate at the 
community level. For example, interventions may involve training opinion leaders to 
communicate with their peers, thus changing perceptions of social norms about risk and 
risk avoidance.
Adolescents deserve specific consideration as at this stage the urge to explore and 
experiment normally develops ahead of decision-making ability (70). Adolescents’ 
evolving cognitive abilities are an important consideration in the design of behavioural 
interventions for them. 
recommendations and guidance
ALL KEY POPULATION GROUPS
A range of behavioural interventions can provide information and skills that support 
risk reduction, prevent HIV transmission and increase uptake of services among all 
key populations. There is insufficient evidence to make general recommendations 
for all key populations. However, specific behavioural approaches for particular key 
population groups have been assessed and can be recommended.  
related recommendations and contextual issues for specific key population groups
MEN WHO HAVE SEx WITH MEN
•	 The following strategies are recommended to increase safer sexual behaviours 
and increase uptake of HIV testing and counselling among men who have sex 
with men: 
– targeted Internet-based information
– social marketing strategies
– sex venue-based outreach (3, 32).
•	 Implementing both individual-level behavioural interventions and community-
level behavioural interventions is suggested (3, 32).
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PEOPLE IN PRISONS AND OTHER CLOSED SETTINGS 
•	 A peer-based, comprehensive approach increases the effectiveness of prison-
based HIV education efforts (9). 
•	 Information and education programmes about HIV and other infectious diseases 
are important for both prisoners and prison staff. Special attention should be paid 
to the needs of prisoners after release. 
PEOPLE WHO INJECT DRUGS 
•	 People who inject drugs and relevant community networks should participate in 
developing and delivering messages. 
•	 Behavioural interventions for people who inject drugs need to address risk related 
to both drug use and sexual behaviour (27). 
•	 For people who inject drugs, peer interventions are particularly effective for the 
prevention of HIV and viral hepatitis (39). 
•	 Information and education about safe injecting and overdose prevention are also 
important. 
SEx WORKERS
Condom promotion programmes, including community-led programmes, can 
increase condom use by sex workers and their clients. Through peer- and 
community-led interventions, these programmes can provide information and skills-
building for condom use and information and create demand for HIV testing, STI 
screening, and HIV treatment and care (71).
TRANSGENDER PEOPLE
The following strategies are recommended to increase safer sexual behaviours and 
increase uptake of HIV testing and counselling among transgender people: 
•	 targeted Internet-based information
•	 social marketing strategies
•	 sex venue-based outreach (3, 32) 
Implementing both individual-level behavioural interventions and community-level 
behavioural interventions is suggested (3, 32). 
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ADOLESCENTS FROM KEY POPULATIONS 
Skills-based interactive and participatory approaches for adolescents from key 
populations, including online, mobile health, peer and outreach approaches, have 
proved acceptable to adolescents and have shown promise in some contexts (72, 73).
further reading
•	 Kennedy	CE	et	al.	Behavioural	interventions	for	HIV	positive	prevention	in	developing	
countries: a systematic review and meta-analysis. Bulletin of the World Health Organization, 
2010, 88(8):615–623. http://www.who.int/bulletin/volumes/88/8/09-068213/en/ 
•	 Prevention and treatment of HIV and other sexually transmitted infections among men who 
have sex with men and transgender people. Geneva, WHO, 2011. http://www.who.int/hiv/
pub/guidelines/msm_guidelines2011/en/ 
4.1.4 prevention of transmission in health-care settings
The essential elements for preventing HIV transmission in health-care settings include:
Primary prevention procedures
•	 blood safety (see http://www.who.int/bloodsafety/publications/en/);
•	 prevention of unsafe injections; 
•	 emergency and essential surgical care that limit the need for blood transfusion;
•	 standard precautions to minimize the spread of infection associated with health care and 
to avoid direct and indirect contact with blood, body fluids, secretions and non-intact 
skin. These basic infection control precautions in health care involve hand hygiene, use of 
personal protective equipment to prevent exposures, safe disposal of sharps and waste, 
and safe cleaning and disinfection of the environment and equipment;
•	 identifying, eliminating and controlling exposure to hazards in the workplace and 
preventing needlestick injuries. 
Secondary prevention – that is, post-exposure prophylaxis (PEP) – is applicable in 
health-care settings when primary prevention has failed or when a health-care worker 
or patient has been exposed to the risk of HIV transmission, whether accidentally or 
through unsafe procedures (see Section 4.1.5.2). 
further reading
•	 Blood donor selection. Guidelines on assessing donor suitability for blood donation. Geneva, 
WHO, 2012. http://www.who.int/bloodsafety/publications/bts_guideline_donor_suitability/en
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4.1.5 arV-related prevention
4.1.5.1 pre-exposure prophylaxis 
WHO has developed new guidance concerning pre-exposure prophylaxis (PrEP) for 
inclusion in this publication. Full discussion of the guidance and its rationale is presented 
here.
Background and rationale
Oral pre-exposure prophylaxis of HIV is the daily use of ARV drugs by HIV-uninfected 
people to block the acquisition of HIV. Studies have demonstrated the effectiveness of 
PrEP in reducing HIV transmission among serodiscordant heterosexual couples, men who 
have sex with men, transgender women, high-risk heterosexual couples, and people who 
inject drugs (4, 74). 
WHO encourages countries to undertake demonstration projects to gain experience in 
implementing PrEP safely and effectively (74). 
recommendations and guidance 
ALL KEY POPULATION GROUPS
Where serodiscordant couples can be identified and where additional HIV 
prevention choices for them are needed, daily oral PrEP (specifically tenofovir or 
the combination of tenofovir and emtricitabine) may be considered as a possible 
additional intervention for the uninfected partner (conditional recommendation, 
high quality of evidence) (74). 
related recommendations and contextual issues for specific key population groups
MEN WHO HAVE SEx WITH MEN
Among men who have sex with men, PrEP is recommended as an additional 
HIV prevention choice within a comprehensive HIV prevention package (strong 
recommendation, high quality of evidence).
Background 
The conditional recommendations of 2012 to offer PrEP to men who have sex with men, 
transgender people and the HIV-negative partner in serodiscordant relationships in the 
context of demonstration projects (74) was reconsidered in 2014 in the light of evolving 
evidence. In addition, continuing high rates of HIV incidence are increasingly reported in 
men who have sex with men in all regions, despite the availability of current prevention 
interventions, suggesting that additional prevention options could be important. 
NEW
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The systematic review that provided the evidence base for the 2012 WHO guidelines 
on PrEP (74) was updated in January 2014. This review examined the following PICO1 
question: “Should oral PrEP (containing tenofovir (TDF)) be used for HIV prevention 
among men who have sex with men?”  
The review of values and preferences of men who have sex with men about PrEP also 
was updated in January 2014, through a review of published literature (see Web Annex 1 
for the full report). Also, further values and preference research was undertaken by the 
Global Forum on MSM (MSMGF) (Web Annex 3).
results
Combining results from the 2012 and 2014 searches for the systematic reviews yielded 
764 citations and 139 conference abstracts. Following screening and review, four studies 
reported in five articles were deemed eligible for inclusion in the review. Of these, one 
was a Phase III efficacy trial, while three were smaller pilot feasibility/acceptability or 
extended safety studies. Given the differences in the studies’ purposes, drug regimens/
dosing schedule and size/statistical power (and, thus, in imprecision and quality, 
according to the GRADE framework), only results from the primary Phase III efficacy trial 
were included in the GRADE tables. These are the results presented below. For further 
information on the other four studies, see Web Annex 1.
The primary Phase III efficacy trial meeting all inclusion criteria was the iPrEx trial (75). 
This was a randomized controlled trial to evaluate the safety and efficacy of once-daily 
oral tenofovir-emtricitabine (FTC-TDF) compared with placebo for the prevention of 
HIV acquisition among men who have sex with men and among transgender women. 
The trial involved 2499 participants in six countries: Brazil, Ecuador, Peru, South Africa, 
Thailand and the United States of America. All study participants were born male; 29 
(1%) reported their current gender identity as female. The study measured all five key 
outcomes for this review: (1) HIV infection, (2) any adverse event, (3) any stage 3 or 4 
adverse event, (4) condom use and (5) number of sexual partners. 
HIV infection. Oral PrEP was associated with reduced risk of new HIV infection in 
both intention-to-treat analysis (HR: 0.53, 95% CI 0.36–0.78, p=0.001) and modified 
intention-to-treat analysis (HR: 0.56, 95% CI 0.37–0.85, p=0.005). 
Adverse events. There were no significant differences in the rates of reported adverse 
events between the FTC-TDF and control arms for either any adverse event (RR: 0.99, 
95% CI 0.94–1.04) for grade 3 and 4 adverse events (RR: 0.92, 95% CI 0.75–1.13). 
Condom use and number of sexual partners. Both the FTC-TDF and control arms 
reported increases in condom use and a reduced number of receptive sexual intercourse 
partners from baseline to follow-up. There were no significant differences between study 
arms over time. 
Quality of the evidence. The quality of evidence was high for all outcomes, without 
serious limitations.
Values and preferences. While the relevant literature has proliferated recently, 
the reported values and preferences on PrEP use of men who have sex with men and 
1 PICO stands for “patients, intervention, comparison and outcome”.
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transgender people have remained fairly consistent with findings of the systematic 
review conducted in 2011. 
Globally, awareness of PrEP among men who have sex with men continues to be limited, 
although several studies suggest awareness has increased since the release of the iPrEx 
results. Willingness to use PrEP varies across studies, but the majority report that 40% 
to 70% of respondents are willing to use PrEP. 
Main factors that would influence PrEP use include effectiveness, side-effects and 
cost. Respondents also mentioned concerns about accessibility, mistrust of health-
care providers, stigma and risk compensation. All studies measuring potential risk 
compensation found that at least some participants anticipated changing their sexual 
behaviour as a result of PrEP. Providers generally expressed awareness and support 
of PrEP, although few had prescribed it. Providers’ concerns included drug resistance, 
risk compensation, limited availability of ART (in Peru), poor adherence, lack of local 
guidelines and concern that PrEP does not fit well in current (US) models of care, which 
do not include frequent, regular clinic visits.
Feasibility. Oral PrEP for men who have sex with men has proved feasible in various 
trial settings and acceptability studies (including among young men who have sex with 
men). Implementation may prove challenging, however, where access to services and 
provision of alternative prevention tools are limited or lacking. Issues of criminalization, 
stigma and discrimination, and violence should be considered during implementation, 
especially where same-sex behaviour is illegal.
additional considerations
In formulating the new recommendation, the Guidelines Development Group took into 
consideration the overall high quality of the evolving evidence base, with benefits clearly 
outweighing harms (see Web Annex 1). In addition, several new studies indicate no 
major variability in values and preferences, with men who have sex with men broadly in 
support of PrEP. 
Data on the cost-effectiveness of PrEP vary widely, depending greatly on drug price. The 
Group noted that in low-income countries PrEP is considerably cheaper than in many 
middle- and high-income countries.
PrEP is best offered as one component of a comprehensive set of HIV prevention 
interventions. Comprehensive HIV prevention programmes should include unfettered 
availability of condoms and lubricants, routine HIV testing, risk-reduction counselling 
and adherence coaching if PrEP is offered. In the introduction of PrEP, it will be 
important to assess the barriers and facilitators to existing HIV prevention strategies 
in the specific community and context. This assessment should be undertaken in 
collaboration with local key population-led and community-based organizations, 
advocates, providers, and researchers who have cultural sensitivity, knowledge and the 
trust of men who have sex with men. This process should include an assessment at local 
levels of:
•	 sexual and HIV stigma
•	 stigma associated with receipt of a particular prevention intervention
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•	 provider attitudes and knowledge about the sexual health needs of men who have sex 
with men
•	 availability, accessibility, quality and use of basic HIV services
•	 knowledge and acceptability of ART-based prevention strategies
•	 laws that criminalize sex between men
•	 personal safety and security
•	 privacy and confidentiality protections
•	 legal literacy among and legal protections and services for men who have sex with 
men and their service providers
•	 community engagement
•	 other concerns particular to the location (identified by local staff of community-based 
organizations and recipients of services).
Based on the assessment, and in collaboration with local community-based 
organizations, it will be helpful to develop a plan to:
•	 address identified barriers
•	 mitigate risk to confidentiality, privacy, personal safety and security
•	 support and enhance facilitators and enablers as needed
•	 assess changes over time.
PEOPLE WHO INJECT DRUGS 
•	 No new recommendation was made for use of oral PrEP for people who inject 
drugs.
•	 The existing recommendation to offer daily oral PrEP as an additional HIV 
prevention choice for the negative partner in a serodiscordant relationship 
remains relevant for people who inject drugs and are in a serodiscordant 
relationship (conditional recommendation, high quality of evidence) (74).  
Background 
In the scoping meeting of October 2013, the External Steering Group decided that the 
use of PrEP for people who inject drugs should be reviewed. 
A systematic review included all studies published in peer-reviewed journals or presented 
as abstracts at scientific conferences between 1 January 1990 and 1 January 2014. This 
systematic review examined the following PICO question: “Should oral PrEP (containing 
tenofovir (TDF)) be used for people who inject drugs?” More detailed information on the 
systematic review is available in Web Annex 2.
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results
The search yielded 183 citations and 243 conference abstracts; following screening and 
review only one study (with data for PICO outcomes reported in one article and one 
conference abstract) was deemed eligible for inclusion in the review – the Bangkok 
Tenofovir Study (76, 77). This was a randomized controlled trial to assess whether daily 
oral use of tenofovir disoproxil fumarate (tenofovir), compared with placebo, reduces 
HIV transmission in injecting drug users. Conducted in Bangkok, Thailand, the trial 
recruited 2413 participants from 17 drug treatment clinics. Participants’ ages ranged 
from 20 to 59 years (mean=32.4), 80% were male, and 63% reported injecting drugs in 
the past 12 weeks. The study measured all seven key outcomes for this review: (1) HIV 
infection, (2) any adverse event, (3) any stage 3 or 4 adverse event, (4) condom use, 
(5) number of sexual partners, (6) injection frequency and (7) needle/syringe sharing. 
HIV infection. Oral PrEP was associated with reduced risk of HIV in both intention-to-
treat analysis (HR 0.53, 95% CI 0.36–0.78, p = 0.001) and modified intention-to-treat 
analysis (HR: 0.56, 95% CI 0.37–0.85, p = 0.005).
Adverse events. There were no significant differences in reported rates of adverse 
events between the TDF and placebo arms for any adverse event (91% versus 90%, 
p = 0.46) or for grade 3 and 4 adverse events (13% versus 13%, p = 0.89).
Injection frequency and needle/syringe sharing. Both the TDF and control arms 
reported reduced injection behaviour and less injecting with used needles over the 
course of the study. There were no significant differences between study arms over time 
or at 12-month follow-up (p = 0.520 for injection frequency and p = 0.874 for needle/
syringe sharing).
Condom use and number of sexual partners. Both the TDF and placebo arms 
reported increased condom use with live-in partners and reduced numbers of sexual 
partners over the course of the study. There was no significant difference between study 
arms over time or at 12-month follow-up. 
Quality of the evidence. The quality of evidence was moderate for all outcomes based 
on one RCT that was downgraded because of risk of bias due to a significant loss to 
follow-up (attrition bias).
Values and preferences. The systematic review described above identified one 
published study examining acceptability of PrEP and factors likely to influence uptake 
among people who inject drugs. This quantitative study involved 128 people in Ukraine. 
Most participants said that they would definitely (53%) or probably (32%) use PrEP 
if it became available. These results changed little when participants were prompted 
on potential side-effects, the need to continue condom use while taking PrEP and the 
need for regular HIV testing. Respondents considered route of administration the most 
important attribute influencing PrEP uptake; they preferred injections over pills. 
Additionally, WHO commissioned a qualitative in-depth values and preferences survey. 
The survey interviewed 21 people who inject drugs as well as experts, service providers 
and activists from all geographic regions about their values and preferences regarding 
PrEP. Those interviewed gave qualified support to PrEP based on its potential usefulness 
for some people who inject drugs in countries where other harm reduction options are 
not available and that have good ART access. Reticence about PrEP as a useful HIV 
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prevention option for people who inject drugs was based on perceptions that investment 
should be made in other proven interventions that are already available (e.g. NSP, OST 
and hepatitis C screening, diagnosis and treatment), that PrEP is “not proven” for people 
who inject drugs, and that it is unethical to give PrEP when not all people living with 
HIV can get ART for treatment; and on concern about “hidden agendas”. The Guidelines 
Development Group concluded: “A recommendation for the use of PrEP as a harm 
reduction intervention for people who inject drugs is not supported by the community at 
this time.”
Feasibility. Groups of people who inject drugs (78) and some members of the Guidelines 
Development Group raised concerns about the operational feasibility of the Bangkok 
Tenofovir Study and whether it could be replicated in standard service delivery settings. 
In addition, members of the Guidelines Development Group commented that PrEP should 
not be seen as a substitute for NSP and other prevention programmes already proven 
to reduce the risk of HIV transmission among people who inject drugs. The Guidelines 
Development Group also stated that issues of criminalization, stigma and discrimination, 
and violence should be considered during implementation, especially where injection 
drug use is illegal.
additional considerations
After reviewing all the available evidence, the Guidelines Development Group concluded 
that no recommendation should be made on PrEP for people who inject drugs. 
There was uncertainty regarding the benefits versus harms and about resource 
utilization and feasibility. 
The Guidelines Development Group pointed out that existing acceptable, cost-effective 
methods of preventing HIV in people who inject drugs (such as NSP, OST) are not 
implemented in many settings. While the Group acknowledged that further effectiveness 
and safety studies are unlikely given the positive efficacy shown in the Bangkok trial, 
the Group considered that further research is needed into the values and preferences of 
injection drug users and to determine the feasibility of implementing PrEP in the context 
of these proven prevention strategies. Therefore, the Group concluded, it was premature 
to make a recommendation, but a recommendation could be reconsidered when further 
information becomes available.
SEx WORKERS
The existing recommendation to offer daily oral PrEP as an additional HIV prevention 
choice for the HIV-negative partner in a serodiscordant couple remains relevant 
for sex workers who are in serodiscordant couple relationships (conditional 
recommendation, high quality of evidence) (74). 
summary of the guidelines development group discussion and other considerations
In the scoping meeting of October 2013, the External Steering Group decided that the 
use of PrEP for sex workers should not be considered in this guidelines process as there 
were no studies of PrEP among sex workers and results from demonstration projects 
were not yet available. Furthermore, studies relating to the values and preferences of sex 
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workers regarding PrEP were underway, and results were not yet available. This decision 
was confirmed in the guidelines meeting. The Guidelines Development Group agreed 
that this question could be considered as a PICO question with subsequent systematic 
review and GRADE assessments for future guidelines and should be prioritized with a 
focus on high prevalence settings with good ART access. Additionally, concerns were 
raised that a recommendation to use PrEP could undermine current comprehensive 
condom programming efforts, which have high acceptability and uptake in many 
settings. 
TRANSGENDER PEOPLE
Where HIV transmission occurs among transgender women who have sex with 
men and additional HIV prevention choices for them are needed, daily oral PrEP 
(specifically the combination of tenofovir and emtricitabine) may be considered as 
a possible additional intervention (conditional recommendation, high quality of 
evidence) (74).  
summary of the guidelines development group discussion and other considerations
In the scoping meeting of October 2013, the External Steering Group decided that 
the conditional recommendation of 2012 should not be reconsidered, as there was no 
new evidence relating to transgender women, and very few transgender women have 
been included in PrEP trials to date. This was confirmed in the guidelines meeting, 
endorsing no change to the 2012 WHO guidelines recommendation for the use of PrEP 
for transgender people in demonstration projects. The Guidelines Development Group 
recognized that a systematic review of values and preferences, resource utilization and 
feasibility had not been conducted in the specific population of transgender women. For 
this reason the 2012 recommendation would remain valid. The Guidelines Development 
Group agreed that this question could be considered as a PICO question with subsequent 
systematic review and GRADE assessments for future guidelines. Additionally, a concern 
was raised that potential drug interactions may exist between regular use of PrEP and 
hormone replacement therapy (see Section 4.4.3); any future assessment of PrEP for 
transgender women will need to consider this issue.
Implementation considerations 
Issues of criminalization, stigma and discrimination, and violence should be considered 
during implementation.
Delivery. It is currently not possible to develop definitive guidance on how best to 
deliver daily oral PrEP; in many settings demonstration projects are needed (74). 
Demonstration projects. Countries that introduce oral PrEP should undertake 
demonstration projects to ascertain the most appropriate user groups and the best 
delivery approaches (74). 
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further reading
•	 Web	Annexes	1,	2	and	3.
•	 Guidance on oral pre-exposure prophylaxis (PrEP) for serodiscordant couples, men and 
transgender women who have sex with men at high risk of HIV: recommendations for use 
in the context of demonstration projects. Geneva, WHO, 2012. http://apps.who.int/iris/
bitstream/10665/75188/1/9789241503884_eng.pdf 
4.1.5.2 post-exposure prophylaxis (pep)
Background and rationale
Post-exposure prophylaxis (PEP) is given to reduce 
the likelihood of acquiring HIV infection after 
possible exposure. Since the early 1990s antiretroviral 
medicines have been prescribed for PEP following 
occupational exposure to HIV. This practice has 
been extended to non-occupational situations, including sexual assault. Other non-
occupational exposures include those arising from sharing of injection equipment among 
people who inject drugs and possible exposure through consensual sex (79). PEP is 
currently the only way to reduce the risk of HIV infection in an individual who has been 
exposed to HIV. As such, it is widely considered an integral part of the overall prevention 
strategy (79). 
WHO PEP guidelines will be updated in late 2014 for all populations. The current 
recommended duration of PEP is 28 days; the first dose should be taken as soon as 
possible and within 72 hours after exposure. There has been a progressive trend 
favouring the adoption of better tolerated PEP regimens, often composed by once daily 
triple ARV drug combinations including nucleotide analogues and heat stable boosted 
protease inhibitors. More recently, other alternative drug classes such as non-nucleside 
analogues and integrase inhibitors have been considered. The 2014 WHO PEP guidance 
will provide updated regimens for adults, adolescents and children.
Despite its short duration, reported completion rates for PEP are low. Therefore, 
counselling and other adherence support measures are recommended. PEP should 
not be considered 100% effective. It is, therefore, imperative that HIV post-exposure 
prophylaxis policies reinforce the importance of primary prevention and risk prevention 
counselling in all settings where HIV could be transmitted (79).  
Offering pre-exposure prophylaxis after completion of the 28 day PEP course could 
be considered for people who present with repeated high risk behaviour or for repeat 
courses of PEP.
PEP should be available to all eligible people from key populations on a voluntary 
basis after possible exposure to HIV.  
PEP is the only way to 
reduce risk of infection after 
exposure to HIV.
PIPELINE
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recommendations and guidance
ALL KEY POPULATION GROUPS
HIV post-exposure prophylaxis should be considered for people presenting within 
72 hours of a sexual assault. Use shared decision-making with the survivor 
to determine whether HIV post-exposure prophylaxis is appropriate (strong 
recommendation, very low quality of evidence) (80).
related recommendations and contextual issues for specific key population groups
PEOPLE IN PRISONS AND OTHER CLOSED SETTINGS 
PEP should be made accessible to all people in prisons and other closed settings 
who have possibly been exposed to HIV, just as in non-prison settings. Clear 
guidelines need to be developed and communicated to prisoners, health-care staff 
and other employees (9, 11). 
Implementation considerations 
An HIV risk assessment and counselling specific to HIV and PEP should be part of the PEP 
intervention (79).
Comprehensive ongoing services should be available for people following PEP, including 
treatment and care for people who seroconvert (79). 
further reading
•	 Guidelines on post-exposure prophylaxis (PEP) to prevent HIV infection. Geneva, WHO and 
ILO, 2007. http://whqlibdoc.who.int/publications/2007/9789241596374_eng.pdf
•	 Responding to intimate partner violence and sexual violence against women: 
WHO clinical and policy guidelines. Geneva, WHO, 2013. http://apps.who.int/iris/
bitstream/10665/85240/1/9789241548595_eng.pdf 
4.1.5.3 early initiation of art/art regardless of cd4 count
Background and rationale
Viral load is the single greatest determinant 
of the risk of HIV transmission. When 
someone is virally suppressed (viral load is 
undetectable), the risk of HIV transmission 
is significantly reduced. There is increasing 
evidence of the potential of ART to reduce 
Evidence supports early initiation 
of ART in individuals, irrespective of CD4 
count, to prevent HIV transmission.
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HIV transmission by lowering viral load. This evidence supports early initiation of ART in 
individuals, irrespective of CD4 count, for prevention of HIV transmission (4). 
Current WHO ARV guidelines recommend initiation of ART regardless of CD4 count 
for the HIV-positive partner in serodiscordant couples for HIV prevention and for all 
pregnant and breastfeeding women living with HIV (option B+) (4). Early ART initiation 
is also recommended for clinical reasons for people coinfected with HIV and hepatitis B 
virus with severe hepatic disease and/or active TB.
The 2013 WHO ARV consolidated guidelines recommend initiation of ART at a CD4 
count of ≤500 cells/mm3 in all populations, including people from key populations. 
WHO will periodically update this guidance and will reconsider this recommendation in 
2015. At this time the guidelines group did not re-review the data or consider earlier 
or immediate ART for key populations, although some countries are considering or 
providing immediate or early ART to key populations for prevention. 
The rationale for initiating ART regardless of CD4 count for people in key populations 
living with HIV is both operational (to increase access to ART in populations that 
currently have low access, poor linkage and high loss to follow-up following diagnosis) 
and for the public health benefits of decreasing HIV transmission. More research and 
implementation evidence are required to evaluate the posited longer-term individual 
health benefits. For its 2015 update WHO will draw on implementation evidence from 
pilot studies and programmes currently underway. 
Although ART has a significant HIV prevention effect, it should be used in 
combination with other biomedical interventions that reduce HIV risk practices and/
or reduce the probability of HIV transmission per contact event, including male and 
female condoms, needle and syringe programmes, opioid substitution therapy with 
methadone or buprenorphine and voluntary medical male circumcision (4). 
recommendations and guidance
ALL KEY POPULATION GROUPS
ART should be initiated in all individuals with HIV regardless of WHO clinical stage 
or CD4 count in the following situations:
•	 Individuals with HIV and active TB disease (strong recommendation, low quality 
of evidence).
•	 Individuals coinfected with HIV and hepatitis B virus (HBV) with evidence of 
severe chronic liver disease (strong recommendation, low quality of evidence).
•	 For programmatic and operational reasons, particularly in generalized epidemics, 
all pregnant and breastfeeding women with HIV should initiate ART as lifelong 
treatment (conditional recommendation, low quality of evidence) (4). 
•	 Partners with HIV in serodiscordant couples should be offered ART to reduce HIV 
transmission to uninfected partners (strong recommendation, high quality of 
evidence) (4). 
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4.1.6 Voluntary medical male circumcision for HIV prevention
Background and rationale
There is compelling evidence from three 
randomized controlled trials in Africa that 
medical male circumcision reduces the risk of 
female-to-male sexual transmission of HIV by 
approximately 60% (81, 82, 83). Thus, WHO 
and UNAIDS recommend voluntary medical male circumcision (VMMC) as an additional 
efficacious intervention for prevention of heterosexually acquired HIV, particularly in 
settings with generalized HIV epidemics (84). The most recent data from Uganda show 
that, in the five years since the Uganda trial was completed, high effectiveness has been 
maintained among the men who were circumcised, with a 73% protective effect against 
HIV infection (85). 
VMMC is safe when provided by well-trained health professionals in properly equipped 
settings. Health messages should be carefully tailored, culturally sensitive, draw on 
local language and symbols, and be appropriate to the particular level of education and 
understanding of the population groups that they address. Messages should address 
both men and women (84). 
recommendations and guidance 
ALL KEY POPULATION GROUPS
•	 VMMC is recommended as an additional, important strategy for the prevention 
of heterosexually acquired HIV infection in men, particularly in settings with 
hyperendemic and generalized HIV epidemics and low prevalence of male 
circumcision (84). 
•	 VMMC service provision should serve as an opportunity to address the sexual 
health needs of men; such services should actively counsel and promote safer 
sexual behaviour (84). 
related recommendations and contextual issues for specific key population groups
MEN WHO HAVE SEx WITH MEN
•	 VMMC is not recommended to prevent HIV transmission in sex between men, as 
evidence is lacking that VMMC is protective during receptive anal intercourse (3). 
•	 Men who have sex with men may still benefit from VMMC if they also engage 
in vaginal sex. Men who have sex with men should not be excluded from VMMC 
services in countries in eastern and southern Africa where VMMC is offered for 
HIV prevention.
Medical male circumcision reduces 
the risk of female-to-male sexual 
transmission of HIV by about 60%.
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PEOPLE IN PRISONS AND OTHER CLOSED SETTINGS 
VMMC is not one of the recommended interventions in the prison package. If 
VMMC is offered to men in prisons in priority countries in eastern and southern 
Africa with generalized epidemics and low rates of male circumcision, it is crucial 
that it is provided with full adherence to medical ethics and human rights principles. 
Informed consent, confidentiality and absence of coercion should be assured. 
SEx WORKERS (AND CLIENTS OF SEx WORKERS)
•	 Health messages and counselling should emphasize that resuming sexual 
relations before complete wound healing may increase the risk of HIV acquisition 
among recently circumcised HIV-negative men and may increase the risk of HIV 
transmission to female partners of recently circumcised HIV-positive men (84). 
•	 “Men’s health services” offering VMMC to clients of sex workers or other men at 
higher risk (such as in serodiscordant couples) may be a promising approach in 
the high-priority countries of eastern and southern Africa to reach men at greater 
risk of HIV infection. This approach has not been systematically reviewed and 
evaluated, however.
TRANSGENDER PEOPLE
VMMC is not recommended for HIV prevention among transgender women (3). 
ADOLESCENTS FROM KEY POPULATIONS 
Countries with hyperendemic and generalized HIV epidemics and low prevalence of 
male circumcision should increase access to male circumcision services as a priority 
for adolescents and young men (84). 
Implementation considerations 
Partial protection. Male circumcision provides only partial protection against female-
to-male HIV infection. Therefore, male circumcision services should not be delivered 
in isolation but rather as part of a recommended minimum package that also includes 
information about the risks and benefits of the procedure, counselling on safer sex 
practices, access to HIV testing, condom promotion and provision, and management of 
STIs (84). 
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Opportunity to expand services. Introduction and expansion of VMMC services in 
high-priority countries of eastern and southern Africa should serve as an opportunity to 
expand HIV services to all males. 
further reading
•	 Male circumcision for HIV prevention. Geneva, WHO, 2014. http://www.who.int/hiv/topics/
malecircumcision/en/ 
•	 Clearinghouse on male circumcision for HIV prevention. Research Triangle Park NC, USA, 
FHI360, 2014. http://www.malecircumcision.org/ 
•	 New data on male circumcision and HIV prevention: policy and programme implications. 
Geneva, WHO, 2007. http://libdoc.who.int/publications/2007/9789241595988_eng.pdf
4.2 HIV testing and counselling 
Background and rationale
HIV testing and counselling (HTC) is the essential first step in enabling people with 
HIV to know their status and obtain HIV prevention, treatment and care services. For 
those who test negative, HTC is an important opportunity to put those at risk for HIV in 
contact with primary prevention programmes and to encourage later retesting (4).
For key populations, especially those whose behaviour is criminalized, HTC services 
are sometimes used in punitive or coercive ways. To the contrary, HTC must always be 
voluntary and free from coercion, in particular by health-care providers, partners, family, 
clients of sex workers or within a prison or other closed setting (4, 8, 9, 10, 86). Like all 
testing and counselling, HTC for key populations needs to emphasize the WHO 5 Cs 
of HTC: consent, confidentiality, counselling, correct results and linkage to care (87) – 
particularly consent and confidentiality. 
Furthermore, HTC must be part of a 
comprehensive prevention, care and treatment 
programme (4). It is important that there are 
clear and robust links between testing and 
HIV prevention, treatment and care services 
for those who test positive and with prevention services for those who test negative; 
poor linkages prevent people from acting on their test results. HIV testing among 
key populations should follow nationally validated testing algorithms, accord with 
WHO testing strategies and have appropriate quality assurance/quality improvement 
mechanisms in place (88). 
Unaware of HIV status. It is estimated that, globally, about half of the people currently 
living with HIV do not know their HIV status (88). For people from key populations, 
access to HTC and, thus, knowledge of HIV status tend to be much less. People from key 
populations often test late and often fail to link from HTC to care and assessment for 
ART (88). Thus, many start treatment when already significantly immunocompromised, 
HTC is the essential first step, but 
about half of people living with HIV do 
not know their HIV status.
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when poor health outcomes – and, for pregnant women presenting late in antenatal care 
or at delivery, vertical HIV transmission – are more likely (4). 
Counselling is an essential component of testing. Pre-test counselling must provide 
accurate information about the test and the implications of a positive or negative result 
in order to enable the person seeking testing to make an informed choice. Post-test 
counselling must offer, among much else, support concerning disclosure of HIV status. 
Also, HTC offers a valuable opportunity to provide accurate information about safer sex 
and harm reduction that is relevant to the person being tested, reflecting the test result. 
Behavioural change and risk reduction counselling may also have value. 
Multiple settings. Rapid HIV testing enables health workers to provide clients with 
same-day results. Thus, HTC can be offered in a variety of settings, including primary 
care clinics (e.g. maternal, neonatal and child health clinics), and by a variety of 
providers, including outreach workers.
Community-based testing, linked to prevention, care and treatment, has the potential to 
reach greater numbers of people than clinic-based HTC – particularly those unlikely to 
go to a facility for testing and those who are asymptomatic (89). It is important to have 
clear procedures in place, following national HIV testing strategies and algorithms, to 
confirm positive HIV test results and to link clients to treatment and care (9). 
Provider-initiated HIV testing and counselling (PITC), where HTC is offered routinely 
in health-care settings, aims to increase coverage of HTC. It is recommended so long as 
it is not compulsory, is not coercive and is linked to treatment and care, in line with WHO 
guidelines. Particular attention should go to providing accurate information; informed 
consent must always be obtained; and results should remain confidential.
All forms of HTC should be voluntary and adhere to the five Cs: consent, 
confidentiality, counselling, correct test results and connections to care, treatment 
and prevention services. Quality assurance of both testing and counselling is 
essential to all HTC approaches (4, 90).  
recommendations and guidance
ALL KEY POPULATION GROUPS
•	 Voluntary HTC should be routinely offered to all key populations in both the 
community and clinical settings (3, 4, 8, 10, 86, 91).
•	 Community-based HIV testing and counselling for key populations, with linkage 
to prevention, care and treatment services, is recommended, in addition to 
provider-initiated testing and counselling (strong recommendation, low quality of 
evidence) (4). 
Additional remark
Couples and partners should be offered voluntary HTC with support for mutual 
disclosure (92).
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related recommendations and contextual issues for specific key population groups
PEOPLE IN PRISONS AND OTHER CLOSED SETTINGS 
It is important to guard against negative consequences of testing in prisons – 
for example, segregation of prisoners – and to respect confidentiality. It is also 
important that people who test positive have access and are linked to HIV care and 
treatment services (9, 93). 
•	 HIV testing and counselling should be voluntary (93). 
•	 The use of HIV rapid testing can increase the likelihood of prisoners receiving 
their results (93). 
•	 Testing in conjunction with other risk-reduction services such as the provision of 
condoms with lubricants and STI screening can increase the benefits of testing 
and counselling (93). 
ADOLESCENTS FROM KEY POPULATIONS 
In all epidemic settings accessible and acceptable HTC services must be available 
to adolescents and provided in ways that do not put them at risk (86). Countries 
are encouraged to examine their current consent policies and consider revising 
them to reduce age-related barriers to access and uptake of HTC and to linkages to 
prevention, treatment and care following testing (86). Young people should be able 
to obtain HTC without required parental or guardian consent or presence.
•	 HIV testing and counselling, with linkages to prevention, treatment and care, is 
recommended for adolescents from key populations in all settings (generalized, 
low and concentrated epidemics) (strong recommendation, very low quality of 
evidence) (4, 86). 
•	 Adolescents should be counselled about the potential benefits and risks of 
disclosure of their HIV status and empowered and supported to determine when, 
how and to whom to disclose (conditional recommendation, very low quality of 
evidence) (86). 
•	 Children of school age should be told their HIV-positive status (strong 
recommendation, low quality of evidence) (86).
Implementation considerations 
Rapid tests. Rapid HIV diagnostic tests at point of care greatly facilitate access to 
testing, return of same-day results and appropriate referral and follow-up (4). 
Continuous supply. Mechanisms should be developed to provide a consistent supply of 
test kits and prevent stock-outs. 
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Quality of services determines the uptake of HTC. Therefore, it is critical to institute a 
quality assurance system at national, subnational, facility and community levels (95).
Prison systems should be an integral part of national efforts to scale up access to HTC. 
Scaling up HIV HTC services in prisons should not be undertaken in isolation, but rather 
as part of a comprehensive HIV programme aimed at improving health care and achieving 
universal access to HIV prevention services in prisons and other closed settings (93).
Couples HTC. There are many potential advantages to supporting couples to test 
together and mutually disclose their HIV status; together, they can make informed 
decisions about HIV prevention and offer each other support for obtaining and adhering 
to ART. HTC for couples or partners should be offered to anyone, regardless of how 
they define their relationships. The principle – and the policy – should be that providers 
support all people in a sexual relationship to receive testing as a couple or as partners, 
irrespective of their sexual orientation or the length or stability of their relationship. 
Self-testing for HIV (HIVST) is a process whereby a person who wants to know his or her 
HIV status collects a specimen, performs a test and interprets the test result in private. 
HIVST is a screening test; it does not provide a diagnosis (96), and so confirmatory 
testing is required if the initial result is positive. HIVST may increase the number of 
people who test, know their status and, if testing positive, link to treatment. To date, 
evidence on this potential is limited, however.
While HIV self-testing kits may have been approved for sale and use, many countries do 
not have formal regulations or policies on their use. WHO has not yet issued normative 
global guidance on HIVST. However, UNAIDS and WHO have issued a short technical 
update to inform stakeholders who are considering or already implementing HIVST (97, 98).
further reading
•	 Guidance on provider-initiated HIV testing and counselling in health facilities. Geneva, WHO, 
2007. http://whqlibdoc.who.int/publications/2007/9789241595568_eng.pdf 
•	 UNODC,	WHO,	UNAIDS.	HIV testing and counselling in prisons and other closed settings. 
Vienna, UNODC, 2009. http://www.who.int/hiv/pub/idu/tc_prison_tech_paper.pdf
•	 Delivering HIV test results and messages for re-testing and counselling in adults. Geneva, 
WHO, 2010. http://whqlibdoc.who.int/publications/2010/9789241599115_eng.pdf  
•	 Service delivery approaches to HIV testing and counselling: a strategic policy framework. 
Geneva, WHO, 2010. http://apps.who.int/iris/bitstream/10665/75206/1/9789241593877_eng.
pdf 
•	 Guidance on couples HIV testing and counselling and antiretroviral therapy for treatment 
and prevention in serodiscordant couples. Geneva, WHO, 2012. http://apps.who.int/iris/
bitstream/10665/44646/1/9789241501972_eng.pdf 
•	 Report on the first International Symposium on Self-testing for HIV: the legal, ethical, gender, 
human rights and public health implications of HIV self-testing scale-up. Geneva, WHO, 
2013. www.who.int/iris/bitstream/10665/85267/1/9789241505628_eng.pdf
•	 HIV and adolescents: guidance for HIV testing and counselling and care for adolescents 
living with HIV: recommendations for a public health approach and considerations 
for policy-makers and managers. Geneva, WHO, 2013. http://www.who.int/iris/
bitstream/10665/94334/1/9789241506168_eng.pdf
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4.3 linkage and enrolment in care
HTC is just the first step in the continuum of HIV care; a positive HIV diagnosis without 
linkage to HIV prevention, care and treatment confers limited benefit. Ensuring that 
people are linked to and enrolled in HIV clinical care is necessary to realize the full 
health and prevention benefits of ART. Unfortunately, substantial losses occur at every 
step of the HIV care continuum. These losses can be particularly great among people 
from key populations. 
Psychological and social barriers. A number of psychological and social barriers 
hinder linkage to care for people newly diagnosed with HIV. The perceived stigma 
associated with attending an HIV clinic continues to be a barrier to early care enrolment. 
Lack of family support and fear of disclosure also hinder access. In addition, how people 
living with HIV perceive both their own health and the effectiveness of ART can affect 
their willingness to seek clinical care. People living with HIV who believe that alternative 
therapies will be effective, who fear the side-effects of ART, or who perceive that 
they are in good health are less likely to enrol in HIV care than those who do not have 
these perceptions (99). Also, injecting drug use is associated with poor linkage to and 
retention in care (100, 101). 
Several interventions to address these psychosocial barriers have been evaluated. 
Intensified post-test counselling combined with follow-up counselling by community 
health workers significantly increases the proportion who enrol in HIV care (102). 
People who inject drugs are more likely to start and stay in HIV treatment if they are 
participating in OST programmes (103). 
Economic constraints. Migration in search of employment opportunities (104) and 
an inability to miss work to attend clinical appointments (105, 106) may also inhibit 
enrolment in HIV clinical care.
Health system factors affecting linkage to care include reliance on passive referral as 
the only linkage strategy, inadequate staffing, long wait times, poor service offered in 
HIV clinics, and poor attitudes of health-care staff. 
Key operational issues need to be considered and addressed in order to improve linkage 
to care, including better partnerships between community and clinical providers and 
increased efforts to improve the quality of services (see Chapter 6).
4.4 HIV treatment and care 
4.4.1 antiretroviral therapy
Background and rationale
The use of ART for HIV in key populations should follow the same general principles and 
recommendations as for all adults (4). They should have the same access, as well. People 
in key populations may experience discrimination and marginalization that can impede 
their access to health care, including treatment for HIV. It is important to ensure that 
people from key populations have equitable access to HIV treatment and care. 
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Updated guidance. The 2013 revision of WHO ART guidelines includes new 
recommendations on when to initiate ART, what drug regimens to use for first-line, 
second-line and third-line treatment, and how to monitor people on ART. These 
guidelines (4) should be consulted for full details on ART management. 
Key populations living with HIV should have the same access to ART and care and 
the same ART management as other populations.  
recommendations and guidance
ALL KEY POPULATION GROUPS
ART initiation
•	 As a priority ART should be initiated in all individuals with severe or advanced 
HIV clinical disease (WHO clinical stage 3 or 4) and individuals with CD4 counts 
of ≤350 cells/mm3 (strong recommendation, moderate quality of evidence) (4). 
•	 ART should be initiated in all individuals with HIV with CD4 counts between 350 
and 500 cells/mm3 regardless of WHO clinical stage (strong recommendation, 
moderate quality of evidence) (4). 
•	 ART should be initiated in all individuals with HIV, regardless of WHO clinical 
stage or CD4 count, in the following situations (4) : 
– individuals with HIV and active TB disease (strong recommendation, low quality 
of evidence);
– individuals co-infected with HIV and HBV with evidence of severe chronic liver 
disease (strong recommendation, low quality of evidence);
– partners with HIV in serodiscordant couples, to reduce HIV transmission to 
uninfected partners (strong recommendation, high quality of evidence);
– pregnant and breastfeeding women (strong recommendation, moderate quality 
of evidence). 
Additional remark
There are no special clinical ART recommendations specific to any key population. 
However, because of stigma, discrimination  and marginalization, they frequently 
present late for treatment.
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related recommendations and contextual issues for specific key population groups
PEOPLE IN PRISONS AND OTHER CLOSED SETTINGS 
•	 HIV treatment adherence can be increased by addressing HIV stigma and 
discrimination, ensuring the confidentiality of a prisoner’s HIV status, and 
allowing people in prisons and other closed settings access to care and treatment 
without discrimination by prison officials. 
•	 If they are being transferred, people in prisons and other closed settings should 
be given a supply of ART to last until health care can be established at the 
new prison location or, if they are being released, until linkage can be made to 
community-based HIV care (60, 107, 108, 109, 110, 111, 112, 113, 114). 
PEOPLE WHO INJECT DRUGS 
•	 Current WHO guidance on the use of ART for treatment of HIV infection in adults 
and adolescents applies to people living with HIV who inject drugs (4). 
•	 When ART is provided in a supportive environment, people who inject drugs have 
treatment outcomes similar to others’ outcomes (115).
ADOLESCENTS FROM KEY POPULATIONS 
Community-based approaches can improve treatment adherence and retention in 
care of adolescents living with HIV (86). 
Training of health-care workers can contribute to treatment adherence and retention 
in care of adolescents living with HIV (86). 
Health-care providers can support adherence among adolescents by: 
•	 assisting them in exploring factors influencing their adherence 
•	 improving their understanding of HIV, ART and adherence 
•	 recognizing developmental needs while supporting their emerging independence
•	 assisting them in integrating ART into daily life
•	 offering simplified ART regimes 
•	 encouraging participation in peer support groups and community-based 
interventions (116, 117, 118).
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Implementation considerations 
ART service delivery. The 2013 WHO consolidated ARV guidelines (4) offer a number of 
service delivery recommendations, including decentralization of ART care and integrating 
ART services into other clinical services such as TB services, ANC and services where OST 
is provided.
Approaches to support ART delivery, retention in care and adherence. People 
from key populations often face more barriers than other populations to access to care 
and continuation in care. They often are hard to reach and mobile, have less access 
to and uptake of health services in general and may face stigma and discrimination in 
health services. Chapter 6 considers a range of approaches to support better access, 
retention and adherence models. 
ART in prisons and other closed settings. HIV treatment, including ART, care and 
support, in prisons should be equivalent to that available to people living with HIV in the 
community and should be in line with national guidelines. 
People who are incarcerated have the additional risk of acquiring TB. However, with 
adequate support and structured treatment programmes, excellent outcomes can 
be achieved in the prison setting (4, 9). Given the high incarceration rates in key 
populations, efforts should be made to ensure that ART (and TB treatment) is available 
as part of prison health services (4, 9).
further reading
•	 Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV 
infection: recommendations for a public health approach. Geneva, WHO, 2013. http://www.
who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf 
4.4.2 prevention of mother-to-child transmission 
Background and rationale
Prevention of mother-to-child transmission (PMTCT) of HIV, also known as prevention 
of vertical transmission, refers to interventions to prevent transmission of HIV from a 
mother living with HIV to her infant during pregnancy, labour and delivery or during 
breastfeeding. PMTCT also focuses on early initiation of ART in the mother and assuring 
the mother’s health.
WHO recommends a four-pronged approach to a comprehensive PMTCT strategy:
1. Primary prevention of HIV infection among women of childbearing age
2. Preventing unintended pregnancies among women living with HIV
3. Preventing HIV transmission from women living with HIV to their infants
4. Providing appropriate treatment, care, and support to mothers living with HIV, their 
children and families.
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In the third prong, which focuses on the direct 
interventions to prevent vertical transmission, the 
preventive interventions consist of a cascade of 
services, from HIV testing and counselling, ART, 
safe delivery, safer infant feeding, postpartum 
interventions in the context of ongoing ART, early infant diagnosis and final diagnosis 
for HIV-exposed infants, through linkage of both the mother and child to appropriate 
care and treatment (prong 4). 
All pregnant women from key populations should have the same access to PMTCT 
services and follow the same recommendations as women in other populations. 
recommendations and guidance
ALL PREGNANT WOMEN1 IN KEY POPULATION GROUPS
•	 All pregnant and breastfeeding women living with HIV should initiate triple 
antiretrovirals (ARV), which should be maintained at least for the duration of 
risk of mother-to-child transmission. Women meeting treatment eligibility criteria 
should continue ART for life (CD4 <500 cells/mm3) (strong recommendation, 
moderate quality of evidence) (4).
•	 For programmatic and operational reasons, particularly in generalized epidemics, 
all pregnant and breastfeeding women living with HIV should initiate ART and 
maintain it as lifelong treatment (option B+) (conditional recommendation, low 
quality of evidence) (4). 
related recommendations and contextual issues for specific key population groups
PEOPLE IN PRISONS AND OTHER CLOSED SETTINGS 
Special consideration should be given to ensuring that pregnant female prisoners 
have ready access to PMTCT services, as women often face greater barriers to HIV 
testing, counselling, care, and treatment in prison than outside prison. 
1 This includes pregnant transgender men.
Direct interventions to prevent 
vertical transmission consist of a 
cascade of services.
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PEOPLE WHO INJECT DRUGS 
All pregnant women and their families affected by substance use disorders should 
have access to affordable prevention and treatment services and interventions 
delivered with a special attention to confidentiality, national legislation and 
international human rights standards; women should not be excluded from health 
care because of their substance use (119).
Implementation considerations 
Equity and overcoming barriers to access. In most countries women from key 
populations have less access to PMTCT than women in the general population. In 
particular, people who inject drugs, their partners, and sex workers have less access. 
Also, adolescent girls generally and adolescent girls from key populations in particular 
have less access to PMTCT interventions and have worse outcomes. Special efforts 
should be made to understand and overcome barriers to access and to provide 
acceptable services that reach adult and adolescent women from key populations. 
Later presentation. Adult and adolescent women from key populations often 
present late to antenatal care (ANC) or first present at labour without any ANC, and 
consequently they access PMTCT interventions very late. Also, they often face special 
challenges to follow-up and ongoing interventions postpartum. This has adverse 
consequences for their own health and their infants’, and it decreases the effectiveness 
of PMTCT interventions. Strategies need to be developed to promote and support earlier 
attendance at ANC by pregnant women from key populations. 
Supporting adherence. Special effort and initiatives are needed to optimize access to 
care and adherence support for women from key populations and to support effective 
linkages to long-term treatment. This is especially true during breastfeeding, a period 
when follow-up is often poor. 
further reading
•	 Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV 
infection: recommendations for a public health approach. Geneva, WHO, 2013. http://www.
who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf 
•	 Guidelines for the identification and management of substance use and substance use 
disorders in pregnancy. Geneva, WHO, 2014. http://apps.who.int/iris/bitstream/ 
10665/107130/1/9789241548731_eng.pdf
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4.4.3 art drug interactions  
Background and rationale
Providers should be aware of all drugs that 
people with HIV are taking when ART is initiated 
and new drugs that are added during continuing 
treatment. For many from key populations, 
this may include recreational drugs, drugs for 
coinfections and co-morbidities, and among transgender people cross-sex hormones. 
Possible drug interactions add complexities when prescribing ARV drugs and monitoring 
treatment. Counselling on the possible consequences of drug interactions and an 
environment that promotes and enables reporting of concomitant medications are 
critical components of high-quality care for all people with HIV.
tuberculosis
WHO TB treatment guidelines review key considerations for managing coinfection with 
TB and HIV (120). A key contraindicated drug combination is rifampicin and protease 
inhibitors (PIs). When people coinfected with TB and HIV are receiving a boosted PI, 
rifabutin may need to be substituted for rifampicin. If rifabutin is not available, only 
lopinavir/ritonavir (LPV/r) can be concomitantly used for the duration of TB treatment, 
provided the boosting dose of ritonavir is increased or double the standard dose of LPV/r 
is used. 
Hepatitis c
Ribavirin and pegylated interferon alpha-2a are often used to treat chronic hepatitis C 
virus (HCV) infection. Administration of these agents along with zidovudine (AZT) has 
been associated with increased risk of anaemia and hepatic decompensation. People 
co-infected with HCV and HIV and receiving AZT may need to be switched to tenofovir 
(TDF) (121).
Hormones used for contraception 
ARV drugs have the potential to either decrease or increase the bioavailability of 
steroid hormones in hormonal contraceptives (122). Limited data suggest potential drug 
interactions between contraceptive hormones and many ARV drugs (especially some 
non-nucleoside reverse transcriptase inhibitors (NNRTIs) and ritonavir (RTV)-boosted 
PIs). These interactions may alter the safety and effectiveness of both the hormonal 
contraceptive and the ARV drug. However, current WHO contraception guidelines 
conclude that none of the drug interactions between currently recommended ARVs for 
treatment and for PrEP, on one hand, and, on the other, hormonal contraceptives are 
significant enough to prevent their use together (122). If women receiving ART decide 
to initiate or continue using hormonal contraceptives, consistent use of condoms is 
recommended both to prevent HIV transmission and to compensate for any possible 
reduction in the effectiveness of the hormonal contraception. 
Hormones used in cross-hormonal treatment protocols for transgender women and men
There are limited data on the interactions between ARVs and a variety of other drugs 
used in cross-hormonal treatment protocols for transgender women, particularly with 
Possible drug interactions add 
complexities when prescribing ARV 
drugs and monitoring treatment.
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anti-androgens (e.g. cyproterone acetate, flutamide). The same is true for androgens 
(e.g. dihydrotestosterone) commonly used by transgender men. Currently, there are 
no documented drug interactions between these medications and ARVs. However, 
this issue deserves more research, as transgender women and men often use several 
drugs combined and sometimes at high doses, with potential for multidirectional 
drug interactions. Meanwhile, as ARV treatment may lead to hormonal fluctuations 
among transgender women taking gender-affirming medications, close monitoring is 
recommended. 
In addition, some ARV drugs may potentiate glucose and lipid metabolic abnormalities 
associated with alterations in hormone levels as well as increase the risk of thrombotic 
events and hepatic toxicity (123). All these risks are further increased by the frequent 
practice of self-medication, which often involves products and doses that are less safe than 
those typically prescribed by health workers. More research in these areas also is needed.
opioids 
WHO recommends methadone and buprenorphine to treat opioid dependence (50). 
Co-administering efavirenz (EFV) decreases methadone concentrations. This could 
subsequently cause withdrawal symptoms and increase the risk of relapse to opioid 
use. People receiving methadone and EFV should be monitored closely, and those 
experiencing opioid withdrawal may need to adjust their methadone dose (50). 
The limited evidence suggests no interactions between ARVs and recreational drugs. 
There can be dangerous interactions between recreational drugs, however. For 
example, concomitant amyl nitrite (“poppers”) and sildenafil may cause cardiovascular 
complications.  
1 If rifabutin is not available, only LPV/r can be used, provided the boosting dose of ritonavir is increased or double the standard dose of 
LPV/r is used.
table 4.1 key arV drug interactions and suggested substitutions
ARV drug Key interactions Suggested management
AZT Ribavirin and peginterferon 
alfa-2a
First-line: substitute AZT with TDF
Second-line: substitute AZT with 
stavudine (d4T) 
Boosted 
PI (ATV/r, 
DRV/r, 
LPV/r)
Rifampicin
Estrogen-based hormonal 
contraception
Methadone and buprenorphine
Substitute rifampicin with rifabutin1
Advise additional use of male or female 
condoms
Adjust methadone and buprenorphine 
doses as appropriate
EFV Methadone
Estrogen-based hormonal 
contraception
Adjust the methadone dose as 
appropriate
Advise additional use of male or female 
condoms
Nevirapine 
(NVP)
Rifampicin
Estrogen-based hormonal 
contraception
Substitute NVP with EFV
Advise additional use of male or female 
condoms
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further reading
•	 HIV-drug interactions. The University of Liverpool. http://www.hiv-druginteractions.org/
4.5 prevention and management of coinfections and co-morbidities 
An essential part of HIV treatment and care is the management of opportunistic 
infections such as TB and viral hepatitis. Addressing HIV effectively also requires 
addressing other co-morbidities such as other sexually transmitted bloodborne 
infections and mental health disorders. To synergize prevention and control efforts, it is 
appropriate to seek opportunities to combine the delivery of HIV testing, treatment and 
prevention services with those for these coinfections and co-morbidities.
4.5.1 tuberculosis 
Background and rationale
Despite being preventable and curable, TB is 
the leading cause of HIV-associated mortality, 
accounting for one of every five HIV-related deaths. 
The risk of developing TB is 30 times higher among 
people living with HIV than among people who 
do not have HIV infection (124). In 2012 there were an estimated 1.1 million cases of TB 
among the 35 million people living with HIV worldwide (124). Independent of their HIV 
status, key populations, in particular people who inject drugs and prisoners, have an 
increased risk of TB, including multidrug-resistant TB (MDR-TB) (50, 125, 126, 127, 128). 
In addition, outbreaks of TB and MDR-TB have been reported among men who have 
sex with men and transgender sex workers (129, 130). Common risk factors and social 
determinants that put key populations at increased risk of TB include HIV infection, 
poverty, malnutrition, stress, alcoholism, smoking, diabetes, indoor air pollution, drug 
use, incarceration and poor living and working conditions (131). 
Prisons play a key role in fuelling the epidemic of TB and MDR-TB, and TB is believed 
to be the leading cause of death among prisoners in high burden settings (132, 133). 
Similarly, other congregate settings frequently attended by people living with HIV and 
marginalized groups can expose them to increased risk of TB if adequate TB infection 
control measures are not in place. Such settings could include brothels, bars, drop-in 
centres, drug treatment centres, health facilities and shelters (130, 134, 135, 136). 
To address TB among people living with HIV, including key populations, WHO 
recommends a 12-point package of collaborative TB/HIV activities. The package seeks to 
establish and strengthen mechanisms for delivering integrated TB and HIV services, to 
reduce the burden of TB among those living with HIV, and to reduce the burden of HIV in 
TB patients (4, 65, 137, 138, 139).
Tuberculosis is preventable and 
treatable, but it accounts for one 
in every five HIV-related deaths.
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Barriers to prevention and care for key populations need to be addressed to ensure 
access to integrated, client-centred services, preferably at the initial point of care, and to 
encourage treatment adherence (65). 
Prevention of TB. Isoniazid preventive therapy (IPT) and ART, given together, can 
reduce the risk of TB among people living with HIV by up to 97% (140). Alone, IPT has 
been shown to reduce the risk of TB among people living with HIV by 68% (137). Once 
active TB is ruled out, people living with HIV should be offered at least six months, IPT 
and support should be provided to ensure adherence. Also, appropriate TB infection 
control measures and contact tracing are essential to reduce transmission of TB in 
congregate settings (50, 125).
Screening and diagnosis of TB. All people living with HIV should be screened 
regularly with the WHO-recommended four TB symptom screening algorithm – that is, 
a current cough, fever, night sweats or weight loss – at each contact with a health-care 
worker (137). This screening helps determine eligibility for IPT by ruling out the likelihood 
of active TB and to identify those who need further evaluation, diagnosis and treatment 
for TB as necessary. WHO recommends using xpert MTB/RIF as the first diagnostic test 
for all TB in all people living with HIV and for anyone suspected of MDR-TB (irrespective 
of HIV status) (141). Stakeholders providing support to key populations can offer 
gateways to early TB detection and timely prevention and treatment of both TB and HIV. 
It is crucial, therefore, that personnel are aware of the symptoms of TB.
TB treatment. TB treatment consists of a standardized regimen of antibiotics taken 
for at least six months, irrespective of HIV status. Completing TB treatment is critical 
to reducing mortality and avoiding the development and spread of drug-resistant TB. It 
is vital to provide a supportive, non-judgemental and non-discriminatory environment 
that enables people from key populations to complete treatment, provides additional 
adherence support measures to improve treatment outcomes, and reduces the risk of 
continued TB transmission (65). 
Timely initiation of ART significantly reduces the risk of mortality from HIV-associated 
TB. As TB is one of the most common AIDS-defining illnesses, all those with presumptive 
or diagnosed TB should be offered HIV testing and counselling as a priority so that those 
testing positive can start ART as soon as possible, in any case no later than eight weeks 
after initiation of TB treatment, regardless of CD4 count. 
Programmes serving key populations need to ensure access to integrated, client-centred 
services, preferably at the initial point of care, including TB screening, prevention and 
treatment, and support for treatment adherence (65).
Key populations should have the same access to TB prevention, screening and 
treatment services as other populations at risk of or living with HIV (138). 
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recommendations and guidance
ALL KEY POPULATION GROUPS
•	 Routine HIV testing should be offered to all people with presumptive and 
diagnosed TB (strong recommendation, low quality of evidence) (138).
•	 ART should be initiated in all individuals with HIV and active TB disease 
regardless of WHO clinical stage or CD4 cell count (strong recommendation, low 
quality of evidence) (4). 
Additional remark
•	 ART should be initiated as soon as possible, no later than eight weeks after 
initiation of TB treatment (4).
•	 Alcohol dependence, active drug use and mental health disorders should not be 
used as reasons to withhold TB treatment (65).
related recommendations and contextual issues for specific key population groups
PEOPLE IN PRISONS AND OTHER CLOSED SETTINGS 
•	 Systematic screening for active TB should be considered in prisons and other 
closed settings (124). It should be a priority where the prevalence of TB is high in 
the general population or in the prison population; where the incarceration rate is 
high; where the prevalence of HIV or MDR-TB is high; or where living conditions 
are poor.
•	 Medical examination, including TB screening, upon entry and any time thereafter, 
conforming to internationally accepted standards of medical confidentiality and 
care, should be conducted for all prisoners (65). 
•	 Prisoners should obtain care equivalent to that provided for the general 
population (65). 
•	 Given the high risk for transmission of TB and high rates of HIV-TB co-morbidity 
in closed settings, all prisons should engage in intensified case-finding, provide 
isoniazid preventive therapy for people living with HIV, and introduce effective 
tuberculosis control measures (65).
•	 Essential for TB prevention in prisons is the improvement of living conditions by 
limiting the number of prisoners per cell and providing adequate ventilation and 
nutrition (65). 
•	 People in prisons or other closed settings known or suspected to have infectious 
TB should be separated (in a clinical setting) from other people until adequately 
treated and shown to be non-infectious (65). 
•	 Education activities for all prisoners should cover coughing etiquette and 
respiratory hygiene (11). 
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•	 Continuity of TB treatment in prisons and other closed settings is essential to 
prevent the development of resistance and must be ensured at all stages of 
detention, including during prison transfer, and following release. This requires 
close collaboration between health services providing care for the general 
population and those caring for detainees, prisoners and the like (11). 
SEx WORKERS
Clinical programmes or community outreach services for sex workers can carry 
out TB screening and can support sex workers throughout the cycle of care, from 
TB prevention through diagnosis and treatment. They can teach sex workers to 
recognize TB symptoms and understand TB transmission, as well as to appreciate 
the importance of infection control and cough etiquette. They also can inform their 
clients of nearby health facilities for TB diagnosis and treatment (71).
Implementation considerations 
Collaboration. TB and HIV programmes, social services, drug treatment services and 
prison health services should collaborate in referrals and services for people from key 
populations to ensure access to comprehensive TB and HIV prevention, treatment and 
care in a holistic, person-centred way – in one setting if possible – that maximizes 
access and adherence (65).
Training. Health-care workers (including community-based persons assisting with 
treatment and prophylaxis) who serve key populations need specific training to provide 
quality TB and HIV care to people from key populations. Personnel, including prison 
staff, should also know how to protect themselves from occupational exposure to HIV 
and TB (65). 
PEOPLE WHO INJECT DRUGS 
•	 People with TB who inject drugs should have equitable access to TB treatment 
(50).
•	 Co-morbidity, including viral hepatitis infection, should not contraindicate TB 
treatment for people who inject drugs and should be properly managed (65). 
•	 For patients with TB, OST should be administered in conjunction with medical 
treatment; there is no need to wait for abstinence from opioids to commence 
either anti-TB medication or antiretroviral medication (50). 
•	 Rifampicin, one of the first-line drugs used to treat TB, can significantly reduce 
the concentration and effect of both methadone and buprenorphine, resulting in 
opioid withdrawal (142, 143, 144). See Section 4.4.3. 
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TB infection control. Every health-care and other congregate setting should have a 
TB infection control plan (preferably included in the general infection control plan), 
supported by all stakeholders, that includes administrative, environmental and personal 
protection measures to reduce transmission of TB and surveillance of TB among workers 
(65). 
Mainstream TB treatment services should be accessible and responsive to the needs 
of key populations (65). 
further reading
•	 WHO,	UNODC,	UNAIDS.	Policy guidelines for collaborative TB and HIV services for injecting 
and other drug users – an integrated approach. Geneva, WHO, 2008 [being updated as of 
spring 2014]. http://whqlibdoc.who.int/publications/2008/9789241596930_eng.pdf 
•	 WHO policy on collaborative TB/HIV activities: guidelines for national programmes 
and other stakeholders. Geneva, WHO, 2012. http://whqlibdoc.who.int/
publications/2012/9789241503006_eng.pdf 
•	 Guidelines for intensified tuberculosis case finding and isoniazid preventive therapy 
for people living with HIV in resource-constrained settings. Geneva, WHO, 2011. http://
whqlibdoc.who.int/publications/2011/9789241500708_eng.pdf
4.5.2 Viral hepatitis 
Background and rationale
Viral hepatitis B and C disproportionally affect key populations, as a result of sexual 
transmission and the sharing of needles, syringes and ancillary injecting equipment. 
It is estimated that, globally, 240 million people are chronically infected with HBV 
and 150–170 million with HCV1. People who inject drugs account for approximately 
1.1 million of those with HBV and 10 million of those with HCV (145).
Worldwide, of the 35 million people living with 
HIV, chronic HBV infection affects an estimated 
5–20% and HCV affects 5–15%. The burden of 
coinfection is greatest in low and middle income 
countries, particularly in South-East Asia, and, 
for HBV, particularly in sub-Saharan Africa. 
Among those living with HIV who are coinfected 
with HBV or HCV, liver disease progresses more rapidly and mortality is greater than 
among those with HBV or HCV who are not living with HIV. 
HCV seroprevalence rates in prisons are even higher than HIV rates, and in many 
countries a history of HCV infection is associated with a history of incarceration (146, 147, 
148, 149, 150).
1 Hepatitis C, Fact sheet N°164 Geneva, WHO, 2014. http://www.who.int/mediacentre/factsheets/fs164/en/
A comprehensive approach to 
addressing viral hepatitis among 
key populations includes prevention, 
screening, HBV vaccination, and 
treatment and care.
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A comprehensive approach to addressing viral hepatitis among key populations includes 
prevention, screening, HBV vaccination, and treatment and care for people coinfected 
with HIV and HBV and/or HCV (4). 
Hepatitis B and c prevention
The major modes of viral hepatitis transmission include unsterile medical injections or 
other procedures, transfusions of contaminated blood, unprotected sexual intercourse 
and unsafe injecting (39, 61, 149, 151, 152, 153). HCV is rarely transmitted through 
heterosexual sex. Over the past decade, however, several outbreaks of presumed 
sexually transmitted HCV infection have been reported among HIV-positive men who 
have sex with men. Similar HCV transmission among HIV-negative men who have sex 
with men and comparable drug-related behaviour has also been reported (154). 
Because modes of transmission for viral hepatitis overlap those for HIV, many 
interventions that prevent HIV also prevent HBV and HCV. Examples include correct and 
consistent condom use, needle and syringe programmes and OST and sterile tattooing 
practices. 
Hepatitis B vaccine 
HBV vaccine is safe, effective and fairly inexpensive. Most countries have both targeted 
and population-wide HBV vaccination programmes, including infant, catch-up and risk-
group vaccination. Risk groups include people who inject drugs, men who have sex with 
men, sexual partners of people living with HIV, prisoners, and others such as recipients 
of blood products and health-care workers. By 2012, 181 countries had incorporated 
HBV vaccination into their national schedule as an integral part of national infant 
immunization (155). An estimated 79% of the 2012 birth cohort globally received three 
doses of the HBV vaccine (156). The implication of national HBV vaccination programmes 
is that HBV vaccination of high-risk groups will become less crucial over time as, 
increasingly, people are immunized in infancy and thus protected (39). 
There is currently no vaccine for HCV. Hence, there is an even greater need to intensify 
current efforts to prevent HCV transmission among key populations (39). 
Hepatitis B and c treatment
It is important to manage HIV coinfection with HBV and/or HCV appropriately. 
Coinfection with HIV and HCV accelerates HCV-related progression of liver fibrosis and 
leads to a higher rate of end-stage liver disease and mortality (121, 151, 157). 
Key populations should have the same access to hepatitis B and C prevention, 
screening and treatment services as other populations at risk of or living with HIV.
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recommendations and guidance
ALL KEY POPULATIONS
Hepatitis B
•	 Catch-up hepatitis B immunization strategies should be instituted in settings 
where infant immunization has not reached full coverage (3, 10, 32). 
•	 People from key populations with HIV and HBV coinfection who have severe 
chronic liver disease should be offered ART with a tenofovir (TDF) and lamivudine 
(3TC) (or emtricitabine (FTC))-based regimen irrespective of CD4 count or WHO 
clinical stage (strong recommendation, low quality of evidence) (4).1
Hepatitis C
•	 HCV serology testing should be offered to individuals from populations with high 
HCV prevalence or who have a personal history of HCV risk exposure/behaviour 
(strong recommendation, moderate quality of evidence) (158).
•	 An alcohol intake assessment is recommended for all persons with HCV infection, 
followed by the offer of a behavioural alcohol reduction intervention for persons 
with moderate-to-high alcohol intake (strong recommendation, moderate quality 
of evidence) (158). 
•	 Assessment for antiviral treatment of all adults and children with chronic 
HCV infection is recommended, including for people who inject drugs (strong 
recommendation, moderate quality of evidence) (158). 
•	 In addition, a number of recommendations on diagnosis and antiviral treatment 
regimens for HCV are available (158). 
Additional remarks
•	 WHO is developing clinical guidance on hepatitis B treatment and screening 
strategies for hepatitis B and C. This guidance should be available in early 2015. 
•	 WHO HCV guidelines provide detailed guidance on treatment and care (158). 
•	 There are challenges in diagnosing and treating active HCV infection in certain 
populations such as people who inject drugs, particularly in settings with limited 
access to HCV antibody and RNA assays, diagnostic tools for staging of liver 
disease and HCV therapy. People receiving ART and HCV drugs require close 
monitoring for possible drug interactions (158, 159). 
1 There is insufficient evidence or favourable risk-benefit profile to support initiating ART in everyone coinfected with HIV and HBV with 
a CD4 count >500 cells/mm3 or regardless of CD4 cell count or WHO clinical stage. Initiating ART regardless of CD4 count is, therefore, 
recommended only for people with evidence of severe chronic liver disease, who are those at greatest risk of progression and mortality 
from liver disease. For people without evidence of severe chronic liver disease, ART initiation should follow the same principles and 
recommendations as for other adults.
PIPELINE
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related recommendations and contextual issues for specific key population groups
PEOPLE IN PRISONS AND OTHER CLOSED SETTINGS 
•	 It is important that prisons offer hepatitis B vaccination (50, 60). 
•	 It is important to offer voluntary HCV/HBV testing, treatment and care for people 
living with HIV soon after entry to prison, with assessment for and provision 
of treatment in accord with current WHO recommendations. Harm reduction 
measures should also be offered to prisoners.
PEOPLE WHO INJECT DRUGS 
In addition to the comprehensive harm reduction package of nine interventions for 
people who inject drugs (8) , which include most importantly NSP and OST, specific 
recommendations include:
•	 offering the rapid hepatitis B vaccination regimen to people who inject drugs (39) ;
•	 needle and syringe programmes should also offer low dead-space syringes (39) ;
•	 offering peer interventions to reduce transmission of viral hepatitis among people 
who inject drugs (39 ).
It is important also to consider the following:
•	 A higher-dose HBV vaccine should be used with the rapid regimen.1
•	 When the rapid vaccine regimen is not available, the standard regimen should be 
offered. 
•	 For both the standard and rapid regimens, delivery of the first dose is the priority.
•	 To reduce transmission of viral hepatitis, needle and syringe programmes 
should offer all types of syringes and other equipment used for the preparation 
of injecting drugs, including cookers, sterile water, alcohol swabs, filters and 
tourniquets, as appropriate to local needs.
Implementation considerations 
Lost opportunities. Opportunities to vaccinate people who inject drugs often may 
be lost because of their poor access or reluctance to be vaccinated (160). Providing 
incentives to people who inject drugs and offering convenient access may increase 
uptake and completion of the HBV vaccination schedule (87, 152). Even partial 
immunization confers some immunoprotection, however (89). The decision whether to 
offer incentives depends on local acceptability and resources (161).
1 The standard vaccination schedule for infants and unvaccinated adults is 0, 1, and 6 months, while the rapid schedule is 1, 7 and 21 days 
(39).
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Immunosuppression. Individuals with inadequately treated HIV or with chronic HCV 
may have suppressed immune response. Therefore, they may benefit more from the 
standard HBV vaccine regimen than the rapid regimen (39). 
further reading
•	 Hepatitis C, Fact sheet N°164. Geneva, WHO, 2014. http://www.who.int/mediacentre/
factsheets/fs164/en/
•	 Guidelines for the screening, care and treatment of persons with hepatitis C infection. 
Geneva, WHO, 2014. http://apps.who.int/iris/bitstream/10665/111747/1/9789241548755_
eng.pdf
•	 Guidance on prevention of viral hepatitis B and C among people who inject drugs. Geneva, 
WHO, 2012. http://www.who.int/iris/bitstream/10665/75357/1/9789241504041_eng.pdf 
4.5.3 mental health 
Background and rationale
People living with HIV – including those from key populations – and their families and 
caregivers may have a wide range of mental health needs. Common mental health 
co-morbidities include depression and anxiety. Dementia and other cognitive disorders 
are also associated with longer-term HIV infection. HIV care settings can provide an 
opportunity for the detection and management of mental health problems among people 
living with HIV, including pre-existing mental health issues.
In addition to being disproportionately burdened 
by HIV, key populations experience higher rates 
of depression, anxiety, smoking, harmful alcohol 
use and alcohol dependence, other substance 
use and suicide as a result of chronic stress, 
social isolation, violence and disconnection from 
a range of health and support services (3).
Studies suggest that mental health disorders in people living with HIV may interfere 
with treatment initiation and adherence and lead to poor treatment outcomes (162). 
The presence of mental health co-morbidities may affect adherence to ART, due to 
forgetfulness or poor organization, motivation or understanding of treatment plans. 
Psychosocial support, counselling, appropriate drug therapies, and interventions such 
as case management may help to improve adherence to ART and retention in care (4). 
The WHO Mental Health Gap Action Programme (mhGAP) intervention guide for 
mental, neurological and substance use issues in non-specialized health settings makes 
recommendations related to general mental health care that can be relevant to people 
living with HIV, including those from key populations (4, 46). 
Adolescents from key populations. Mental health co-morbidities among adolescents 
are a particular concern. Suicide is one of the leading causes of death of adolescents 
worldwide; unipolar depressive disorders and self-harm are major causes of disability-
People from key populations 
may face the double burden of 
mental health issues associated with 
HIV infection and of marginalization, 
discrimination and stigma.
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adjusted life years (DALYs) lost in 10–19-year-olds (163). Adolescents from key 
populations may face social isolation, harassment and discrimination, which may add to 
their vulnerability to mental health co-morbidities, emotional distress and self-stigma. 
recommendations and guidance 
ALL KEY POPULATION GROUPS
Routine screening and management for mental health disorders (particularly 
depression and psychosocial stress) should be provided for people from key 
populations living with HIV in order to optimize health outcomes and improve 
adherence to ART. Management can range from co-counselling for HIV and 
depression to appropriate medical therapies (4). 
related recommendations and contextual issues for specific key population groups
ADOLESCENTS FROM KEY POPULATIONS
Peer support groups and safe spaces can help improve self-esteem and address 
self-stigma. Additionally, individual and family counselling can address adolescents’ 
mental health co-morbidities. The involvement of supportive parents or guardians 
can be beneficial, especially for those requiring ongoing treatment and care. It is 
important, however, to have the adolescent’s express permission before contacting 
parents or care-givers (86). 
Implementation considerations 
Integrated and comprehensive services provide the opportunity for patient-centred 
prevention, care and treatment for the multiple emotional and mental health issues 
affecting key populations. In addition, integrated services enhance the likelihood of 
improved communication among, and thus of better care by, the different service 
providers working with key populations (39).
further reading
•	 mhGAP intervention guide for mental, neurological and substance use disorders in non-
specialized health settings. Geneva, WHO, 2011. http://www.who.int/mental_health/
publications/mhGAP_intervention_guide/en/ 
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4.6 general care
4.6.1 nutrition
Background and rationale
Low energy intake combined with increased 
energy demand because of HIV infection and 
related infections or conditions often leads to 
HIV-related weight loss and wasting. In addition, 
an altered metabolism, reduced appetite, and 
diarrhoeal diseases may lower nutrient intake 
and absorption and so can also contribute to nutrient losses (164). These effects may 
be magnified in low-income and food-insecure contexts, such as those experienced 
by many key populations. In turn, poor nutritional status can hasten the progression 
of HIV disease; low body mass index (BMI) in adults (BMI less than 18.5 kg/m2) is an 
independent risk factor for HIV disease progression and mortality (4). 
Collaboration between HIV programmes and existing national programmes for 
nutritional support is necessary and feasible to achieve optimal health outcomes in 
food-insecure settings. Consideration should be given to providing nutritional support to 
people from key populations living with HIV in food-insecure circumstances (4). ART in 
conjunction with nutritional support could accelerate recovery. 
WHO is currently developing recommendations for nutritional care and support of 
adolescents and adults living with HIV. 
related recommendations and contextual issues for specific key populations 
PEOPLE IN PRISONS AND OTHER CLOSED SETTINGS 
Inadequate nutrition is a major problem for many people in prisons and can have 
a significant impact on people with HIV or TB, jeopardizing treatment outcomes 
and adherence. Protecting and promoting the health of people in prisons and other 
closed settings should include provision of adequate nutrition, including access to 
safe drinking water and nutritional supplements (11). 
4.6.2 sexual and reproductive health interventions 
Members of key populations, regardless of whether 
or not they are living with HIV, should be able to 
experience full, pleasurable sexual lives and have 
access to a range of reproductive options. Women 
from key populations should enjoy the same 
reproductive health rights as all other women; it 
is important that they have access to family planning and other reproductive health 
services, including reproductive tract cancer prevention, screening and treatment (32). 
For many women from key populations, their main concerns often are not just HIV and 
Collaboration between HIV 
programmes and existing national 
programmes for nutritional 
support is necessary and feasible.
Health-care providers 
often overlook the sexual and 
reproductive health of people 
living with HIV.
PIPELINE
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STIs, but also other reproductive health issues. Health-care providers, however, often 
overlook the sexual and reproductive health of people living with HIV. 
4.6.2.1 sexually transmitted infection prevention, screening and treatment
Background and rationale
Globally, STIs are a major cause of acute illness, infertility, long-term disability and 
death. Several STIs may facilitate the sexual transmission of HIV infection (165).
In both men and women, STIs, particularly those involving genital ulcers, increase 
susceptibility to HIV infection. Also, acute STIs are an important marker for unsafe 
sexual behaviour and risk of HIV transmission. Men who have sex with men, sex workers 
and transgender people are often at increased risk of STIs.
Thus, it is important to offer clinical management of STIs to people from key populations 
who present with STIs, in keeping with existing WHO guidance (138). In the absence of 
laboratory tests, syndromic management can be used. Testing and treatment should 
always be voluntary and free from coercion. Because the majority of STI cases are 
asymptomatic, particularly in women, STI screening programmes should be made 
available to key population groups.
Full updating of WHO STI guidelines is underway and should be completed by the end of 
2014.
Screening, diagnosis and treatment of STIs should be offered routinely as part of 
comprehensive HIV prevention and care for key populations (4). 
recommendations and guidance
ALL KEY POPULATION GROUPS
•	 Screening, diagnosis and treatment of STIs are crucial parts of a comprehensive 
response to HIV; this includes services for key populations (4). STI management 
should accord with existing WHO guidance and be adapted to the national 
context (166). Also, it should be confidential and free from coercion, and patients 
must give informed consent for treatment (32, 166).
•	 Periodic screening of people from key populations for asymptomatic STIs is 
recommended (conditional recommendation, low quality of evidence) (4, 10).
•	 In the absence of laboratory tests, symptomatic people from key populations 
should be managed syndromically in line with national STI management 
guidelines (166). 
PIPELINE
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related recommendations and contextual issues for specific key population groups
PEOPLE WHO INJECT DRUGS 
Health-care providers need to be alert to provide STI control and management for 
people who inject drugs. People who inject drugs may also engage in sex work, and 
men who inject drugs may have sex with other men, and thus they face higher STI 
risks (153, 167).  
SEx WORKERS
•	 We suggest offering periodic presumptive treatment (PPT) for asymptomatic 
STIs to female sex workers in settings with high prevalence and limited clinical 
services (conditional recommendation, moderate to high quality of evidence). 
•	 PPT should be implemented only as a free, voluntary, confidential, short-term 
measure as part of comprehensive sexual health services and while HIV/STI 
services are being further developed in settings where STI prevalence is high, e.g. 
>15% prevalence of N. gonorrhoea and/or C. trachomatis infection (10). 
TRANSGENDER PEOPLE
Health-care providers should be sensitive to and knowledgeable about the specific 
health needs of transgender people. In particular, genital examination and specimen 
collection can be uncomfortable or upsetting whether or not the person has 
undergone genital reconstructive surgery (32). 
Implementation considerations 
Possible strategies to increase STI screening and treatment rates include the 
following (3) :
•	 Mainstream STI treatment services should be accessible and responsive to the needs 
of key populations. 
•	 In settings where key populations are largely marginalized, specific and targeted 
services should be considered, including outreach and peer support. 
•	 Active referral pathways should be established, and screening and testing 
programmes should be integrated with other services used by key populations.
•	 STI diagnosis and treatment services should be co-located with HIV services used by 
key populations. 
Prisons and other closed settings should provide STI testing and related treatment 
that are voluntary, confidential and ensure the informed consent of the patient. If 
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adequate care cannot be provided in prisons, detainees should be able to obtain health 
services in the community (11). 
further reading
•	 Guidelines for the management of sexually transmitted infections. Geneva, WHO, 2004. 
http://www.who.int/hiv/pub/sti/pub6/en/
•	 Training modules for the syndromic management of sexually transmitted infections. Geneva, 
WHO, 2007. http://www.who.int/reproductivehealth/publications/rtis/9789241593407/en/
index.html
•	 WHO,	UNFPA,	UNAIDS,	NSWP,	World	Bank.	Implementing comprehensive HIV/STI 
programmes with sex workers: practical approaches from collaborative interventions. 
Geneva, WHO, 2013. http://www.who.int/hiv/pub/sti/sex_worker_implementation/en/
4.6.2.2 contraceptive services
Background and rationale
Contraception is a service that is often overlooked 
for key populations (32). It is important that health-
care providers strongly recommend dual protection 
to all persons at significant risk of HIV – either the 
simultaneous use of condoms with other methods or  
the consistent and correct use of condoms alone (122). 
Full updating of WHO contraception guidelines is currently underway and will be 
completed in 2015. 
Members of key populations, including people living with HIV, should be able to 
experience full, pleasurable sex lives and have access to a range of reproductive 
options (32, 122). 
recommendations and guidance
ALL KEY POPULATION GROUPS
It is important that contraceptive services are free, voluntary and non-coercive for 
all people from key populations. 
It is important that 
health-care providers strongly 
recommend dual protection.
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related recommendations and contextual issues for specific key population groups
PEOPLE IN PRISONS AND OTHER CLOSED SETTINGS 
It is important that prison health services offer contraception to women in closed 
settings (9, 169, 170, 171, 172). 
PEOPLE WHO INJECT DRUGS 
It is important that health-care providers in contact with women who use drugs 
offer contraception, including hormonal contraceptives, as part of a standard 
package of care.
SEx WORKERS
Women at higher risk of HIV, including sex workers, initiating or using hormonal 
contraceptives should be strongly advised always to use condoms, male or female, 
and other HIV prevention measures because of evidence, albeit inconclusive, of 
possibly increased risk of HIV acquisition among women using progestogen-only 
injectable contraception (4, 168).  
Additional remarks
Female sex workers should be offered contraceptive counselling to explore 
pregnancy intention and offered a range of contraceptive options including dual 
protection.
TRANSGENDER PEOPLE
•	 It is important to counsel transgender women who use oral contraceptive pills 
for feminization about the higher risk of thrombotic events with ethinyl estradiol 
than with 17-beta estradiol. 
•	 Consideration should be given to offering transgender men who have sex with 
men appropriate contraceptive options that do not lead to unwanted systemic 
feminization.
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ADOLESCENTS FROM KEY POPULATIONS 
•	 In order to meet the educational and service needs of adolescents, it is 
recommended that sexual and reproductive health services, including 
contraceptive information and services, be provided for adolescents without 
mandatory parental and guardian authorization/notification (173).
•	 To act in the best interest of adolescents, health services may need to prioritize 
their immediate health needs, while being attentive to signs of vulnerability, 
abuse and exploitation. Appropriate and confidential referral, if and when 
requested by the adolescent, can provide linkage to other services and sectors for 
support (73).
further reading
•	 Ensuring human rights in the provision of contraceptive information and services: 
guidance and recommendations. Geneva, WHO, 2014. http://apps.who.int/iris/
bitstream/10665/102539/1/9789241506748_eng.pdf 
•	 Medical eligibility criteria for contraceptive use: fourth edition. Geneva, WHO, 2010. http://
whqlibdoc.who.int/publications/2010/9789241563888_eng.pdf. Currently updating, next 
edition 2015. 
4.6.2.3 safe abortion and post-abortion care 
Abortion laws and services should protect the health and human rights of all 
women, including those from key populations. 
related recommendations and contextual issues for specific key population groups
ALL WOMEN FROM KEY POPULATIONS
•	 Where abortion is legal, it is important to establish linkages to safe abortion 
services. 
•	 Where abortion is illegal, unsafe abortion may be common and present serious health 
risks. Women from key populations should be informed about these risks (174). 
•	 Access to appropriate post-abortion care is essential to reduce morbidity and 
mortality.  
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ADOLESCENTS FROM KEY POPULATIONS 
Adolescents may be deterred from accessing health services if they think they will be 
required to obtain permission from their parents or guardians; this can increase the 
likelihood that they will go to providers of unsafe abortion (174).
Implementation consideration 
Safe abortion services. To the full extent permitted by law, safe abortion services 
should be readily available and affordable to all. This means services should be available 
at the primary care level, with referral systems in place for all required higher-level care.
further reading
•	 Safe abortion: technical and policy guidance for health systems. Geneva, WHO 2012 http://
www.who.int/reproductivehealth/publications/unsafe_abortion/9789241548434/en/ 
4.6.2.4 cervical cancer screening and treatment 
Cervical cancer screening and treatment is performed to detect cervical cancer or 
cervical changes that are precursors to cervical cancer and to treat adequately. Women 
living with HIV are at increased risk for human papillomavirus (HPV) infection and HPV-
related tumours, including cervical intraepithelial neoplasia grade 2 or 3 (CIN2/3) and 
invasive cervical carcinoma (175). The prevalence of HPV and CIN has been reported to 
increase with the increase in immunosuppression (176, 177).
It is important to offer cervical screening to all women from key populations, and 
to transgender men where appropriate, as indicated in the WHO 2013 cervical 
screening guidelines (178). 
related recommendations and contextual issues for specific key population groups
ALL WOMEN FROM KEY POPULATIONS
It is important in areas with high rates of endemic HIV infection to offer cervical 
cancer screening to sexually active girls and women as soon as they have tested 
positive for HIV (178).
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TRANSGENDER PEOPLE
Specific considerations are needed for transgender men (178) : 
•	 Transgender men who retain their female genitalia often miss out on cervical 
screening and other sexual health services, as they may not seek out or may be 
excluded from those services. As a result, they face increased risk of ovarian, 
uterine and cervical disease.
•	 Following total hysterectomy, if there is a history of high-grade cervical dysplasia 
and/or cervical cancer, a Papanicolaou test of the vaginal cuff can be performed 
annually until three normal tests are documented, and then every two to three 
years. 
•	 Following removal of ovaries, but where the uterus and cervix remain intact, 
WHO cervical screening guidelines for natal females can be followed. This may be 
deferred if there is no history of genital sexual activity. It is important to inform 
the pathologist of current or prior testosterone use, as cervical atrophy can mimic 
dysplasia.
ADOLESCENTS FROM KEY POPULATIONS 
•	 HPV vaccination does not replace cervical cancer screening. In countries where 
the HPV vaccine is introduced, screening programmes may need to be developed 
or strengthened (179).
•	 The WHO recommended target group for HPV vaccination is girls ages 9–13 years 
who have not yet become sexually active, including those living with HIV (179).
4.6.2.5 screening for anal cancer 
People infected with HIV are at least 20 times more likely to be diagnosed with anal 
cancer than uninfected people (180). Like cancer of the cervix, anal cancer is associated 
with human papillomavirus (HPV). Screening can be performed for anal cancer and 
its precursors, known as anal high-grade squamous intraepithelial lesions (HSIL), 
particularly for men who have sex with men, transgender people and other people from 
key populations who are more likely to engage in anal sex.
further reading
•	 WHO guidelines for screening and treatment of precancerous lesions for cervical cancer 
prevention. Geneva, WHO, 2013. http://www.who.int/reproductivehealth/publications/
cancers/screening_and_treatment_of_precancerous_lesions/en/   
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4.6.2.6 conception and pregnancy 
 
It is important that all women from key populations have the same support and 
access to services related to conception and pregnancy care as women from other 
groups, as indicated by WHO guidelines.  
related recommendations and contextual issues for specific key population groups
ALL WOMEN FROM KEY POPULATIONS
•	 All adult and adolescent women from key populations who are living with HIV 
and are pregnant should receive appropriate HIV treatment and care, in line with 
WHO guidance, to prevent HIV transmission from mother to child (4).
•	 Women living with HIV and those in serodiscordant couples who wish to have 
children should be provided information and support to help them to conceive as 
safely as possible. 
•	 Many women from key populations, in particular adolescents, have inadequate 
access to antenatal care, attend late in pregnancy and have less access to PMTCT 
services (see Section 4.4.2).
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5 crItIcal enaBlers
HIV epidemics, particularly among key populations, continue to be fuelled by stigma and 
discrimination, gender inequality, violence, lack of community empowerment, violations 
of human rights, and laws and policies criminalizing drug use and diverse forms of 
gender identity and sexuality. These socio-structural factors limit access to HIV services, 
constrain how these services are delivered and diminish their effectiveness.
Thus, it is important to understand the varied political, geographic and social contexts 
in which key populations live and where HIV services for them are delivered. It also 
needs to be recognized that each key population group is heterogeneous, and effective 
programmes must account for this diversity.
Despite the challenges of marginalization, criminalization of the behaviour of certain 
key populations and in some settings direct human rights abuses, it remains necessary 
and feasible to deliver HIV-related services and to do so in ways that protect the 
safety and well-being of people from key populations and of service providers. Health-
care providers have an ethical obligation to care for and treat people impartially and 
equitably. Programmes and countries can ensure confidentiality of services, facilitate 
access by people from key populations to mainstream health services, improve quality, 
train and sensitize health-care providers, and reduce stigma and discrimination. As 
safety allows, people from key populations should be encouraged and supported to 
participate in designing and delivering HIV prevention and response efforts. Despite 
legislative restrictions people from key populations in most countries persevere, still 
finding ways of acting in association to provide support, and they may also be reached 
online and through regional networks.
Integrating HIV and related health services into primary health care can contribute to 
increased and more equitable access to HIV services for key populations. To increase the 
effectiveness of HIV services in primary health care, health-care providers will benefit 
from understanding gender identity and the diversity of sexual behaviours and identities, 
as well as drug use and dependence, and how to address these when providing services. 
The health sector can take action to change the attitudes and behaviours of health-care 
providers to reduce stigma and discrimination, particularly that relating to homophobia, 
transphobia, sex work and drug use. Health-care workers should be given the necessary 
resources, training and support to provide services to key populations. At the same 
time, health-care providers should be held accountable when they fail to meet standards 
based on professional ethics and internationally agreed human rights principles (1). 
Monitoring and evaluation is important to ensure not only technical quality and impact 
of services but also the spirit in which they are provided and, thus, their acceptability to 
people from key populations.
“Critical enablers”, as used in this document, means strategies, activities and 
approaches that aim to improve the accessibility, acceptability, uptake, equitable 
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coverage, quality, effectiveness and efficiency of HIV interventions and services. 
Enablers operate at many levels – individual, community, institutional, societal 
and national, regional and global. They are crucial to implementing comprehensive 
HIV programmes for key populations in all epidemic contexts. Critical enablers 
aim to overcome major barriers to service uptake, including social exclusion and 
marginalization, criminalization, stigma and inequity. If left unaddressed, such barriers 
will undermine the provision of HIV services, especially for key populations (2). 
The barriers and critical enablers outlined in this chapter apply to both adults and 
adolescents in key populations. For adolescents from key populations, these factors may 
be further exacerbated by their rapid physical and mental development and complex 
psychosocial and socioeconomic vulnerabilities. Also, adolescents from key populations 
experience socio-structural barriers to services, notably policy and legal barriers related to 
age of consent. Those close to people from key populations, including partners and children, 
also can experience stigma and discrimination and so face the same difficulties in access to 
services. Thus, including dependents in the provision of HIV services can be important. 
The health sector has an important role to 
play, but successful implementation of critical 
enablers requires collaboration across different 
sectors, such as health, justice, housing, 
welfare and labour. It also requires multiple 
partners from government, civil society and the private sector. Full involvement of key 
populations and people living with HIV also is crucial (3, 4).
This chapter outlines a range of barriers that compromise access to appropriate 
and good-quality HIV services for key populations, identifies critical enablers to 
overcome these barriers (as illustrated in Fig. 5.1) and makes a number of good-
practice recommendations. These good practice recommendations are based on earlier 
WHO documents addressing key populations. While these barriers and enablers are 
interrelated, we attempt to discuss each individually.
fig. 5.1 critical enablers for key populations
1.	 Reviewing	laws,	policies	
and	practices	(includes	
decriminalization		
&	age	of	consent)
2.	 Reducing	stigma		
and	discrimination
4.	 Preventing	violence 3.	 Empowering	the	
community
Critical	
enablers
Successful implementation of 
critical	enablers	requires	collaboration	
across different sectors.
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5.1 law and policy 
5.1.1 legal barriers
Sixty percent of countries report having laws, regulations or policies that are barriers 
to effective HIV services for key populations and vulnerable groups (5). In particular, 
over 100 countries criminalize some or all aspects of sex work. At least 76 countries 
criminalize sexual relations between people of the same sex. Indeed, some countries 
impose the death penalty for convictions under such laws. 
Additionally, transgender people are legally unrecognized in many countries (5) and 
face restrictive policies toward their gender expression. In many settings punitive 
policies on drug use call for harsh penalties for the possession of small amounts of 
drugs for personal use, and in some settings policies mandate compulsory detention as 
“treatment” for people who use or inject drugs (5). In many prisons and other closed 
settings, HIV services are sub-standard or entirely lacking (6). 
While laws vary, in many settings adolescents under 18 years of age are classified legally 
as minors and, therefore, must have parental consent for medical care, including HIV-
related services. Such laws and policies can be barriers to or can discourage adolescents 
from seeking services (7). These restrictions may create complex dilemmas for providers 
who endeavour to act in the best interest of their clients but who may have concerns 
about their own legal liability as well as for the safety of their young clients. 
5.1.2 critical enablers
reviewing laws and policies 
Laws and policies can help to protect the human rights of key populations – both those 
living with HIV and those at risk for HIV. Legal reforms, such as decriminalizing sexual 
behaviours and drug use, legal recognition of transgender status, and lowering the 
age of consent and considering exceptions to a standard age of consent policy (such 
as mature minors), are critical enablers that can change a hostile environment for key 
populations to a supportive environment (8). Specific consideration should be given to 
such legal reforms as part of any revision of policies or programmes for key populations. 
For example, in many countries possession, use and sale of clean needles and syringes or 
of condoms remains justification for arrest. If so, this warrants review. 
decriminalizing the behaviour of key populations
Supporting the health and well-being of key 
populations whose sexual behaviours, drug 
use, gender expression or perceived sexual 
orientation are currently criminalized may 
require changing legislation and adopting new 
policies and protective laws in accordance with 
international human rights standards. Without protective policies and decriminalization 
of the behaviour of key populations, barriers to essential health services will remain; 
many people from key populations may fear that seeking health care will expose them to 
adverse legal consequences (9).
Without protective policies and 
efforts to decriminalize the behaviour 
of key populations, barriers to essential 
health services will remain.
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Laws, legal policies and practices should be reviewed and, where necessary, 
revised by policy-makers and government leaders, with meaningful engagement of 
stakeholders from key population groups, to allow and support increased access to 
services for key populations (10, 11, 13). 
 
good practice recommendations concerning decriminalization
ALL KEY POPULATION GROUPS
Countries should work toward decriminalization of behaviours such as drug use/
injecting, sex work, same-sex activity and nonconforming gender identities, and 
toward elimination of the unjust application of civil law and regulations against 
people who use/inject drugs, sex workers, men who have sex with men and 
transgender people (10, 11, 12, 13, 14).
MEN WHO HAVE SEx WITH MEN 
Countries should work toward developing policies and laws that decriminalize same-
sex behaviours (11). 
PEOPLE WHO USE AND/OR INJECT DRUGS 
•	 Countries should work toward developing policies and laws that decriminalize 
injection and other use of drugs and, thereby, reduce incarceration. 
•	 Countries should work toward developing policies and laws that decriminalize the 
use of clean needles and syringes (and that permit NSPs) and that legalize OST 
for people who are opioid-dependent.
•	 Countries should ban compulsory treatment for people who use and/or inject 
drugs (12, 13, 14). 
SEx WORKERS
•	 Countries should work toward decriminalization of sex work and elimination of 
the unjust application of non-criminal laws and regulations against sex workers.
•	 The police practice of using possession of condoms as evidence of sex work and 
grounds for arrest should be eliminated (10). 
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TRANSGENDER PEOPLE
•	 Countries should work toward developing policies and laws that decriminalize 
same-sex behaviours and nonconforming gender identities. 
•	 Countries should work towards legal recognition for transgender people (11). 
good practice recommendations concerning age of consent policies and laws
ADOLESCENTS FROM KEY POPULATIONS
•	 Countries are encouraged to examine their current consent policies and consider 
revising them to reduce age-related barriers to HIV services and to empower 
providers to act in the best interest of the adolescent (7).
•	 It is recommended that sexual and reproductive health services, including 
contraceptive information and services, be provided for adolescents without 
mandatory parental and guardian authorization/notification (15). 
case study: decriminalizing drug use in portugal 
GIRUBarcelos, APDES, Portugal 
http://www.apdes.pt/en/
As of 2012, 21 countries globally had taken steps to decriminalize drug use and possession (16). 
For example, Portugal changed its legislation in 2001 to turn possession of controlled drugs 
into an “administrative offence”, with those caught with drugs for personal use being sent to a 
“dissuasion board” rather than face prosecution and possible jailing. An independent study (17) 
examined the impact of the changes and found that:
•	 The	number	of	drug	users	in	treatment	expanded	from	23	654	in	1998	to	38	532	in	2008.
•	 Between	2000	and	2008	the	annual	number	of	new	cases	of	HIV	among	drug	users	fell	from	
907 to 267, a decrease attributed to the expansion of harm reduction services.
•	 Contrary	to	predictions,	major	increases	in	drug	use	did	not	take	place;	instead,	evidence	
indicated reductions in problematic use, drug-related harms and overcrowding of the criminal 
justice system.
Community organizations continue to be essential to tackling stigma and discrimination and 
improving access to services. Agência Piaget para o Desenvolvimento (APDES), founded in 
2004, works with vulnerable people and communities on access to health care, employment 
and education, seeking to empower these populations and reinforce social cohesion. They 
run GIRUBarcelos, a multidisciplinary outreach team working primarily with heroin and 
cocaine users and sex workers in northern Portugal, focusing their efforts on harm reduction. 
Through their efforts, discrimination towards people who use drugs, including by health-
care professionals, has been reduced following regular meetings, mediation efforts between 
communities and service providers, debates and a radio programme on a local radio station 
entitled “GIRU Conversations”. The presence of a peer educator on the team and the constant 
involvement of people who inject drugs are the cornerstones of GIRUBarcelos’ interventions and 
considered critical to its success.
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case study: In uruguay a national dialogue supports legislative change 
In 2010 the United Nations Development Programme (UNDP) launched the Global Commission 
on HIV and the Law to develop actionable, evidence-based answers and recommendations for a 
response to HIV that protects and promotes the human rights of people living with and who are 
more vulnerable to HIV (http://www.hivlawcommission.org). The Commission’s work focuses on 
generating constructive dialogues between civil societies and governments on issues related to 
HIV and the law, going beyond identifying problems to develop and share practical solutions.
In Uruguay a national inter-sectoral commission was organized jointly by the Ministry of 
Health, the Ministry of Social Development, trade union organizations, the National Council for 
HIV/AIDS Response (CONASIDA), the Federation of Sexual Diversity and the Parliamentarian 
Commissioner for Prisons. This commission called for a national dialogue on HIV and human 
rights to harmonize and improving national legislation related to the HIV response. Conducted 
with the strong support of the UNDP Regional Office, UNFPA and UNAIDS, the two-month 
initiative provided an opportunity for people affected by and vulnerable to HIV to present 
evidence on issues that have been silenced or were unknown. Individuals and civil society 
organization presented almost three dozen selected cases of human rights violations. Those 
involved, in particular civil society organizations, provided technical support for the development 
and presentation of HIV-related issues of sexual orientation and gender identity; discrimination 
in health services, employment and education; sex work; police brutality; access to treatment; 
intellectual property; and the human rights of people living with HIV.
This national dialogue contributed to the on-going development of a new, comprehensive 
HIV law. The final report of the dialogue, presented to parliament in May 2014, identifies 
gaps in legislation, laws detrimental to the HIV response and the lack of implementation 
of laws that would promote the response. In addition, it suggests best practices and makes 
recommendations from a human rights perspective. The advocacy and mobilization of civil 
society , in particular people living with HIV and lesbian, gay, bisexual and transgender groups 
have driven this dialogue, along with the concerted efforts and the partnerships of UN agencies, 
the government and academia.
CONASIDA-CMM (National Council for the Prevention and Control of HIV/AIDS – Country 
Coordination Mechanism) will implement and follow up the main recommendations from 
the dialogue to support the HIV Law Project. Additionally, the recently developed National 
Institute on Human Rights in Uruguay, also affiliated with the dialogue, is now committed to 
contributing, monitoring and advocating the implementation of the updated laws. 
addressing other policy issues for key populations
Along with decriminalization efforts, there are other policy changes that can enable 
people from key populations to exercise their human and health rights. Some 
common current policies limit access to the justice system and to health services. Key 
considerations are these: 
Recognize transgender people in the law. For transgender people the legal 
recognition of preferred gender and name may be important to reduce stigma, 
discrimination and ignorance about gender variance. Such recognition by health services 
can support better access, uptake and provision of HIV services (11). 
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Improve access to justice and legal support for key populations. Policies that 
criminalize and punish the behaviour of key populations constrain people from obtaining 
justice and legal services. Policies and procedures are needed to ensure that individuals 
from key populations can report rights violations such as discrimination, gender-based 
violence, issues with policing, violations of informed consent, violations of medical 
confidentiality and denial of health-care services. Reporting options beyond going to 
the police will encourage reporting of human rights violations. For example, persons 
from key populations can be trained as paralegals; an organization that works with key 
populations can serve as a third-party reporter of complaints.
Improve policies on access to health services and information. Ensuring that 
people from key populations are aware of their legal and human rights as individuals, 
specifically their right to health, can increase their access to health services. Since key 
populations are often the target of exploitation, marginalization, criminalization, stigma 
and discrimination, programmes are particularly needed to ensure that key populations 
know their legal and human rights, including applicable protective laws and where and 
how to obtain legal services and report violations. Health literacy, sexuality education 
and support programmes can help improve awareness (18). If better informed, key 
population groups can better organize to advance their rights and raise awareness of 
their rights, needs and the policies and legal issues that critically affect them (10, 19, 20). 
Additionally, countries can review laws that penalize health-care providers for working 
with key populations (e.g. laws that make it illegal for outreach workers to carry 
condoms or clean needles and syringes for distribution).
Law enforcement can play an important role by ensuring that the human rights of key 
populations are not violated. Police should receive continual training on ways to support 
– or at least not to impede – key populations’ access to essential health services, 
including not arresting people leaving drug treatment clinics; avoiding confiscation of 
drug treatment medication; avoiding surveillance of harm reduction centres; and not 
using possession of clean needles or condoms to justify arrest. Systems to promote good 
policing practices and to provide safe avenues for reporting human rights violations will 
help ensure that police are protecting both the public health and the human rights of all 
persons. Ensuring that medical records are kept confidential is one step that health-care 
providers can take to increase trust between health services and key populations.
good practice recommendations for other policy issues
ALL KEY POPULATION GROUPS
•	 Countries should work toward developing non-custodial alternatives to 
incarceration of drug users, sex workers and people who engage in same-sex 
activity (12). 
•	 It is recommended that third-party authorization requirements be eliminated, 
including spousal authorization requirements for women obtaining contraceptives 
and related information and services (15). 
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PEOPLE IN PRISONS AND OTHER CLOSED SETTINGS 
•	 As countries work toward developing non-custodial strategies, targets can be set 
for reducing prison overcrowding generally (12).  
SEx WORKERS
•	 The police practice of using possession of condoms as evidence of sex work and 
grounds to arrest sex workers should be eliminated (10). 
•	 The wide latitude of the police to arrest and detain sex workers without cause, 
including police extortion, should be eliminated (10). 
TRANSGENDER PEOPLE
•	 Countries should work towards legal recognition for transgender people (11). 
Additional remark: It is important that countries secure political commitment, with 
appropriate investment in advocacy and adequate financial resources for HIV-
related key population programmes and health services.
case study: In Indonesia methadone maintenance treatment in prison  
Australia Indonesia Partnership for HIV (AIPH) – HIV Cooperation Program for Indonesia (HCPI)
Methadone maintenance treatment (MMT) for incarcerated injecting drug users was pilot-tested 
in Kerobokan Prison, Bali, in 2005 after prison officials visited MMT programmes in Australian 
prisons. Accomplishments of the Kerobokan Prison pilot project include: 
•	 Establishment	of	comprehensive	harm	reduction	services	(including	MMT)	and	high	levels	of	
participation among prisoners with opioid dependence;
•	 The	scaling-up	of	MMT,	education	and	care,	support	and	treatment	services	in	11	other	
prisons, detention centres and parole services; Kerobokan prison provides ongoing mentoring 
to many of these facilities;
•	 High	levels	of	integration	with	other	community	health	services	in	Bali,	ensuring	smooth	
transition from prison to community MMT programmes (and vice versa) and early or 
continuing access to HIV treatment.
Additionally, HIV testing and treatment now have been efficiently implemented in many prisons. 
More than 90% of high-risk prisoners have been tested, and a high proportion of those testing 
positive have begun ART. 
As part of mainstreaming this initiative, in 2013 the Ministry of Health (MOH) and the General 
Directorate of Corrections signed a memorandum of understanding that the MOH would fully 
cover the cost of methadone. HCPI continues to provide training and limited financial support.
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5.2 stigma and discrimination 
5.2.1 Barriers 
People from key populations are often particularly subjected to stigma, discrimination 
and negative attitudes related to their behaviour – and doubly so if also living with HIV 
– by their families, communities and health workers. Such stigma is common in many 
health facilities and law enforcement services. It may seem to be tacitly endorsed by 
the lack of national laws and policies against discrimination. The effects of such HIV-
related stigma and discrimination against key populations can be delayed HIV testing, 
concealment of positive serostatus, and poor uptake of HIV services (21, 22, 23, 24, 25). 
It can undermine the efforts of national health programmes to effectively link people to 
HIV care and to engage and retain them in long-term care (26, 27). 
Within the health sector stigma and discrimination can take many forms at the individual 
and systems levels. The lack of training and educational programmes to inform health 
workers of the needs, health issues and strategies and interventions for key populations 
contributes to marginalization. It leaves providers ill-equipped to address health needs 
and perpetuates stigmatizing and discriminating practices, even to the point of refusing 
services. 
5.2.2 critical enablers
Efforts to reduce stigma and discrimination at a national level, such as promoting 
antidiscrimination and protective policies for all key populations, can foster a supportive 
environment, particularly within the health-care and justice systems (20). Policies are 
most effective when they simultaneously address individual, organizational and public 
policy factors that enable or allow stigma and discrimination (28). Programmes, within 
and outside the health sector, need to institute anti-stigma and antidiscrimination 
policies and codes of conduct. Monitoring and oversight are important to ensure that 
standards are implemented and maintained. Additionally, mechanisms should be made 
available to key populations to anonymously report occurrences of stigma and/or 
discrimination when they try to obtain health services. 
good practice recommendations for implementing and enforcing anti-stigma and 
antidiscrimination and protective policies
ALL KEY POPULATION GROUPS
•	 Countries should work towards implementing and enforcing antidiscrimination 
and protective laws, derived from human rights standards, to eliminate stigma, 
discrimination and violence against people from key populations.
•	 Policy-makers, parliamentarians and other public health leaders should work 
together with civil society organizations in their efforts to monitor stigma, 
confront discrimination against key populations and change punitive legal and 
social norms (3, 10, 11, 12, 13, 19). 
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providing key population-friendly services
It is important to make health services available, accessible and acceptable to key 
populations and to tailor these services to their needs (20). Interventions and services 
for key populations, including adolescents from key populations, can adopt principles 
friendly to key populations, paying particular attention to accessibility and the expertise 
and attitudes of staff members (7). 
Approaches to making services friendly to key populations include: 
•	 integrated health services, involving co-locating interventions and cross-training 
providers, such as providing ARVs at drug treatment centres; 
•	 scheduling service hours that are regular, dependable and suit the intended clients; 
•	 locating services strategically where key populations congregate or transit; 
•	 involving the peer community in service development, promotion, delivery, and 
monitoring and evaluation; 
•	 training staff to work with different key populations; 
•	 taking steps to ensure that law enforcement activities do not interfere with clients’ 
access to HIV services (11, 12, 13, 20). 
case study: sensitizing health-care workers in south africa  
South African National AIDS Council and the South African Department of Health, South Africa 
http://www.health.gov.za/ and http://www.sanac.org.za 
Discrimination by public health-care providers towards people from key populations and 
“unfriendly” health facilities are barriers to access to services, contributing to poorer health 
outcomes (29). A multi-partner project in South Africa has developed an integrated approach 
to sensitizing health-care providers on issues affecting key populations and to empower public 
health staff members to interact appropriately (regarding both their attitude and their clincial 
expertise) with people from key populations. Trainings have been conducted in preparation for 
the implementation of the National Operational Guidelines for HIV, STIs and TB Programmes 
for Key Populations in South Africa. The full training programme includes in-person training and 
mentoring. Thirty trainers participated in an initial training of trainers (TOT) workshop and were 
linked to local training centres and health facilities. In turn, they trained 420 health-care workers 
in six months.
Where these trainings took place, people from key populations have reported improvements 
in health-care workers’ attitudes. Communities’ trust has increased, and so has use of health 
facilities, where the sensitization training has been linked with peer outreach and the prevention 
activities of civil society organizations. Further evaluation is planned to inform scale-up.
training and sensitizing health workers 
Creating inclusive health services requires sensitizing and educating providers and other 
staff members in health care and social services. This can be done in both pre-service 
and in-service training, through on-the-job support and supervision, and by creating an 
organizational norm of inclusiveness and non-discrimination. 
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Attitudes. Health-care providers working with adults or adolescents from key 
populations should be non-judgemental, supportive, responsive and respectful and 
should understand the issues that people from key populations face (7, 10, 11, 20). 
Training, with the involvement of key population representatives and groups, can be 
developed to sensitize and educate health workers on issues specific to key populations, 
non-discriminatory attitudes and practices, and key populations’ right to health, 
confidentiality, non-coercive care and informed consent. 
Skills. It is important that health workers be able to respond to the specific needs of key 
populations and provide quality services, know what interventions, tools and materials 
are available to provide information, can advise on HIV risk reduction strategies, and 
know how to support treatment adherence and retention in care (20). 
Improving and maintaining providers’ attitudes and skills is a continual process 
consisting of multiple components such as formal training events, job aids, supportive 
supervision, training follow-up and mentorship. Multi-disciplinary trainings and work 
environments can strengthen linkage to community-based providers so that referrals 
and adequate follow-up are more available. Particularly where there are workforce 
shortages, it is important that all providers receive adolescent-specific training, including 
lay counsellors, to enable task-shifting (7). 
Health services should be made available, accessible and acceptable to people from 
key populations, based on the principles of medical ethics, avoidance of stigma, 
non-discrimination and the right to health (3, 7, 10, 11, 12, 13, 15). 
good practice recommendations for providing key population-friendly services
ALL KEY POPULATION GROUPS
•	 Health-care workers should receive appropriate recurrent training and 
sensitization to ensure that they have the skills and understanding to provide 
services for adults and adolescents from key populations based on all persons’ 
right to health, confidentiality and non-discrimination. 
•	 It is recommended to make contraceptives affordable to all, including 
adolescents, and that law and policy support access to contraception for 
disadvantaged and margfrom inalized populations (3, 7, 10, 11, 12, 13, 15). 
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ADOLESCENTS FROM KEY POPULATIONS 
•	 Services for adolescents from key populations should include psychosocial 
support, through counselling, peer support groups and networks, to address 
self-stigma and discrimination. Additional provision of counselling for families, 
including parents – where appropriate and requested by the adolescent – may be 
important to support and facilitate access to services, especially where parental 
consent is required (7).
•	 Health-care providers should ensure adolescents from key populations know their 
rights – to confidentiality, health, protection and self-determination – so that 
they can advocate for themselves and seek the types of support they are entitled 
to (7).
•	 Services should provide developmentally appropriate, comprehensive information 
and education, focusing on skills-based risk reduction (7). 
•	 Services should be safe spaces that increase protection from the effects of 
stigmas and discrimination, where adolescents can freely express their concerns, 
and where providers demonstrate patience, understanding, acceptance and 
knowledge about the choices and services available to the adolescent (7). 
case study: In south africa expanding competence to serve men who have 
sex with men
Health4Men, Anova Health Institute 
www.anovahealth.co.za
The Health4Men project addresses men’s diverse sexual health needs, particularly those of 
vulnerable and marginalized groups including men who have sex with men. The project’s goal is 
to institutionalize competence in serving men who have sex with men in existing public clinics. 
The process involves:
•	 sensitization,	to	change	attitudes
•	 medical	training,	to	expand	knowledge
•	 mentoring,	to	translate	knowledge	into	skill
•	 on-going	technical	support	including	consultation,	training	and	mentoring	and	provision	of	
educational materials. 
Under the leadership of the Anova Health Institute, Health4Men has developed two MSM Centres of 
Excellence, in Cape Town and Johannesburg, each supported by satellite clinics. The clinics provide 
services for men who have sex with men, while outreach activities stimulate demand for services. 
Health4Men has developed innovative training content and materials to equip nurses, 
counsellors and medical officers to respond to the special needs of men who have sex with men 
in a sensitive and empathic manner. In partnership with provincial departments of health, the 
project establishes at least one Regional Leadership Site in each province to serve as the hub 
for competency development; nurse mentors and outreach teams operate from these sites. As of 
mid-2014, over 3000 health workers have been trained, 584 clinicians have been mentored and 
64 clinics in four provinces have been declared medically competent to serve men who have sex 
with men. By the end of 2014, there will be over 120 competent sites across six provinces and, 
by the end of 2015, over 160 sites nationally.
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5.3 community empowerment 
5.3.1 Barriers 
Key populations often have little or no control over HIV risk factors driven by the legal, 
political and social environment and the context of their lives. For instance, sex workers 
are frequently exposed to HIV and other STIs, but they may not have the power to 
negotiate consistent condom use (30, 31). This lack of control is exacerbated if people 
are unaware of available HIV-related services and of their legal and human rights, 
specifically their right to health, and what to do if these rights are violated. 
In particular, few young people from key populations receive adequate information and 
education for their sexual lives. Instead, they receive conflicting or confusing messages 
about gender and sexuality. This leaves young people vulnerable to coercion, abuse 
and exploitation and to unintended pregnancy and STIs, including HIV (18). The lack of 
community empowerment, too, and of community-wide awareness and knowledge limits 
the overall effectiveness of interventions to reduce HIV risk (10, 20).
5.3.2 critical enablers
Evidence shows that health policies and programmes are more effective and have 
a more positive impact on health outcomes when affected populations take part in 
their development (32). Community empowerment is a guiding principle for all HIV 
programming and activities. Community empowerment is a collective process that 
enables key populations to address the structural constraints to health, human rights 
and well-being; make social, economic and behavioural changes; and improve access to 
health services (10). Community empowerment can foster the wider reach and greater 
effectiveness of services for key populations (10). Community empowerment has been 
undertaken in various settings, such as for sex workers (Fig. 5.2). 
Community empowerment is a critical enabler for improving key populations’ 
living conditions, developing strategies for health and rights interventions and 
redressing violations of the human rights of people from key populations. Community 
empowerment can take many forms, such as meaningful participation of people from key 
populations in designing services, peer education, implementation of legal literacy and 
service programmes, and fostering key population-led groups and key population-led 
programmes and service delivery (10, 20). 
Key populations are heterogeneous and mobile. Therefore, to be effective, programmes 
must account for the diverse legal, political, social and health environments in 
which people from key populations live and must remain sensitive to a diversity of 
cultures (20). This flexibility, responsiveness and adaptability are essential to community 
empowerment initiatives. Initiatives should be able to evolve over time to meet the 
changing needs of key populations. 
programmes led by key-population organizations
It is important to foster and support services, facilities and research led by organizations 
of people from key populations. Key population-led organizations, collectives and 
networks can play key roles in training the staffs of health services, police and social 
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case study: Building health literacy among young injecting drug users in 
mexico
Programa de Política de Drogas (Espolea, A.C), Mexico 
http://www.espolea.org/
Espolea, a youth-led organization in Mexico City, opened its Drug Policy and Harm Reduction 
Programme in 2008 and has since developed online and face-to-face channels to provide 
objective information about drugs and risk reduction to young people ages 15–29 years.
The organization has found that information is most effective when disseminated at places 
where young people use drugs, particularly electronic dance music festivals, rock concerts and 
cultural gatherings. At these events Espolea sets up a stand as a safe space for young people to 
obtain information about drugs that may be being consumed. The organization also facilitates 
workshops in schools and in communities with concentrations of most-at-risk young people.
Espolea has an active outreach strategy, using social media, including Facebook and Twitter as well 
as Internet blogs. One blog – www.universodelasdrogas.org – serves as a databank on drugs and 
has become the axis of the programme’s harm reduction campaign. Staff members, collaborators, 
and young people produce the information. Printed materials offer facts and recommendations 
about nightlife, alcohol consumption, risky sexual behaviours, HIV and other STIs.
service agencies, facilitating interaction with the communities of key populations, and 
managing services. In fact, they may have special strengths in providing community-
based and outreach services.
fig. 5.2 key elements of community empowerment among sex workers (20) 
While this figure refers to sex workers, these community empowerment elements could 
be adapted for other key populations. 
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meaningful participation
Even if key population-led organizations are not taking the lead, the meaningful 
participation of representatives of the community in programming is critical to assure 
the appropriateness and acceptability of services to the intended clientele. It is also 
important for building trusting relationships between the community and service 
providers, who may be accustomed to establishing the parameters by which services are 
provided and prescribing how relationships or partnerships are to be conducted (20). 
Meaningful participation means that key populations: (1) choose whether to participate; 
(2) choose how they are represented, and by whom; (3) choose how they are engaged in 
the process; and (4) have an equal voice in how partnerships are managed. 
Meaningful participation can mean not only 
having a voice in decision-making but also 
contributing to service delivery. For example, 
adolescents from key populations can be given 
opportunities, empowered and trained as 
peer educators, counsellors, trainers and advocates (33). Peer education is a successful 
strategy for improving young people’s HIV knowledge, testing and counselling, 
and linking to care; it is more likely to lead to behaviour change than many other 
interventions. Additionally, peer education can help to mobilize communities and social 
networks (34). 
Partnerships are crucial, but they must be built and maintained in a way that risks no 
harm to the persons involved. The success of interventions that facilitate participation 
is measured not only by effectiveness of outcomes but also by the degree to which key 
populations are engaged and by the process and mechanisms of engagement (35). 
Key population-led groups and organizations should be made essential partners and 
leaders in designing, planning, implementing and evaluating health services.
good practice recommendations for community empowerment
ALL KEY POPULATION GROUPS
•	 Programmes should implement a package of interventions to enhance community 
empowerment among key populations (10, 11, 12, 15).
•	 Programmes should be put in place to provide legal literacy and legal services 
to key populations so that they know their rights and applicable laws and can 
receive support from the justice system when aggrieved (10, 11, 12, 15).
Policies and programmes are more 
effective when affected populations 
take part in their development.
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MEN WHO HAVE SEx WITH MEN
•	 Men’s health groups and organizations of men who have sex with men are 
essential partners in providing comprehensive training on human sexuality and 
delivering services and so should be actively engaged. They also can facilitate 
interaction with members of sexually diverse communities, thereby generating 
greater understanding of their emotional health and social needs and the cost of 
inaction against homophobia (11). 
SEx WORKERS
•	 Programmes should be put in place to sensitize and educate health-care providers 
on non-discrimination and sex workers’ right to high-quality and non-coercive 
care, confidentiality and informed consent (10). 
•	 Programmes should implement a package of interventions to enhance community 
empowerment among sex workers (strong recommendation, very low quality of 
evidence) (10).
Additional remarks: The interventions delivered through a community empowerment 
model include, but are not limited to, sustained engagement with local sex workers 
to raise awareness of rights, establishment of community-managed drop-in centres, 
formation of collectives that determine the range of services to be provided, as well 
as shaping outreach and advocacy activities.
•	 Community empowerment is a necessary component of sex worker interventions 
and should be led by sex workers.
TRANSGENDER PEOPLE
•	 Organizations of transgender people are essential partners in delivering 
comprehensive training on human sexuality and gender expression. They also can 
facilitate interaction with members of communities with diverse gender identities 
and expressions, thereby generating greater understanding of their emotional 
health and social needs and the cost of inaction against transphobia (11).  
ADOLESCENTS FROM KEY POPULATIONS 
It is recommended that sexuality education programmes for adolescents, both in 
and outside of schools, be scientifically accurate and comprehensive and include 
information on contraceptives, including how to use them and where to get them (15).
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case study: In nepal meaningful participation of people who inject drugs
Bridging the Gap: Health and Human Rights for the Key Population, Naya Goreto, Nepal 
www.nayagoreto.org.np
Recognizing the lack of specific laws or policies in Nepal to support people who inject drugs 
and the lack of services at the community level, Naya Goreto created “Bridging the Gap: 
Health and Human Rights Programme for the Key Population”. This programme aims to engage 
stakeholders across the spectrum, from parliamentarians to local councillors, public health 
officials to health volunteers, in advocacy on issues of concern to people who inject drugs. 
Naya Goreto emphasizes the meaningful participation of people who inject drugs at all levels 
of the programme. More than 200 people from the community have been trained to lead 
activities ranging from situation analysis to advocacy campaigning and programme monitoring. 
The programme also has brought together various stakeholders, including former politicians, 
councillors, public health personnel, and the community to create a committee that lobbies for 
the health and human rights of people who inject drugs. Empowerment activities have included 
the following:
•	 conducting	advocacy	programmes	in	stigma-free	small	group	environments,	such	as	meetings	
at a local cafe, which make possible more personal and meaningful discussion of issues;
•	 forming	key	population-led	networks	such	as	Lalitpur	Drug	User’s	Advocacy	Network;
•	 linking	people	who	inject	drugs	with	experts	and	other	concerned	stakeholders	for	easy	
access to adequate information on programmes and budgets;
•	 mobilization	of	trained	people	from	the	community	to	participate	in	consultation	meetings	
with key governmental bodies, lobbying with duty bearers for the health and human rights of 
people who inject drugs.
Naya Goreto has built strong partnerships among people who inject drugs, creating a shared 
feeling of solidarity to collectively address the issues that directly affect them. Such issues are 
now included in the yearly action plans of local government and civil society organizations. 
Annual budgets have been secured from local government bodies to conduct drug awareness 
programmes by and for communities. There is now a seat for a community member on the 
District AIDS Coordination Committee. At a civil society level, there has been a rise in positive 
community awareness – for example, through national media – of issues that affect people who 
inject drugs.
case study: youth-led advocacy, leadership, and empowerment of young 
key populations
Youth LEAD, NewGen leadership programme, Asia–Pacific 
http://youth-lead.org/
Youth LEAD is a network of and for young key populations most affected by HIV in 20 countries 
across Asia and the Pacific. In 2011 Youth LEAD created the NewGen Asia leadership course, a 
five-day youth-led programme for young people in advocacy, leadership, and empowerment. 
The course was pilot-tested in the Philippines; evaluations led to revisions and the development 
of training materials. A seven-day training of trainers took place the following year with 
21 participants from five countries. This led to the implementation of NewGen and the 
adaptation of national trainings in Myanmar, the Philippines and Indonesia. 
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5.4 Violence 
5.4.1 Barriers
Violence against people from key populations has been shown to be a risk factor for HIV 
acquisition (36). Such violence is common. It can take various forms – physical, sexual 
or psychological (37). Violence is fuelled by the imbalance in the power dynamics of 
gender and by prejudice and discrimination against persons perceived to depart from 
conventional gender and sexuality norms and identities. Also, multiple structural factors 
influence vulnerability to violence, including discriminatory or harsh laws and policing 
practices and cultural and social norms that legitimate stigma and discrimination. 
Women, especially young women, from key populations, including female drug users, 
female sex workers and transgender women, experience particularly high rates of 
physical, sexual, and psychological abuse (38, 39, 40). Reported rates of violence against 
sex workers and transgender women are high (41, 42, 43) but nonetheless are likely to be 
underreported where certain behaviours of key populations are illegal.
Homophobic violence, too, is increasing in some countries, as more policies and laws 
have banned same-sex activity and made it a criminal offense (44). This is likely to 
increase HIV risk (45). 
5.4.2 critical enablers
Efforts to address violence against people from key populations must involve 
other sectors along with the health sector. Together, they must create an enabling 
environment to promote physical, sexual, and emotional well-being and safety. Critical 
enablers include mechanisms for documenting and monitoring violence, training people 
from key populations and other stakeholders to understand human rights and fostering 
the accountability of law enforcement officials to prevent and respond to violence and 
infringements of human rights (46).
prevention of violence against key populations 
Law enforcement practices can increase the risk of violence faced by key populations. 
Indeed, law enforcement officers themselves can be perpetrators. Work with law officers 
NewGen uses a range of participatory activities to help young people to think critically about 
the way in which social, political and institutional environments influence the well-being of 
members of key populations. Participants learn formal advocacy and communication skills and 
the use of data through speech-making and participation in meetings as representatives of their 
communities.
Overall, participants rate NewGen very highly. Participants find the training particularly 
useful for learning new leadership and advocacy skills, and they enjoy the participatory 
training methodology. Through working and learning together, participants develop a sense of 
community. Course graduates have helped establish new community networks of young people 
from key populations in many countries, often through social media. 
106 Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations
can involve training on the human rights of key populations as well as promoting 
accountability for rights-based law enforcement (46). Efforts to prevent violence can 
be promoted through advocacy for law and policy reforms that protect the rights 
and safety of key populations, by increasing awareness of reporting mechanisms and 
disciplinary action, by conducting sensitization workshops for people with pivotal roles 
in the community (e.g. government officials, police, media, health-care workers and 
religious leaders), through the creation of safe spaces, and by creating early warning 
and rapid response mechanisms with the involvement of key population community 
members, health workers and law enforcement officials. Integrating community 
representatives into these efforts also helps to create channels of communication among 
key populations, civic officials and police (47).
support for persons experiencing violence 
Those who experience sexual violence need timely access to post-rape care, including 
emergency contraception, post-exposure prophylaxis for HIV and other STIs, hepatitis B 
immunization and psychosocial care and support, as well as referrals to police and legal 
services. HIV prevention, treatment and care should include clinical and psychosocial 
care and support for survivors of violence, in line with WHO guidelines for responding to 
sexual violence (46). Survivors may need treatment for physical injuries and longer-term 
mental health care. Health services also can document medico-legal evidence, which 
can assist survivors’ access to justice. Supportive services also include hotlines staffed 
by trained peer counsellors to offer psychosocial support as well as crisis response 
interventions, with multi-disciplinary teams, linking survivors to various services and 
safe spaces (10). 
It also is important to monitor and document incidents of violence, both as evidence for 
advocacy and to inform programme design. Documenting the levels of violence faced by 
key populations is often the first step in creating awareness. 
good practice recommendations for reducing violence
ALL KEY POPULATION GROUPS
•	 Violence against people from key populations should be prevented and addressed 
in partnership with key population-led organizations. All violence against people 
from key population groups should be monitored and reported, and redress 
mechanisms should be established to provide justice (10, 11, 12, 46). 
•	 Health and other support services should be provided to all persons from 
key populations who experience violence. In particular, persons experiencing 
sexual violence should have timely access to comprehensive post-rape care in 
accordance with WHO guidelines. 
•	 Law enforcement officials and health- and social-care providers need to be 
trained to recognize and uphold the human rights of key populations and to be 
held accountable if they violate these rights, including perpetration of violence 
(10, 11, 12, 46). 
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PEOPLE IN PRISONS AND OTHER CLOSED SETTINGS
•	 Prison authorities should provide adequate staffing, effective surveillance, 
disciplinary sanctions, and education, work and leisure programmes for prisoners. 
•	 Prisons and other closed settings and their staffs should make efforts to change 
institutional culture that tolerates rape and other sexual violence. Prisons should 
adopt multiple approaches to combating sexual violence, including policies and 
programmes for prevention (e.g. prisoner education, classification, and structural 
interventions such as better lighting, better shower and sleeping arrangements), 
staff training, investigation, disciplinary action, victim services (e.g. medical and 
mental health) and documentation of incidents (12). 
case study: Building partnerships in India to address violence and improve 
legal literacy
The Karnataka Health Promotion Trust (KHPT) 
http://www.khpt.org/
Addressing violence against sex workers is complex and requires partnership among like-
minded organizations. The Karnataka Health Promotion Trust (KHPT) has been working on 
HIV prevention among sex workers in Karnataka, India, for the last 10 years. Sex workers 
have strongly expressed the need to prevent and respond to violence. KHPT has sensitized 
law enforcement police and the judiciary and advocated that they not perpetrate or condone 
violence against sex workers. In partnership with KHPT:
•	 The	state’s	Women	and	Child	Welfare	Department	made	services	for	violence	against	women	
available to sex workers.
•	 Community-based	organizations	worked	with	sex	workers	in	30	districts	to	alert	them	to	their	
rights.
•	 The	Alternative	Law	Forum	and	the	National	Law	School	of	India	developed	and	conducted	
legal literacy training for sex workers.
•	 The	Centre	for	Advocacy	and	Research,	a	nongovernmental	organization,	conducted	media	
advocacy and trained sex workers as media spokespersons to talk about the violence they 
face, their resilience and actions to prevent and respond to violence.
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6 serVIce delIVery
6.1 overview
The comprehensive package of interventions, outlined in Chapters 3 and 4, includes 
health interventions common to all key populations as well as additional services for 
specific population groups. Most of these interventions are the same HIV prevention, 
diagnosis, treatment and care interventions as for the general population (1). However, 
there are often complex challenges and barriers, as discussed in Chapter 5, to 
implementation and delivery of these services to key populations. Programmes need to 
address these challenges and barriers and provide sustainable HIV services for diagnosis, 
linkage, retention and adherence for key populations. To maximize impact, services 
should be made 1) accessible, 2) acceptable, 3) affordable and 4) equitable. 
Furthermore, key populations need to be made aware of the available services.
This chapter focuses on the service delivery elements important to the comprehensive 
package of health interventions for key populations. Box 6.1 lists a number of WHO tools 
that can help guide implementation.
Box 6.1 wHo guidance on HIV-related service delivery approaches 
The consolidated guidelines on the use of antiretroviral drugs for treating and 
preventing HIV infection (1) provides broad guidance in six essential operational 
and service delivery areas:  
•	adherence to ART
•	retention across the continuum of care
•	service delivery, comprising service integration and linkage and decentralization 
of HIV care and treatment
•	human resources, including task shifting
•	laboratory and diagnostic services
•	procurement and supply management systems.
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Implementation tools to support HIV programming for key populations  
WHO and other UN agencies have produced normative guidance on HIV 
prevention, treatment and care for key populations, which this publication 
consolidates. To support implementation of HIV programming for these groups, 
these agencies are now partnering to develop implementation tools. The first 
of these is Implementing comprehensive HIV/STI programmes with sex workers: 
practical approaches from collaborative interventions (2). Other tools will address 
HIV programming for men who have sex with men, people who inject drugs and 
transgender people. Also, WHO and other UN agencies have developed tools to 
support the design and implementation of specific interventions, such as needle 
and syringe programmes (3).
WHO regional guidance on service delivery for key populations groups
Regional WHO offices have developed tools for the specific priorities and needs in 
their regions, including:  
Regional Office for Africa:
Preventing HIV in sex work settings in sub-Saharan Africa (4)
Regional Office for the Eastern Mediterranean: 
MENAHRA: The Middle East and North Africa Harm Reduction Association 
best practices in strengthening civil society’s role in delivering harm reduction 
services (5)
Regional Office for Europe:
How to improve opioid substitution therapy implementation (6)
Regional Office for the Americas:
Improving access of key populations to comprehensive HIV health services (7)
Blueprint for the provision of comprehensive care to gay men and other men who 
have sex with men in Latin America and the Caribbean (8)
Regional Office for South-East Asia:
Management of common health problems of drug users (9)
Priority HIV and sexual health interventions in the health sector for men who have 
sex with men and transgender people in the Asia–Pacific Region (10)
Regional Office for the Western Pacific:
Joint technical brief: HIV, sexually transmitted infections and other health needs 
among transgender people in Asia and the Pacific (11)
The time has come: enhancing HIV, STI and other sexual health services for MSM 
and transgender people in Asia and the Pacific (12)
Regional assessment of HIV, STI and other health needs of transgender people in 
Asia and the Pacific (13)
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6.2 key service delivery strategies
Based on evidence and experience, WHO recommends three overarching strategies 
that can improve service delivery (1) : 1) integration, 2) decentralization and 3) task 
shifting. These strategies, separately or in combination, can improve the accessibility of 
care. The community and community-led and community-based approaches are integral 
to these strategies, particularly for key populations. Given the heterogeneity of key 
populations and of social and epidemiological contexts, their application will need to be 
based on a situational assessment and undertaken in consultation with key population 
groups and service providers. 
6.2.1 Integration of services
WHO recommends the integration of HIV services with a range of other relevant clinical 
services, such as those for TB, maternal and child health, sexual and reproductive health 
services and drug dependence treatment (1).
Integration of services facilitates provision of comprehensive and consistent care. It 
allows individuals to take care of their various health needs at the same time and in the 
same location. 
Integration of services involves not only providing 
related services in a single setting but also linkage 
systems to share information and provisions for 
referrals across settings and among providers (1). 
Collaboration between programmes at every level 
of the health system is important to the success of 
HIV and other related health and social services.
Aspects of coordination that need consideration include mobilizing and allocating 
resources; training, mentoring and supervising health workers; procuring and managing 
drugs and other medical supplies; and monitoring and evaluation. The goal of 
programme planning should be to create delivery systems that best facilitate access. 
recommendations and guidance
ALL KEY POPULATION GROUPS
Delivering ART in antenatal care and maternal and other child health settings 
•	 In generalized epidemic settings ART should be initiated and maintained in 
eligible pregnant and postpartum women and in infants at maternal, newborn 
and child health-care settings, with linkage and referral to ongoing HIV care 
and ART where appropriate (strong recommendation, very low quality of 
evidence) (1).
WHO recommends integration 
of HIV services into other relevant 
clinical services, such as TB, MCH, 
sexual and reproductive health 
services and drug dependence 
treatment.
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Delivering ART in TB treatment settings and TB treatment in HIV care settings
•	 In settings with a high HIV prevalence (≥5%) among TB patients, ART should 
be initiated for HIV-positive individuals with TB in TB treatment settings, with 
linkage to ongoing HIV care and ART (strong recommendation, very low quality 
of evidence) (1). 
•	 In settings with a high burden of HIV and TB, TB treatment should be provided for 
individuals with HIV in HIV care settings where TB diagnosis has also been made 
(strong recommendation, very low quality of evidence) (1). 
PEOPLE WHO INJECT DRUGS 
ART in settings providing opioid substitution therapy 
•	 In settings where opioid substitution therapy is provided, ART should be 
initiated and maintained in people with HIV who are eligible for ART (strong 
recommendation, very low quality of evidence) (1).  
case study: Integrated services for sex workers in Zimbabwe
CeSHHAR, Zimbabwe 
http://www.ceshhar.co.zw
The nongovernmental organization Centre for Sexual Health and HIV AIDS Research (CeSHHAR) 
Zimbabwe runs the Sisters with a Voice programme, which provides integrated services for sex 
workers in multiple sites across Zimbabwe on behalf of the National AIDS Council. Collaboration 
with key government ministries (AIDS, Health, and Social Welfare) and the involvement of sex 
workers in implementation have contributed greatly to the programme’s successes.
Supported by a network of peer educators trained in participatory community mobilization 
and empowerment, the Sisters with a Voice programme offers HTC, syndromic STI treatment, 
contraceptives, health education and legal advice. Cervical screening is being rolled out; nurses 
are being trained in visual inspection and treatment of pre-cancerous lesions using cryotherapy.
Peer educators run community mobilization sessions. The 36 sessions cover issues for sex 
workers themselves (self-worth, behaviour change, contraception, HIV and cervical cancer), 
issues relating to clients and partners (communication, assertiveness, serodiscordance, sexual 
networks and multiple concurrent partnering) and issues relating to the “sisterhood” (advocacy, 
stigma, rights and support).
Since 2009 the programme has expanded from five sites to a comprehensive network of 36 sites 
nationally. By 2013 the six fixed facilities and 30 outreach sites together served more than 
14 000 women. Moreover, at a site where two population-based surveys were conducted, the 
proportion of HIV-negative women that reported having a recent HIV test increased from 35% 
in 2011 to more than 70% in 2013. Over the same period the proportion of women living with 
HIV who were obtaining ART increased from 28% to 45%. 
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An example of integrating services is provided by the next case study, where specific 
health services for transgender people are provided within a general health facility.
case study: comprehensive transgender services within a community 
health clinic
Transgender Family Program, Community Healthcare Network, United States of America 
http://www.chnnyc.org/
The Transgender Family Program was established in 2004 at the Community Healthcare Network 
clinics in New York City to improve access to HIV prevention and linkages to primary health care.
To understand how best to integrate comprehensive transgender services into a community 
health clinic, the Network undertook community mapping, consultations and forums and 
learning from similar programmes. Importantly, the programme asked patients to form the Client 
Advisory Board to help guide integration and implementation of services for the transgender 
community.
Integrated services include transgender care, HTC, medical case management, support for 
treatment adherence, STI screening and treatment, prevention interventions and mental health 
and nutritional services. In addition, the programme provides risk reduction counselling, support 
groups, outreach, bilingual educational workshops and referrals to legal and social services. 
Recruitment strategies of staff members and trained peer leaders include face-to-face contacts, 
community-based activities and online methods including advertising and social media tools. 
Clients are encouraged to engage family members. This has proved to be an important strategy 
to encourage access and attendance. 
Over 750 people have received transgender-specific services. Identified benefits of integrated 
transgender services include:
•	 improved	tolerance	of,	sensitivity	to	and	long-term	acceptance	of	this	population	in	the	larger	
community
•	 improved	accessibility	through	convenient	location	of	services
•	 flexible	hours	as	a	result	of	larger	capacity
•	 increased	access	to	a	range	of	in-house	support	services.
In addition, in-depth evaluation has found significant decreases in sex work, needle sharing and 
unregulated hormone injections and increased likelihood of regular condom use.
6.2.2 decentralization of services
Decentralization aims to deliver all HIV services closer to the individual. In many settings 
transport costs and long waiting times in central hospitals are significant barriers to 
access to services and retention in care. Particularly in rural areas, decentralization can 
reduce the difficulty and cost of travel and shorten waiting times. If carefully planned 
and implemented, decentralization may provide safer, discreet and more accessible 
health-care options, particularly for key populations. However, decentralization of 
services for key populations may not always be appropriate or acceptable. In some 
settings general HIV services may provide greater anonymity.
115Chapter 6: Service delivery 
WHO recommends decentralization of ART services specifically. Decentralization of a 
full range of HIV prevention, diagnosis, treatment, care and support services for key 
populations can also be considered. Decentralizing HIV care and treatment can further 
strengthen community engagement, can link community-based interventions with health 
facilities, and may improve access to services, care-seeking behaviour and retention in 
care (1). 
recommendations and guidance
ALL KEY POPULATION GROUPS
•	 The following options should be considered for decentralization of ART initiation 
and maintenance:
– Initiation of ART in hospitals, with maintenance of ART in peripheral health 
facilities (strong recommendation, low quality of evidence).
– Initiation of ART and maintenance of ART in peripheral health facilities (strong 
recommendation, low quality of evidence).
– Initiation of ART at peripheral health facilities, with maintenance at the 
community level between regular clinic visits (i.e. outside of health facilities, 
in settings such as outreach sites, health posts, home-based services or 
community-based organizations) (strong recommendation, moderate quality of 
evidence) (1).
case study: mobile outreach to sex workers in south africa 
Re-Action Consulting, South Africa 
http://www.re-action.co.za
In conjunction with the Department of Health, Re-Action! operates a five-year programme 
to reduce new HIV infections among sex workers and their clients in two rural districts in 
Mpumalanga province of South Africa. Currently, the programme reaches about 4100 female sex 
workers.
A nursing team offers multiple free services including health risk screening and testing 
(including Point of Care CD4 testing), HTC, care and treatment and referral to other health and 
social services through a mobile clinic. The team visits locations at least twice per week at times 
convenient to their clientele. With the help of a 28-day calendar, sex workers know where they 
can obtain services in case of emergencies. If needed, the nurse can provide services, including 
ART, in the client’s workplaces. 
Nurses trained in nurse-initiated and managed ART can diagnose, stage clients and enrol 
them into the appropriate ART services. The nurses supply patients with medication from 
the Department of Health, and they visit patients to follow up and teach about adherence 
to treatment. When a client defaults on treatment, outreach workers provide assistance and 
follow-up. The programme has a very low default rate of 2.3%, most of it attributed to women 
moving elsewhere.
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6.2.3 task-shifting the delivery of services
Task shifting involves the rational redistribution 
of tasks among health-care workers. Where 
appropriate, tasks are reassigned from highly 
qualified health workers to health workers 
with shorter training and fewer complementary qualifications (1). Many countries face 
a shortage of health-care workers; task shifting can increase the effectiveness and 
efficiency of available personnel, enabling the existing workforce to serve more people. 
Community-led organizations can also play important roles in reaching key populations, 
engaging with them, linking them to services and providing ongoing care and support. 
Peer-support workers can provide valuable services and can link the community and 
health services. Like other health workers, they need regular training, mentoring 
and supervision (1). They should receive adequate wages and/or other appropriate 
incentives (14).
recommendations and guidance
ALL KEY POPULATION GROUPS
•	 Trained non-physician clinicians, midwives and nurses can initiate first-line ART 
(strong recommendation, moderate quality of evidence).
•	 Trained non-physician clinicians, midwives and nurses can maintain ART (strong 
recommendation, moderate quality of evidence).
•	 Trained and supervised community health workers can dispense ART between 
regular clinical visits (strong recommendation, moderate quality of evidence) (1).
case study: community distribution of naloxone in India
Social Awareness Service Organisation (SASO), Manipur, India 
http://sasoimphal.org/
In the state of Manipur, India, since 2000 the Social Awareness Service Organisation (SASO) 
has provided, among other services, opioid overdose management with free naloxone, through 
outreach (e.g. at “shooting sites”) and at drop-in centres. Also, through small meetings, one-to-
one contacts and counselling, SASO provides information and education about drug overdose 
and its management to all people who inject drugs and their family members.
The programme was scaled up and strengthened in 2008–09 by involving key stakeholders to 
facilitate community implementation of naloxone to ensure wider coverage. Ethical concerns 
about non-medical staff dispensing a medication to people who inject drugs have been 
overcome through the demonstration of the life-saving nature of overdose management. 
Between 2004 and 2012 more than 450 overdoses were managed at five centres, and over 90% 
of those lives were saved. In addition, more than one-third of overdose clients have increased 
access to drug treatment and other health care, such as HIV/HCV testing and ART.
Task shifting can enable the existing 
workforce to serve more people.
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6.2.4 community-based approaches
Community-based approaches to service delivery can increase accessibility and 
acceptability for key populations. Outreach, mobile services, drop-in centres and venue-
based approaches are useful for reaching those with limited access to, or underserved 
by, formal health facilities. These approaches allow for critical linkages and referrals 
between the community and health facilities, and they support decentralization (see 
Section 6.2.2). Community-based programmes can also refer to programmes that 
are led and delivered by members of the key population community. Staff members, 
including peers, involved in community-based approaches need to be appropriately 
supported, in terms both of training, supervision and management and of incentives and 
remuneration.
Community-led services, in which community 
members take the lead in delivering outreach and 
overseeing an HIV prevention programme, have 
demonstrated significant benefits in terms of HIV 
outcomes. They also enable community members to address structural barriers to 
the exercise of their rights and empower them to change social norms, thus reducing 
vulnerabilities that go beyond HIV. 
Community-led services are interventions designed, delivered and monitored by 
community members. They can play many roles – for example:
•	 providing adequate and reliable access to commodities (condoms, lubricants, and 
needles and syringes) and clinical services through outreach and referrals;
•	 responding to violence against community members and implementing other 
structural interventions;
•	 supporting the safe and effective use of naloxone in the community by people who 
witness an opioid overdose;
•	 promoting behavioural and social change that strengthens not only knowledge 
but also skills and systems in order to sustain prevention and retention in care and 
treatment;
•	 offering formal and informal means for the community to provide feedback on the 
quality of services and to engage with services beyond the HIV programme (2).
Peer interventions – also termed peer-based or peer-driven interventions – are an 
important modality for delivering services and exchanging information and skills that 
promote safer behaviours to individuals or networks of people from key populations. 
Beyond providing services, peers can act as role models and offer non-judgemental and 
respectful support that may contribute to reducing stigma, facilitating access to services 
and improving their acceptability.
The community plays a vital 
role in the HIV response.
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case study: community-led service delivery centres in pakistan
Naz Male Health Alliance, Pakistan
Naz Male Health Alliance is a community-based organization in Pakistan serving the community 
of men who have sex with men and of transgender people. As part of its on-going work to 
empower the community, the organization operates six service delivery centres in five cities, 
with 47 000 registered clients. Each service delivery centre is divided into a clinic and a drop-in 
centre that provides a safe and relaxing atmosphere for the low-income beneficiaries. The 
centres are located strategically close to “hotspots” for men who have sex with men and where 
there are concentrations of hijra deras (dwellings of transsexual people). Drop-in centres and 
outreach activities are complementary: The drop-in centres allow the establishment of long-
lasting relationships with the clients, and outreach provides linkage to the drop-in centre.
Service sites are separate for each key population community in order to effectively address 
their different needs. Each centre has a multidisciplinary staff of about 15 people, including STI 
specialist doctors, a psychologist, and peer educators. The teams consist primarily of community 
members; more than 95% of staff staff are men who have sex with men and transgender 
people.
recommendations and guidance
ALL KEY POPULATION GROUPS
In all HIV epidemic settings, WHO recommends community-based HIV testing 
and counselling with linkage to prevention, care and treatment services for key 
populations in addition to provider-initiated testing and counselling (strong 
recommendation, low quality of evidence) (1). 
PEOPLE WHO INJECT DRUGS 
See Section 4.1.2.4 for specific recommendations on peer support and community 
delivery of naloxone.  
ADOLESCENTS FROM KEY POPULATIONS 
Community-based approaches can improve treatment adherence and retention in 
care of adolescents living with HIV (conditional recommendation, very low quality of 
evidence) (15). (See Box 6.2.)
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Box 6.2 adolescents from key populations  
The service delivery approaches and considerations discussed in this chapter for 
all key populations are applicable for adolescents from key populations. However, 
additional considerations are required. It is essential that services for adolescents 
from key populations are designed and delivered in ways that take into account 
the multiple, overlapping vulnerabilities that confront adolescents from key 
populations and the diversity of their needs, based on their age, their specific 
behaviours and the complexities of their social and legal environment.
Additional considerations and approaches for adolescents from key populations 
include:1
•	Acknowledge and build upon the strengths, competencies and capacities of 
adolescents from key populations, especially their ability to articulate what services 
they need. Engage them in decisions about services, recognizing their evolving 
capacity and their right to have their views taken into account. This is an important 
consideration when addressing issues of parental consent for services and treatment 
(see Section 5.1.2).
•	Give primary consideration to the best interests of young people in all laws and 
policies aimed at protecting their rights (Convention on the Rights of the Child, 
Article 3) (16).
•	Make the most of existing services and infrastructure for youth and add components 
for reaching and providing services to adolescents from key populations, ensuring 
that services are friendly to youth from key populations as well as to other youth. 
•	Adopt a multidisciplinary approach, ensuring that services are as comprehensive as 
possible so as to address overlapping vulnerabilities.
•	Provide developmentally appropriate information and education for adolescents 
from key populations, focusing on skills-based risk reduction. Information can be 
disseminated via multiple media, including the Internet, mobile phone technology 
and participatory approaches.
•	Provide psychosocial support, through counselling, peer support groups and 
networks, to address self-stigma and discrimination and other mental health 
issues. Additional provision of counselling for families, including parents – where 
appropriate and requested by the adolescent – may be important to support and 
facilitate access to services, especially where parental consent is required (7).
•	Facilitate access to social services and state benefits, including immediate shelter 
and long-term housing, and address food security issues, including nutritional 
assessments.
•	Support access to livelihood development and economic strengthening, and 
encourage adolescents to stay in school or, if out of school, to return to school, 
where appropriate.
•	Address social norms and stigma concerning sexuality, gender identities and sexual 
orientation through comprehensive sexuality education in schools, supportive 
information for families, training of educators and health-care providers and non-
discrimination policies in employment.
1 See also Web Annex 6 briefs on young key populations.
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6.3 key factors to consider when providing services for all key 
populations
In summary, assuring access, acceptability and affordability requires attention to multiple, 
specific elements of programme design and delivery. Action on all these elements, 
appropriate to the specific context, will yield programmes that best serve key populations.
access
generate demand 
Demand for HTC and prevention services can be generated through targeted 
campaigns in identified key population settings, using community-based outreach, 
mobile phone technology, social networking and broadcast and online media. 
case study: online strategies to increase uptake of Htc services in Bangkok
Thai Red Cross AIDS Research Centre, Bangkok, Thailand 
http://en.trcarc.org/
In Bangkok the Men’s Health Clinic provides comprehensive and friendly services to men who have sex 
with men. One of the Clinic’s tools to increase uptake of HTC has been the first bilingual (Thai/English) 
edu-tainment web site for men who have sex with men (http://adamslove.org), launched in 2011.
The web site’s goal is to encourage regular HIV testing among men who have sex with men. To link 
web site visitors to HTC services, a section titled “HIV testing site near you” offers information about 
how to obtain HTC at sites that are friendly to men who have sex with men in Bangkok and other 
provinces. Other means of continuous demand creation for HTC services include mass media and 
targeted media activities such as regular columns in gay magazines, peer-driven interventions and 
celebrity meet-and-greet HIV testing events.
The number of clients who have obtained HTC services has increased almost fivefold, from 967 in 
2008 to 4371 in 2012. The Adam’s Love web site attracted more than 500 000 visitors in two years 
and has its own Facebook page as well, with more than 15 000 fans. One-quarter of clients of the 
Men’s Health Clinic report obtaining HTC services because of the site.
address age barriers 
Age of consent laws should be examined to determine their effect on access to 
services. Countries can consider revising age of consent policies and creating 
exceptions to age limits (i.e. mature minor status). Countries also can consider how 
best to assess adolescents’ capacity to consent.  
make services convenient 
Programmes can consider offering mobile and/or drop-in services and weekend and/
or night service times that facilitate access. Outreach, including venue-based and 
home-visiting services, also can increase access.  
decentralize services 
Shifting services from centralized locations to community-based and/or mobile 
outreach and peripheral health facilities can increase access. For example, school-
based sex education, peer counselling and community-level activities can disseminate 
behavioural messages, promote follow-up on referrals to services, improve adherence 
to treatment and increase people’s participation in their own health care. 
121Chapter 6: Service delivery 
case study: In Vietnam decentralization facilitates earlier access to HIV 
services 
Vietnam Authority of HIV/AIDS Control/Ministry of Health and WHO Vietnam
In 2012 the Vietnam Authority of HIV/AIDS Control in the Ministry of Health started pilot-testing a 
project to expand earlier access to HIV services among key populations, particularly to people who 
inject drugs, and thus to maximize the therapeutic and preventive benefits of ART by enabling people 
to start treatment as soon as possible. The pilot project involved decentralizing HTC services from 
district facilities to commune health stations in Dien Bien and Can Tho provinces. The pilot project 
introduced such innovations in Vietnam as a fixed dose combination ARV formulation, point-of-care 
HIV and CD4 testing, and decentralized follow-up.
The project actively engaged community partners, including peer educators, self-support groups 
and village health-care workers, providing them with community mobilization trainings and holding 
regular meetings to discuss outreach activities and challenges. Commune health station staff 
received training on HIV service delivery, including HIV testing using rapid tests, pre- and post-test 
counselling, adherence support, basic care and dispensing ARV drugs.
This decentralized, community-based model has been shown to promote earlier diagnosis and 
treatment. People diagnosed at communes have significantly higher median CD4 counts when 
starting ART (median 294 cells/mm3) than those diagnosed at district facilities (median 88 cells/mm3). 
Community outreach and trust-building are recognized as critical to facilitating earlier access to HIV 
services among people who inject drugs.
Integrate services and assure referrals and linkage to care 
Service integration, including integrated HTC and care services and integrated HIV 
and drug dependence services (e.g. OST, NSP), makes services more convenient 
and thus facilitates access. To decrease loss to follow-up, standard operating 
procedures should specify linkages to care and help with transport from HTC to ART 
sites. Systems that share information between clinics (e.g. TB and HIV clinics), use 
of outreach workers for follow-up and support from peers can facilitate retention 
in care.  
case study: promoting regular testing and supporting linkage to care in spain
Projecte dels NOMS-Hispanosida (BCN Checkpoint), Spain 
http://www.bcncheckpoint.com/
BCN Checkpoint is a community-based centre in the gay district of Barcelona for the detection of HIV 
and other STIs among men who have sex with men. Managed by the nongovernmental organization 
Projecte dels NOMS-Hispanosida, BCN Checkpoint offers free rapid HIV and syphilis testing by 
peers for early detection, vaccination against hepatitis A and B and promotion of sexual health. To 
encourage annual repeat HIV testing, BCN Checkpoint uses e-mail, text messages and telephone 
reminders. 
Between 2007 and 2013 the programme performed over 22 000 HIV tests, detecting 756 new 
infections. For those with HIV-positive results, BCN Checkpoint offers an education and information 
programme with trained HIV-positive peer counsellors and referrals within one week to the hospital’s 
HIV treatment unit. To ensure linkage to care, all recently diagnosed individuals are followed through 
a register. Currently, nearly 90% are linked directly to care, while 5% find their own care, and about 
4% are in Barcelona only temporarily and obtain care in their home countries. Less than 2% are lost 
in linkage to care.
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Invest in critical enablers 
Countries can support key populations’ access to services by investing in critical 
enablers such as integrated treatment and rights literacy programmes, legal services, 
programmes to reduce stigma and discrimination, and training for health-care 
workers and law enforcement personnel.
case study: using social media in ghana to reach men who have sex with men 
SHARPER project, FHI360, Ghana 
http://www.fhi360.org/projects/strengthening-hivaids-response-partnership-evidenced-based-results-
sharper
The SHARPER project tested use of social media by community liaison officers to identify unreached 
networks of men who have sex with men. The project launched MSM.net in two locations through 
informal mapping of the community’s networks. Community liaison officers were selected from 
networks not previously reached by peer educators and were trained on HIV, health information and 
services. They used social media on smart phones and laptop computers to reach men who have sex 
with men. “Reached” is defined as receiving a risk assessment, information on HIV prevention and a 
referral to HIV testing and counselling (or another HIV service).
In 2013 more than 15 000 men who have sex with men were reached through Facebook (45.6%), 
WhatsApp (13.4%) and other social media platforms. In Accra 82% of the men reached by this 
approach had not had previous contact with a peer educator. In Kumasi 66% had never been reached 
before by any intervention. The community liaison officer in Accra identified eight male sex worker 
brothels and networks previously unknown to the project and other MSM organizations. 
Social media proved to be an important means to reach men who have sex with men that peer 
educators would not usually reach. MSM reached by community liaison officers tended to be older, 
more educated, single, have a higher monthly income, and (in Accra) to report a larger social network 
of men who have sex with men than those reached by peer educators. 
acceptaBIlIty
train health-care providers 
Sensitize and educate health-care providers (including community workers, 
peer outreach workers, support staff and management) on issues specific to key 
populations and on non-discriminatory practices and eliminating stigma, using pre-
service and in-service training, job aids, supportive supervision, and training follow-
up. Where possible, training should involve representatives of key populations.
create a safe and supportive environment 
Safe spaces (for both health-care and social services) and confidential and stigma-
free environments can encourage access by people from key populations. For 
example, providing separate and well-lit entrances or locating services in an 
appropriate setting can decrease barriers to services.
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provide high-quality services 
Services should be acceptable and of high quality. One way to assess quality is 
monitoring clients’ experience, using national and global indicators.
assure voluntary and informed consent 
Programmes must promote individuals’ right to decide on their own treatment and 
accept their right to refuse services. All services should be voluntary, without any 
feeling of coercion or conditional requirements for obtaining services or commodities 
such as HIV testing, condoms or clean needles. Information on services and treatment 
should be clear, explicit and in the appropriate language. Additionally, information for 
adolescents needs to be suited to their specific developmental stage. 
ensure confidentiality 
Attention should be devoted to protecting privacy and confidentially, e.g. closing the 
consultation room door or finding a private place to talk. Clients should be reassured 
of confidentiality, e.g. seeking permission before disclosing information to other 
health-care providers. Programmes should address the complexities of maintaining 
confidentiality in community, outreach and peer approaches particularly.
case study: confidential and anonymous services in lebanon 
Marsa Sexual Health Center, Lebanon 
http://www.marsa.me
Marsa Sexual Health Center in Beirut, Lebanon, offers sexual health and reproductive health services 
to the public in a friendly environment free of stigma and discrimination against age, sex, gender and 
sexual orientation. Intended clients are youth, unmarried sexually active women and marginalized 
communities with limited access to other sexual health care facilities, including men who have sex 
with men and transgender people.
Clients’ anonymity and confidentiality when they obtain Marsa services play a key role in attracting 
the clientele. The center uses a unique file number for each client as a form of identification. The 
client decides if they would like to provide identifying information for their file.
In addition, the staff of experienced and sensitized professionals is required to maintain 
confidentiality. Clients feel comfortable to open up to their care providers, disclose intimate details 
about their lifestyles and seek information from specialists, knowing that their identity will not be 
disclosed, even among staff members.
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case study: online and telephone counselling assures anonymity for young 
men who have sex with men living with HIV in the russian federation 
Positive Life programme, menZDRAV Foundation & Phoenix PLUS NGO, Russia
In partnership with a nongovernmental organisation, the menZDRAV Foundation offers services 
to young men who have sex with men, ages 18–25, living with HIV in six regions of the Russian 
Federation. Many young men are reluctant to attend support groups for fear that their sexual 
orientation or HIV status will be publicly identified, and so the Positive Life programme offers 
individual counselling via phone, social media and Skype.
In each of six cities, peer counsellors staff a telephone hotline with a publicized number. Counselling 
is also offered via Skype, and young men can send questions to counsellors via email, Facebook, 
Vkontakte or via a counsellor’s profile on gay-oriented web sites.
Counsellors offer callers information on sexuality, safe sex, STIs, adherence to ART, ARV side-effects 
and disclosure of HIV status to sexual partners. Callers are informed about project services and 
encouraged to visit the project office for assessments or referrals. Those who are reluctant to visit for 
fear of being identified can be referred to one of 20 medical specialists across the six regions who 
have been trained and sensitized to the specific needs of men who have sex with men living with HIV 
and will provide services without stigma or discrimination. 
There are about 80 trained peer counsellors, both project staff members and volunteers. All Positive 
Life counsellors take part in a centralized training. They receive further training and supervision at 
the project’s regional offices as well as from central project staff who travel to the regions. In 2013 
Positive Life counsellors provided almost 1900 phone consultations and 1350 online consultations.
engage members of key populations 
Members of the key population should be involved in the design of programmes, 
including their planning, implementation and monitoring and evaluation. Such 
involvement can increase the community’s sense of ownership and, thus, programme 
success. People from key populations also can be involved as service providers and 
advocates. 
case study: capacity building for transgender community services in the usa 
Center of Excellence for Transgender Health, University of California, USA 
http://transhealth.ucsf.edu 
The mission of the Center of Excellence for Transgender Health is to increase access to 
comprehensive, effective and affirming health-care services for transgender and gender-variant 
communities. The ultimate goal is to improve the overall health and well-being of transgender people 
by developing and implementing programmes in response to community-identified needs. Core 
faculty and staff with diverse backgrounds and experience offer programmes informed by a national 
advisory board of 14 trans-identified leaders from throughout the United States of America. 
The projects of the Center of Excellence address a wide range of health issues for transgender 
people. One activity is developing guidelines on a range of primary care topics, including primary and 
preventive care, hormone therapy, mental health, youth and surgery. Protocols have been published 
online (http://Transhealth.UCSF.edu/protocols). In addition, the Transitions Project helps build the 
capacity of community-based organizations to adapt, implement and evaluate evidence-based HIV 
prevention interventions for transgender communities. 
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case study: capacity building and training sessions in tanzania
Médecins du Monde, Tanzania 
http://doctorsoftheworld.org/where-we-work/africa/tanzania/
Médecins du Monde, Tanzania, provides comprehensive harm reduction services, including needle 
and syringe programmes and referral to OST, as well as income generating activities and legal aid. 
More broadly, Médecins du Monde is involved in building the capacity of nongovernmental and 
community-based organizations to run harm reduction services, especially drop-in centres with 
needle and syringe programmes; these include dedicated centres for women, with additional services 
offered for their children. In 2013 more than 2000 stakeholders were trained in harm reduction 
approaches and interventions.
The organization also has helped create national and district-level harm reduction committees 
with representation from governmental and nongovernmental institutions. Sub-committees at both 
levels focus on resource mobilization. A continuous dialogue with municipal, district and national 
authorities and sensitization sessions for police, medical staff and journalists have been important 
elements of the work. 
affordaBIlIty
ensure monetary resources 
Government commitment and funding are important. Public–private partnerships can 
spread costs.
minimize or eliminate fees 
Wherever possible, services should be provided free of charge or at reduced price. 
Insurance or health subsidies should cover any fees for services. 
reduce costs 
Costs to the health system and for the user can be reduced through the integration 
and decentralization of services, community outreach and venues, and convenient 
locations. Costs to the individual can be reduced also by shortening waiting times at 
the facility through a flexible appointment systems and separating clinic consultation 
visits from picking up medicines.
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7 deVelopIng tHe response: 
tHe decIsIon-makIng, plannIng 
and monItorIng process
7.1 Introduction
Action on the recommendations in these guidelines requires a strategy informed by 
evidence and appropriate to the local context. Planning, decision-making and monitoring 
are parts of an ongoing process: Once an evidence-based plan is developed and 
implemented, it must be monitored and evaluated. The resulting findings then inform 
revision of the strategy and its implementation (Fig. 7.1).
fig. 7.1 the programme planning, implementation and evaluation cycle
Understand
the	situation
Plan	and	
implement	the	
response
Monitor	and	
evaluate	the	
response
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7.1.1 guiding principles
An effective process for developing and implementing a national or sub-national 
response to HIV among key populations follows these guiding principles:
•	 An ethical and rights-based approach should inform all decision-making. The 
planned response to HIV among key populations, and the decision-making process 
itself, should be non-discriminatory and accountable to the populations it seeks to 
serve, respecting and upholding their autonomy and rights. Principles of fairness and 
equity should be followed.
•	 Meaningful participation by affected communities is critical to ensure that 
the decisions made, the plans formulated and the programmes developed are 
acceptable to community members, equitable, and responsive to community needs. 
Representatives from key population constituencies should be involved at all stages 
from designing the response through its implementation to monitoring and evaluation 
(M&E) (1). Successful community empowerment (see Section 5.3) develops the 
capacity of community members and organizations to participate in these processes 
in a meaningful way. Community-led organizations play a crucial role in delivering 
services that best meet the needs of key populations. 
•	 Involvement of all stakeholders. Addressing HIV among key populations requires 
a multisectoral response. Accordingly, planning of the response needs to involve 
multiple sectors. Box 7.1 lists potential stakeholders to include in the planning 
process. 
•	 Coordinated approach. The national HIV programme manager and an appropriate 
body such as a national HIV/AIDS commission should take responsibility for managing 
the overall planning process and facilitating stakeholder and community participation. 
Designating an individual to work specifically on developing and coordinating services 
and issues related to key populations within the national AIDS commission (or similar 
peak body) may facilitate this. In large and diverse countries, developing a national 
programme requires formulating strategies at the local and sub-national levels as 
well, with guidance and coordination centrally, at the national level.
•	 Openness and transparency. The evidence and rationale for decisions should be 
publicly available, including information on expected effectiveness and risk and the 
distribution of health benefits and burdens for different groups.
•	 Evidence-based. Policies, interventions and approaches should be based on sound 
evidence or experience.
•	 Equity. Programmes should aim to achieve equitable health outcomes across all 
populations and settings and to promote gender equity.
•	 Efficiency and sustainability. Programmes should seek to deliver effective services 
most efficiently and to ensure that they are sustainable over the long term.
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7.2 understanding the situation
The efficacy of the interventions in the essential package is well proven. Experience in 
multiple countries has demonstrated the generalizability of these interventions in diverse 
settings. Local factors do, however, have a bearing on intervention effectiveness and 
impact. It is critical to understand local epidemic dynamics; the characteristics of the 
populations affected; the physical, social and political environments that influence risk 
and vulnerability; the needs of people from key populations and any factors that might 
enable or hinder efforts to address these needs; and the health systems and community 
infrastructure. With this information in hand, an evidence-based plan can be developed 
and implemented. 
People from key populations face greater HIV risk than the general population and have 
specific health-related needs. While many of these risks and needs may be common to 
people from key populations in different settings, some factors will differ among key 
populations, and some will be specific to a particular context. Accordingly, for a local 
Box 7.1 potential stakeholders to include in the planning process 
•	Programme experts, managers and health-care workers from the following fields 
in both the public and private sectors: HIV programmes and clinics (HIV testing 
and counselling, ART and PMTCT, sexual and reproductive health, maternal and 
child health, mental health, hepatology and TB services, drug dependence and 
harm reduction services, and prison health programmes;
•	civil society, including people living with HIV, women’s and youth groups, 
religious leaders, people with disabilities;
•	technical specialists in specific areas, such as laboratory services, pharmacology, 
drug resistance, toxicity management, supply chain and community health;
•	government partners, including representatives of relevant ministries, such as 
health, justice and law enforcement, internal affairs, finance and planning, and 
regional (such as provincial) authorities;
•	nongovernmental organizations, including international agencies, faith-
based organizations, other local nongovernmental and community-based 
organizations, and private-sector service organizations;
•	finance and budget experts, such as programme budget officers and health 
economists;
•	academic institutions, including experts in operational research, implementation 
science, ethics, training and supervision;
•	professional associations of various cadres of health workers (such as 
physicians, nurses and community health workers).
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response to be appropriate, acceptable and most effective, these risks and needs must 
be examined locally, and local people from key populations must be consulted and 
actively involved in the situational analysis. 
It is also important to recognize the considerable diversity and varying levels of risk 
within each key population. Those most at risk are likely to be people who could be 
considered members of more than one key population; for example, some men who have 
sex with men may also inject drugs or engage in sex work. Thus, they risk exposure to 
HIV by several routes. People from key populations may also have other characteristics 
that could increase their risk or vulnerability or create additional health or welfare 
needs. For example, people from key populations may be homeless, experience mental 
health conditions or have other acute or chronic health concerns.
Key population size and distribution 
vary from place to place. To determine 
the required scale of the response, the 
appropriate balance among different 
interventions and where interventions 
should be targeted, it is important to appreciate the size and distribution of key 
populations, among other factors (see Box 7.2 and Section 7.3).
It is critical that information gathering processes, and the information itself, serve to 
protect, and not put at risk, the safety and privacy of people from key populations. 
At all times ethical principles must be observed, and the human rights of people from 
key populations, protected. In some circumstances, determining population size or 
mapping key populations can unintentionally endanger community members or subject 
them to stigma by identifying these populations and where they are located. Such 
information could also lead to arrest or imprisonment of people from key populations 
whose behaviour is criminalized. When undertaking information-gathering exercises, 
it is important to strictly maintain privacy, confidentiality and the security of the 
information collected. If the safety and the human rights of people from key populations 
cannot be protected, collection of certain data, such as mapping where people from key 
populations congregate, is better avoided.
The makeup, characteristics and needs of key populations change over time, as do 
various contextual and environmental factors. Ongoing M&E will identify changing 
parameters and make it possible to refine or refocus the response. 
A situational analysis will almost certainly identify gaps in knowledge. An agenda for 
further research can address these gaps. 
It is also important, whenever analysing and interpreting data, to evaluate the quality of 
the data and the presence of any sources of bias. 
Data should guide the response, but lack of 
data is not a reason to stop or not initiate a 
response to HIV among key populations.
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Box 7.2 key information required for decision-making and planning 
Information required Source of information (see also Box 7.4)
Key population size •	 population size estimation
HIV prevalence among key 
populations
•	 sero-surveillance 
Key population location/geographic 
distribution
•	mapping exercises
Key population characteristics, risk 
behaviours and health concerns
•	 demographic surveys
•	 behavioural surveys
•	 general health surveys
Important structural factors, barriers 
to implementing a response to HIV, 
and the needs of key populations
•	 audit of current legislation, policy and practice
•	 consultation with community members, 
community-led organizations and other 
stakeholders
•	 behavioural surveys
Accessibility, coverage, quality, 
outcome and impact of intervention
•	 programmatic (administrative) data
•	 disease notification registries
•	 integrated bio-behavioural surveys.
(See Box 7.3 for further description of national 
programme monitoring and evaluation framework.)
Rapid assessment and response guides are available to help guide initial and 
ongoing assessments, using multiple methods to gather data and to conduct 
analyses at multiple levels:
•	Rapid assessment and response adaptation guide on HIV and men who have 
sex with men. Geneva, WHO, 2002. http://www.who.int/hiv/pub/prev_care/en/
msmrar.pdf?ua=1
•	The rapid assessment and response guide on injecting drug use (IDU-RAR). 
Geneva, WHO, 1998. http://www.who.int/substance_abuse/publications/en/
IDURARguideEnglish.pdf?ua=1 
•	The rapid assessment and response guide on psychoactive substance use and 
sexual risk behaviour (SEx-RAR). Geneva, WHO, 2002. http://www.who.int/
entity/mental_health/media/en/686.pdf?ua=1 
•	Rapid assessment and response adaptation guide for work with especially 
vulnerable young people. Geneva, WHO, 2004 http://www.who.int/hiv/pub/
prev_care/en/youngpeoplerar.pdf?ua=1
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7.3 planning and implementing the response
The following are some of the decisions that need to be taken while developing and 
implementing a national response to HIV among key populations. 
targeting the response
•	 Which key populations and which sub-groups within key populations are most at risk?
•	 Which legislation, policies and guidelines need to be developed or revised?
Implementation
•	 Which interventions need to be implemented, and how should their implementation 
be prioritized?
•	 Where and at what scale do interventions need to be provided?1
•	 What targets and timelines should be set for the implementation and scale-up of 
interventions?
•	 How and to what extent should services be decentralized and integrated to provide 
the best service coverage for key populations?
•	 Which modes of service delivery are most appropriate?
•	 What are the roles and responsibilities of the various stakeholders in implementing 
the response and achieving the agreed targets?
resources required 
•	 Do the costs of implementing the response outweigh the costs of inaction?
•	 What financial, human and other resources and infrastructure are required to 
implement the response? What resources are currently available, what additional 
inputs will be required, and how might these be obtained? What types of health-care 
and other workers are required, and how will they be recruited and trained? How can 
task shifting and sharing optimize the use of available human resources and expand 
service delivery? 
•	 How will economies of scale and synergies among HIV interventions and with other 
health interventions save on costs and improve service provision?
monitoring and evaluation
•	 How will implementation of the response be monitored and evaluated?
•	 How do strategic information systems for M&E need to be strengthened?
1 For ART the WHO Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection (2013) provides 
information on considerations for implementing and scaling up services in line with key recommendations.
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risks, outcomes and impacts
•	 What are potential risks and vulnerabilities of the planned response, and what 
strategies would mitigate their impact? Risks might include domestic factors such as 
budget cuts, theft of consumables, attrition of health-care workers, and emergence 
of drug resistance. External factors could include loss of external financial support, 
political instability, and natural disasters.
7.4 monitoring and evaluating the response
A monitoring and evaluation system is needed to assess both structural and health 
sector components of the response to HIV in key populations. It is critical that these 
systems are practical, not overly complicated, and that they collect information that is 
current, useful and readily used. 
WHO and UN partner agencies have developed 
frameworks for monitoring the response to HIV in 
the general population and key populations. The 
following documents described these frameworks: 
•	 Tool for setting and monitoring targets for 
prevention, treatment and care for HIV and other sexually transmitted infections 
among men who have sex with men, sex workers and transgender people. Geneva, 
WHO, forthcoming. 
•	 Technical guide for countries to set targets for universal access to HIV prevention, 
treatment and care for injecting drug users – 2012 revision. Geneva, WHO, 2012. 
http://www.who.int/hiv/pub/idu/targets_universal_access/en/
•	 Consolidated HIV M&E guidelines. Geneva, WHO, forthcoming.
Each of these frameworks recommends a set of national-level indicators. These 
indicators assess key factors related to the enabling environment; measure the 
availability, coverage and quality of specific interventions; and examine their outcome 
and impact (Box 7.3). The indicators can also be used when preparing proposals or 
reporting progress to donor organizations. 
The following documents provide additional guidance on M&E, including how to 
undertake assessments at the sub-national level: 
•	 Operational guidelines for monitoring and evaluation of HIV programmes for sex 
workers, men who have sex with men and transgender people. Geneva, UNAIDS, 
2012. http://unaids.org.cn/en/index/Document_view.asp?id=712
•	 Operational guidelines for monitoring and evaluation of HIV programmes for people 
who use drugs. Geneva, UNAIDS, 2011, draft. http://www.cpc.unc.edu/measure/
tools/hiv-aids/operational-guidelines-for-m-e-of-hiv-programmes-for-people-who-
inject-drugs/idu-service-delivery-level-guidelines/view
The M&E process requires data from a variety of sources, including behavioural and 
sero-surveillance surveys, programmatic and administrative data, as well as information 
gathered through reviewing policy documents and legislation and consultation with 
An M&E system is an essential 
part of the HIV response for key 
populations.
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experts and stakeholders (Box 7.4). The quality and limitations of these data should be 
assessed and considered when undertaking analysis and interpretation. 
7.5 ongoing planning and development of the response 
Setting clear, achievable but ambitious targets is crucial when planning to scale up 
interventions to meet the objectives of the HIV response. Targets concretely define what 
a successful national programme or project should achieve within a specified time frame. 
Targets can be set for both intervention-specific indicators and cross-cutting outcome 
and impact indicators (Box 7.3).
Intervention and enabling environment indicators reflect the availability, coverage 
and quality of an intervention or service or assess changes in environmental factors, 
such as revision of legislation, within a specified timeframe. Targets are set with the 
aims of achieving reductions in HIV and STI risk sufficient to control the epidemic and 
ensuring the adequate provision of appropriate treatment and care for those living with 
HIV or with an STI.
Outcome and impact indicators seek to gauge the impact that interventions have 
had on outcomes that affect exposure to risk, such as changes in risk behaviours (for 
example, the percentage of people who use condoms consistently) or on impacts on the 
course of HIV or STI epidemics (for example, reductions in incidence of HIV or STIs).
Like planning overall, the target-setting process should be collaborative, involving 
the range of stakeholders. Those setting the targets should consider whether they 
are realistic and whether data can be practically collected. Targets, in keeping with 
programme strategies, should be tailored to the local epidemic and what the strategy 
can realistically achieve with obtainable funding and resources. Modelling can help to 
identify how different target levels would affect the epidemic. 
Baseline assessment. Initial assessment should measure the scale of the current 
response, assessing the availability, coverage, and quality of current interventions, and 
appraising current environmental enablers and barriers. This information serves as a 
baseline for tracking progress. Also, currently available resources and technical capacity 
must be determined in order to estimate what more is needed and how to scale the 
intervention appropriately. From this information, realistic, achievable targets can be set 
and the time frame, specified.
Estimating cost. Estimating the costs associated with implementation is a key step 
in planning the roll-out. Several costing tools and resources are available. Spectrum, 
for example, is a suite of models and analytical tools to support decision-making. It 
comprises several software applications, including AIM (AIDS Impact Model) and Goals 
(Cost and Impact of HIV Interventions). Most countries already have AIM files prepared 
as part of their national epidemiological estimates, and so both modules can be rapidly 
applied. Spectrum can be accessed online at: http://www.unaids.org/en/dataanalysis/
datatools/spectrumepp2013/. 
OneHealth is a software tool designed to strengthen health system analysis and costing 
and to develop financing scenarios at the country level. It is specifically designed for 
low- and middle-income countries. It provides planners with a single framework for 
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planning, costing, impact analysis, budgeting and financing of strategies for all major 
diseases and health system components. OneHealth can be downloaded free of charge 
(Futures Institute, 2013) at: http://www.futuresinstitute.org/onehealth.aspx.  
UNAIDS has developed The human rights costing tool (HRCT), a flexible tool for costing 
investments in critical enablers (such as integrated treatment and rights literacy 
programmes, legal services, stigma and discrimination reduction programmes, and training 
for health-care workers and law enforcement). This, too, can be downloaded free of charge 
along with a user guide (2,3) at: http://www.unaids.org/en/media/unaids/contentassets/
documents/data-and-analysis/tools/The_Human_Rights_Costing_Tool_v_1_5_May-
2012.xlsm and http://www.unaids.org/en/media/unaids/contentassets/documents/
document/2012/The_HRCT_User_Guide_FINAL_2012-07-09.pdf 
Box 7.3 Indicators for monitoring and evaluating the response
To understand how well the response is functioning and its effects, its various 
key requirements need to be monitored for each key population. For each of these 
requirements there are a number of useful indicators. 
These indicators are described in detail in WHO key population guidance: Tool 
for setting and monitoring targets for prevention, treatment and care for HIV and 
other sexually transmitted infections among men who have sex with men, sex 
workers and transgender people, forthcoming; and Technical guide for countries 
to set targets for universal access to HIV prevention, treatment and care for 
injecting drug users – 2012 revision, http://www.who.int/hiv/pub/idu/targets_
universal_access/en/.
Successful implementation and impact requires supportive policy, 
legislation and other structural factors.
Measured by structural (or enabling environment) indicators:
•	audit of current legislation and policy
•	number of key population-led organizations
•	meaningful involvement of people from key populations in policy and strategy 
formulation
•	legal support services for key populations
•	support services for people from key populations who experience violence
•	sensitization training on key populations for law enforcement officers
•	sensitization training on key populations for health-care and social services providers.
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Interventions need to be accessible to people from key populations.
Measured by availability indicators:
•	the number of sites where the intervention is available
•	the number and percentage of key population-focused programme sites where 
the intervention is provided
•	the number and percentage of mainstream programme sites where the 
intervention is provided and that meet key population sensitization standards
•	the percentage of all sites where the intervention is currently provided that are 
either mainstream programmes meeting key population sensitization standards 
or are key population-focused programmes
•	the percentage of the key population sample reporting that the intervention is 
readily accessible
•	geographic mapping of key populations in relation to where interventions are 
provided.
Interventions must reach those who need them.
Measured by coverage indicators:
•	number and percentage of key population provided with the intervention during 
a specified reporting period
•	number of consumable items (such as needles and syringes or condoms) 
distributed per member of key population during a specified reporting period 
•	percentage of the key population sample reporting that they received the 
intervention during a specified reporting period.
Interventions need to be properly implemented to be effective.
Measured by quality indicators:
•	review of programme policy and practice using programme quality assessment 
checklist
•	percentage of staff that has received key population sensitization training
•	percentage of key population reporting intervention was received and also a 
specific important activity or service was delivered (such as the provision of 
compatible lubricant with condoms)
•	percentage of occasions when intervention was provided along with specific 
important activity of service (see previous).
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Box 7.4 data sources
Behavioural and sero-surveillance surveys of key populations can provide 
prevalence data and information on the experiences, risks and service utilization 
of people from these groups. Many countries already undertake bio-behavioural 
surveys of key populations periodically as part of the ongoing monitoring 
of the HIV epidemic. The generalizability of survey findings depends on how 
representative the sample is of the entire key population; it is important to 
consider selection bias in how participants were recruited. Behavioural surveys are 
susceptible to bias toward socially desirable responses and to recall bias.
Programmatic or administrative data. Most programmes routinely record at 
least some basic information when providing a service. This might include the 
number of people who received a service, basic information about the client, and 
numbers of supplies used or distributed. 
To assess services provided to people from key populations, programme data must 
be disaggregated by key population. Key population-focused programmes may be 
able to provide data specific to the populations they serve, but this information is 
not commonly available from programmes that provide services to many different 
groups or to the general population.
Desk review and expert consultation. Reviewing various policy documents and 
legislation can identify the presence or absence of various laws or policies that 
may affect people from key populations.
Population size estimation. Deriving reliable population size estimates for 
key populations can be challenging. Various methods can be employed; each 
has its own advantages and limitations. Common methods include census and 
enumeration, general population surveys, and capture-recapture, multiplier, 
and network scale-up methods. Deriving multiple estimates through different 
methodologies and triangulating the results is helpful. Definitions of key 
populations should be clear. 
Intended aims should be achieved.
Measured by outcome and impact indicators:
•	prevalence of risk behaviour in key population
•	incidence of infection in key population
•	prevalence of infection in key population
•	incidence of HIV-related mortality in key population
•	prevalence in key population of experiencing stigma or discrimination
•	incidence of violence against people from key population.
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sources of guidance
•	 Tool for setting and monitoring targets for prevention, treatment and care for HIV and 
other sexually transmitted infections among men who have sex with men, sex workers and 
transgender people. Geneva, WHO, forthcoming.
•	 Technical guide for countries to set targets for universal access to HIV prevention, treatment 
and care for injecting drug users – 2012 revision. Geneva, WHO, 2012. http://www.who.int/
hiv/pub/idu/targets_universal_access/en/
•	 Consolidated HIV monitoring and evaluation guidelines. Geneva, WHO, in preparation. 
•	 Interim guidelines on protecting the confidentiality and security of HIV information: 
proceedings from a workshop 15–17 May 2006, Geneva, Switzerland. Geneva, UNAIDS, 
2007. http://data.unaids.org/pub/manual/2007/confidentiality_security_interim_
guidelines_15may2007_en.pdf 
•	 Guidelines on estimating the size of populations most at risk to HIV. Geneva, WHO, 2010. 
http://www.who.int/hiv/pub/surveillance/final_estimating_populations_en.pdf  
•	 HIV in prisons: Situation and needs assessment toolkit. Vienna, UNODC, 2010. http://
www.unodc.org/documents/hiv-aids/publications/HIV_in_prisons_situation_and_needs_
assessment_document.pdf
•	 Rapid assessment and response adaptation guide on HIV and men who have sex with 
men (MSM-RAR). Geneva, WHO, 2002. http://www.who.int/hiv/pub/prev_care/en/msmrar.
pdf?ua=1
•	 The rapid assessment and response guide on injecting drug use (IDU-RAR). Geneva, WHO, 
1998. http://www.who.int/substance_abuse/publications/en/IDURARguideEnglish.pdf?ua=1  
•	 The rapid assessment and response guide on psychoactive substance use and sexual risk 
behaviour (SEx-RAR). Geneva, WHO, 2002. http://www.who.int/entity/mental_health/media/
en/686.pdf?ua=1   
•	 Rapid assessment and response adaptation guide for work with especially vulnerable young 
people. Geneva, WHO, 2004. http://www.who.int/hiv/pub/prev_care/en/youngpeoplerar.
pdf?ua=1  
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definitions of key terms
1. Global health sector strategy on HIV/AIDS 2011–2015. Geneva, World Health Organization, 2011 
(http://whqlibdoc.who.int/publications/2011/9789241501651_eng.pdf, accessed 25 February 2014).
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